activity programmes	0	1.0	2	Physical activity programmes for people with persistent subthreshold depressive symptoms or mild to moderate depression should: be delivered in groups with support from a competent practitioner consist typically of three sessions per week of moderate duration (45 minutes to 1 hour) over 10 to 14 weeks (average 12 weeks).	Physical activity programmes for people with persistent subthreshold depressive symptoms or mild to moderate depression should: be delivered in groups with support from a competent practitioner consist typically of three sessions per week of moderate duration (45 minutes to 1 hour) over 10 to 14 weeks (average 12 weeks).	
additional social	0	1.0	2	For people with long-standing moderate or severe depression who would benefit from additional social or vocational support, consider: befriending as an adjunct to pharmacological or psychological treatments; befriending should be by trained volunteers providing, typically, at least weekly contact for between 2 and 6 months a rehabilitation programme if a person's depression has resulted in loss of work or disengagement from other social activities over a longer term.	For people with long-standing moderate or severe depression who would benefit from additional social or vocational support, consider: befriending as an adjunct to pharmacological or psychological treatments; befriending should be by trained volunteers providing, typically, at least weekly contact for between 2 and 6 months a rehabilitation programme if a person's depression has resulted in loss of work or disengagement from other social activities over a longer term.	
adverse events	0	1.0	2	Discuss antidepressant treatment options with the person with depression, covering: the choice of antidepressant, including any anticipated adverse events, for example side effects and discontinuation symptoms (see recommendation ), and potential interactions with concomitant medication or physical health problems their perception of the efficacy and tolerability of any antidepressants they have previously taken.	Discuss antidepressant treatment options with the person with depression, covering: the choice of antidepressant, including any anticipated adverse events, for example side effects and discontinuation symptoms (see recommendation ), and potential interactions with concomitant medication or physical health problems their perception of the efficacy and tolerability of any antidepressants they have previously taken.	
age-appropriate dose	0	1.0	2	When prescribing antidepressants for older people: prescribe at an age-appropriate dose taking into account the effect of general physical health and concomitant medication on pharmacokinetics and pharmacodynamics	When prescribing antidepressants for older people: prescribe at an age-appropriate dose taking into account the effect of general physical health and concomitant medication on pharmacokinetics and pharmacodynamics	
anti-inflammatory drugs	0	1.0	2	In particular, consider prescribing a gastroprotective drug in older people who are taking non-steroidal anti-inflammatory drugs (NSAIDs) or aspirin.	In particular, consider prescribing a gastroprotective drug in older people who are taking non-steroidal anti-inflammatory drugs (NSAIDs) or aspirin.	
anticipated adverse	0	1.0	2	Discuss antidepressant treatment options with the person with depression, covering: the choice of antidepressant, including any anticipated adverse events, for example side effects and discontinuation symptoms (see recommendation ), and potential interactions with concomitant medication or physical health problems their perception of the efficacy and tolerability of any antidepressants they have previously taken.	Discuss antidepressant treatment options with the person with depression, covering: the choice of antidepressant, including any anticipated adverse events, for example side effects and discontinuation symptoms (see recommendation ), and potential interactions with concomitant medication or physical health problems their perception of the efficacy and tolerability of any antidepressants they have previously taken.	
anxiety disorder	1	1.0	2	When the person has an anxiety disorder and comorbid depression or depressive symptoms, consult the NICE guideline for the relevant anxiety disorder (see find guidance) and consider treating the anxiety disorder first (since effective treatment of the anxiety disorder will often improve the depression or the depressive symptoms).	When the person has an anxiety disorder and comorbid depression or depressive symptoms, consult the NICE guideline for the relevant anxiety disorder (see find guidance) and consider treating the anxiety disorder first (since effective treatment of the anxiety disorder will often improve the depression or the depressive symptoms).	
behavioural therapy	0	1.0	4	Last updated April 2018 consider offering one or more of the following interventions, guided by the person's preference: individual guided self-help based on the principles of cognitive behavioural therapy (CBT) computerised cognitive behavioural therapy (CCBT) a structured group physical activity programme.	For people with persistent subthreshold depressive symptoms or mild to moderate depression, consider offering one or more of the following interventions, guided by the person's preference: individual guided self-help based on the principles of cognitive behavioural therapy (CBT) computerised cognitive behavioural therapy (CCBT) a structured group physical activity programme.	Last updated April 2018 consider offering one or more of the following interventions, guided by the person's preference: individual guided self-help based on the principles of cognitive behavioural therapy (CBT) computerised cognitive behavioural therapy (CCBT) a structured group physical activity programme.	For people with persistent subthreshold depressive symptoms or mild to moderate depression, consider offering one or more of the following interventions, guided by the person's preference: individual guided self-help based on the principles of cognitive behavioural therapy (CBT) computerised cognitive behavioural therapy (CCBT) a structured group physical activity programme.	
british national	1	1.0	2	The guideline assumes that prescribers will use a drug's summary of product characteristics (SPC) and the 'British national formulary' (BNF) to inform their decisions made with individual patients.	The guideline assumes that prescribers will use a drug's summary of product characteristics (SPC) and the 'British national formulary' (BNF) to inform their decisions made with individual patients.	
care mental	1	1.0	2	Medication in secondary care mental health services should be started under the supervision of a consultant psychiatrist.	Medication in secondary care mental health services should be started under the supervision of a consultant psychiatrist.	
clear information	0	1.0	2	Ensure that consent to treatment is based on the provision of clear information (which should also be available in written form) about the intervention, covering: what it comprises what is expected of the person while having it likely outcomes (including any side effects).	Ensure that consent to treatment is based on the provision of clear information (which should also be available in written form) about the intervention, covering: what it comprises what is expected of the person while having it likely outcomes (including any side effects).	
cognitive behavioural	0	1.0	4	Last updated April 2018 consider offering one or more of the following interventions, guided by the person's preference: individual guided self-help based on the principles of cognitive behavioural therapy (CBT) computerised cognitive behavioural therapy (CCBT) a structured group physical activity programme.	For people with persistent subthreshold depressive symptoms or mild to moderate depression, consider offering one or more of the following interventions, guided by the person's preference: individual guided self-help based on the principles of cognitive behavioural therapy (CBT) computerised cognitive behavioural therapy (CCBT) a structured group physical activity programme.	Last updated April 2018 consider offering one or more of the following interventions, guided by the person's preference: individual guided self-help based on the principles of cognitive behavioural therapy (CBT) computerised cognitive behavioural therapy (CCBT) a structured group physical activity programme.	For people with persistent subthreshold depressive symptoms or mild to moderate depression, consider offering one or more of the following interventions, guided by the person's preference: individual guided self-help based on the principles of cognitive behavioural therapy (CBT) computerised cognitive behavioural therapy (CCBT) a structured group physical activity programme.	
cognitive impairments	0	1.0	2	When assessing a person with suspected depression, be aware of any learning disabilities or acquired cognitive impairments, and if necessary consider consulting with a relevant specialist when developing treatment plans and strategies.	When assessing a person with suspected depression, be aware of any learning disabilities or acquired cognitive impairments, and if necessary consider consulting with a relevant specialist when developing treatment plans and strategies.	
competent practitioner	0	1.0	8	All interventions for depression should be delivered by competent practitioners	All interventions for depression should be delivered by competent practitioners.	Physical activity programmes for people with persistent subthreshold depressive symptoms or mild to moderate depression should: be delivered in groups with support from a competent practitioner consist typically of three sessions per week of moderate duration (45 minutes to 1 hour) over 10 to 14 weeks (average 12 weeks).	Group-based CBT for people with persistent subthreshold depressive symptoms or mild to moderate depression should: be based on a structured model such as 'Coping with Depression' be delivered by two trained and competent practitioners consist of 10 to 12 meetings of eight to ten participants normally take place over 12 to 16 weeks, including follow-up.	All interventions for depression should be delivered by competent practitioners	All interventions for depression should be delivered by competent practitioners.	Physical activity programmes for people with persistent subthreshold depressive symptoms or mild to moderate depression should: be delivered in groups with support from a competent practitioner consist typically of three sessions per week of moderate duration (45 minutes to 1 hour) over 10 to 14 weeks (average 12 weeks).	Group-based CBT for people with persistent subthreshold depressive symptoms or mild to moderate depression should: be based on a structured model such as 'Coping with Depression' be delivered by two trained and competent practitioners consist of 10 to 12 meetings of eight to ten participants normally take place over 12 to 16 weeks, including follow-up.	
complete relief	0	1.0	2	Where possible, the key goal of an intervention should be complete relief of symptoms (remission), which is associated with better functioning and a lower likelihood of relapse.	Where possible, the key goal of an intervention should be complete relief of symptoms (remission), which is associated with better functioning and a lower likelihood of relapse.	
complex multiprofessional	0	1.0	2	Referral to specialist mental health services should normally be for people with depression who are at significant risk of self-harm, have psychotic symptoms, require complex multiprofessional care, or where an expert opinion on treatment and management is needed.	Referral to specialist mental health services should normally be for people with depression who are at significant risk of self-harm, have psychotic symptoms, require complex multiprofessional care, or where an expert opinion on treatment and management is needed.	
depression short-term	0	1.0	2	For people with depression who decline an antidepressant, CBT, IPT, behavioural activation and behavioural couples therapy, consider: counselling for people with persistent subthreshold depressive symptoms or mild to moderate depression short-term psychodynamic psychotherapy for people with mild to moderate depression.	For people with depression who decline an antidepressant, CBT, IPT, behavioural activation and behavioural couples therapy, consider: counselling for people with persistent subthreshold depressive symptoms or mild to moderate depression short-term psychodynamic psychotherapy for people with mild to moderate depression.	
discuss antidepressant	0	1.0	2	Discuss antidepressant treatment options with the person with depression, covering: the choice of antidepressant, including any anticipated adverse events, for example side effects and discontinuation symptoms (see recommendation ), and potential interactions with concomitant medication or physical health problems their perception of the efficacy and tolerability of any antidepressants they have previously taken.	Discuss antidepressant treatment options with the person with depression, covering: the choice of antidepressant, including any anticipated adverse events, for example side effects and discontinuation symptoms (see recommendation ), and potential interactions with concomitant medication or physical health problems their perception of the efficacy and tolerability of any antidepressants they have previously taken.	
drug treatments	0	1.0	2	Do not use ECT routinely for people with moderate depression but consider it if their depression has not responded to multiple drug treatments and psychological treatment.	Do not use ECT routinely for people with moderate depression but consider it if their depression has not responded to multiple drug treatments and psychological treatment.	
effects person	0	1.0	2	The choice of intervention should be influenced by the: duration of the episode of depression and the trajectory of symptoms previous course of depression and response to treatment likelihood of adherence to treatment and any potential adverse effects person's treatment preference and priorities.	The choice of intervention should be influenced by the: duration of the episode of depression and the trajectory of symptoms previous course of depression and response to treatment likelihood of adherence to treatment and any potential adverse effects person's treatment preference and priorities.	
expert opinion	1	1.0	2	Referral to specialist mental health services should normally be for people with depression who are at significant risk of self-harm, have psychotic symptoms, require complex multiprofessional care, or where an expert opinion on treatment and management is needed.	Referral to specialist mental health services should normally be for people with depression who are at significant risk of self-harm, have psychotic symptoms, require complex multiprofessional care, or where an expert opinion on treatment and management is needed.	
follow-up appointments	0	1.0	2	Last updated April 2018 provide information about the nature and course of depression arrange a further assessment, normally within 2 weeks make contact if the person does not attend follow-up appointments.	Last updated April 2018 provide information about the nature and course of depression arrange a further assessment, normally within 2 weeks make contact if the person does not attend follow-up appointments.	
gastroprotective drug	0	1.0	2	In particular, consider prescribing a gastroprotective drug in older people who are taking non-steroidal anti-inflammatory drugs (NSAIDs) or aspirin.	In particular, consider prescribing a gastroprotective drug in older people who are taking non-steroidal anti-inflammatory drugs (NSAIDs) or aspirin.	
general physical	0	1.0	2	When prescribing antidepressants for older people: prescribe at an age-appropriate dose taking into account the effect of general physical health and concomitant medication on pharmacokinetics and pharmacodynamics	When prescribing antidepressants for older people: prescribe at an age-appropriate dose taking into account the effect of general physical health and concomitant medication on pharmacokinetics and pharmacodynamics	
health problems	0	1.0	2	Discuss antidepressant treatment options with the person with depression, covering: the choice of antidepressant, including any anticipated adverse events, for example side effects and discontinuation symptoms (see recommendation ), and potential interactions with concomitant medication or physical health problems their perception of the efficacy and tolerability of any antidepressants they have previously taken.	Discuss antidepressant treatment options with the person with depression, covering: the choice of antidepressant, including any anticipated adverse events, for example side effects and discontinuation symptoms (see recommendation ), and potential interactions with concomitant medication or physical health problems their perception of the efficacy and tolerability of any antidepressants they have previously taken.	
health professionals	0	1.0	2	Non-reversible monoamine oxidase inhibitors (MAOIs), such as phenelzine, should normally be prescribed only by specialist mental health professionals.	Non-reversible monoamine oxidase inhibitors (MAOIs), such as phenelzine, should normally be prescribed only by specialist mental health professionals.	
high-priority routine	0	1.0	2	The teams should monitor risk as a high-priority routine activity in a way that allows people to continue their lives without disruption.	The teams should monitor risk as a high-priority routine activity in a way that allows people to continue their lives without disruption.	
individual patients	0	1.0	2	The guideline assumes that prescribers will use a drug's summary of product characteristics (SPC) and the 'British national formulary' (BNF) to inform their decisions made with individual patients.	The guideline assumes that prescribers will use a drug's summary of product characteristics (SPC) and the 'British national formulary' (BNF) to inform their decisions made with individual patients.	
information section	0	1.0	2	The update information section has a list of recommendations for which the evidence has not been updated since the original guideline.	The update information section has a list of recommendations for which the evidence has not been updated since the original guideline.	
inpatient treatment	0	1.0	2	Consider inpatient treatment for people with depression who are at significant risk of suicide, self-harm or self-neglect.	Consider inpatient treatment for people with depression who are at significant risk of suicide, self-harm or self-neglect.	
key goal	0	1.0	2	Where possible, the key goal of an intervention should be complete relief of symptoms (remission), which is associated with better functioning and a lower likelihood of relapse.	Where possible, the key goal of an intervention should be complete relief of symptoms (remission), which is associated with better functioning and a lower likelihood of relapse.	
long-standing moderate	0	1.0	2	For people with long-standing moderate or severe depression who would benefit from additional social or vocational support, consider: befriending as an adjunct to pharmacological or psychological treatments; befriending should be by trained volunteers providing, typically, at least weekly contact for between 2 and 6 months a rehabilitation programme if a person's depression has resulted in loss of work or disengagement from other social activities over a longer term.	For people with long-standing moderate or severe depression who would benefit from additional social or vocational support, consider: befriending as an adjunct to pharmacological or psychological treatments; befriending should be by trained volunteers providing, typically, at least weekly contact for between 2 and 6 months a rehabilitation programme if a person's depression has resulted in loss of work or disengagement from other social activities over a longer term.	
marketing authorisation	0	1.0	4	This guideline recommends some drugs for indications for which they do not have a UK marketing authorisation at the date of publication, if they are already in use in the NHS for that indication, and there is good evidence to support that use	UK marketing authorisation for depression or the indication stated at the time of publication.	This guideline recommends some drugs for indications for which they do not have a UK marketing authorisation at the date of publication, if they are already in use in the NHS for that indication, and there is good evidence to support that use	UK marketing authorisation for depression or the indication stated at the time of publication.	
moderate duration	0	1.0	2	Physical activity programmes for people with persistent subthreshold depressive symptoms or mild to moderate depression should: be delivered in groups with support from a competent practitioner consist typically of three sessions per week of moderate duration (45 minutes to 1 hour) over 10 to 14 weeks (average 12 weeks).	Physical activity programmes for people with persistent subthreshold depressive symptoms or mild to moderate depression should: be delivered in groups with support from a competent practitioner consist typically of three sessions per week of moderate duration (45 minutes to 1 hour) over 10 to 14 weeks (average 12 weeks).	
monoamine oxidase	1	1.0	2	Non-reversible monoamine oxidase inhibitors (MAOIs), such as phenelzine, should normally be prescribed only by specialist mental health professionals.	Non-reversible monoamine oxidase inhibitors (MAOIs), such as phenelzine, should normally be prescribed only by specialist mental health professionals.	
multiple drug	0	1.0	2	Do not use ECT routinely for people with moderate depression but consider it if their depression has not responded to multiple drug treatments and psychological treatment.	Do not use ECT routinely for people with moderate depression but consider it if their depression has not responded to multiple drug treatments and psychological treatment.	
national formulary	0	1.0	2	The guideline assumes that prescribers will use a drug's summary of product characteristics (SPC) and the 'British national formulary' (BNF) to inform their decisions made with individual patients.	The guideline assumes that prescribers will use a drug's summary of product characteristics (SPC) and the 'British national formulary' (BNF) to inform their decisions made with individual patients.	
non-reversible monoamine	0	1.0	2	Non-reversible monoamine oxidase inhibitors (MAOIs), such as phenelzine, should normally be prescribed only by specialist mental health professionals.	Non-reversible monoamine oxidase inhibitors (MAOIs), such as phenelzine, should normally be prescribed only by specialist mental health professionals.	
non-steroidal anti-inflammatory	0	1.0	2	In particular, consider prescribing a gastroprotective drug in older people who are taking non-steroidal anti-inflammatory drugs (NSAIDs) or aspirin.	In particular, consider prescribing a gastroprotective drug in older people who are taking non-steroidal anti-inflammatory drugs (NSAIDs) or aspirin.	
original guideline	0	1.0	2	The update information section has a list of recommendations for which the evidence has not been updated since the original guideline.	The update information section has a list of recommendations for which the evidence has not been updated since the original guideline.	
oxidase inhibitors	0	1.0	2	Non-reversible monoamine oxidase inhibitors (MAOIs), such as phenelzine, should normally be prescribed only by specialist mental health professionals.	Non-reversible monoamine oxidase inhibitors (MAOIs), such as phenelzine, should normally be prescribed only by specialist mental health professionals.	
pharmacodynamics depression	0	1.0	0	
potential adverse	0	1.0	2	The choice of intervention should be influenced by the: duration of the episode of depression and the trajectory of symptoms previous course of depression and response to treatment likelihood of adherence to treatment and any potential adverse effects person's treatment preference and priorities.	The choice of intervention should be influenced by the: duration of the episode of depression and the trajectory of symptoms previous course of depression and response to treatment likelihood of adherence to treatment and any potential adverse effects person's treatment preference and priorities.	
potential interactions	0	1.0	2	Discuss antidepressant treatment options with the person with depression, covering: the choice of antidepressant, including any anticipated adverse events, for example side effects and discontinuation symptoms (see recommendation ), and potential interactions with concomitant medication or physical health problems their perception of the efficacy and tolerability of any antidepressants they have previously taken.	Discuss antidepressant treatment options with the person with depression, covering: the choice of antidepressant, including any anticipated adverse events, for example side effects and discontinuation symptoms (see recommendation ), and potential interactions with concomitant medication or physical health problems their perception of the efficacy and tolerability of any antidepressants they have previously taken.	
prescribed dose	0	1.0	2	If the person's depression shows no improvement after 2 to 4 weeks with the first antidepressant, check that the drug has been taken regularly and in the prescribed dose.	If the person's depression shows no improvement after 2 to 4 weeks with the first antidepressant, check that the drug has been taken regularly and in the prescribed dose.	
product characteristics	0	1.0	4	Known risk factors for these conditions, including increased age, should be carefully evaluated before treatment: see the manufacturers' summaries of product characteristics for details	Known risk factors for these conditions, including increased age, should be carefully evaluated before treatment: see the manufacturers' summaries of product characteristics for details	The guideline assumes that prescribers will use a drug's summary of product characteristics (SPC) and the 'British national formulary' (BNF) to inform their decisions made with individual patients.	The guideline assumes that prescribers will use a drug's summary of product characteristics (SPC) and the 'British national formulary' (BNF) to inform their decisions made with individual patients.	
psychological treatment	0	1.0	4	For people with long-standing moderate or severe depression who would benefit from additional social or vocational support, consider: befriending as an adjunct to pharmacological or psychological treatments; befriending should be by trained volunteers providing, typically, at least weekly contact for between 2 and 6 months a rehabilitation programme if a person's depression has resulted in loss of work or disengagement from other social activities over a longer term.	Do not use ECT routinely for people with moderate depression but consider it if their depression has not responded to multiple drug treatments and psychological treatment.	For people with long-standing moderate or severe depression who would benefit from additional social or vocational support, consider: befriending as an adjunct to pharmacological or psychological treatments; befriending should be by trained volunteers providing, typically, at least weekly contact for between 2 and 6 months a rehabilitation programme if a person's depression has resulted in loss of work or disengagement from other social activities over a longer term.	Do not use ECT routinely for people with moderate depression but consider it if their depression has not responded to multiple drug treatments and psychological treatment.	
psychological treatments	0	1.0	2	For people with long-standing moderate or severe depression who would benefit from additional social or vocational support, consider: befriending as an adjunct to pharmacological or psychological treatments; befriending should be by trained volunteers providing, typically, at least weekly contact for between 2 and 6 months a rehabilitation programme if a person's depression has resulted in loss of work or disengagement from other social activities over a longer term.	For people with long-standing moderate or severe depression who would benefit from additional social or vocational support, consider: befriending as an adjunct to pharmacological or psychological treatments; befriending should be by trained volunteers providing, typically, at least weekly contact for between 2 and 6 months a rehabilitation programme if a person's depression has resulted in loss of work or disengagement from other social activities over a longer term.	
rehabilitation programme	0	1.0	2	For people with long-standing moderate or severe depression who would benefit from additional social or vocational support, consider: befriending as an adjunct to pharmacological or psychological treatments; befriending should be by trained volunteers providing, typically, at least weekly contact for between 2 and 6 months a rehabilitation programme if a person's depression has resulted in loss of work or disengagement from other social activities over a longer term.	For people with long-standing moderate or severe depression who would benefit from additional social or vocational support, consider: befriending as an adjunct to pharmacological or psychological treatments; befriending should be by trained volunteers providing, typically, at least weekly contact for between 2 and 6 months a rehabilitation programme if a person's depression has resulted in loss of work or disengagement from other social activities over a longer term.	
relative advantage	0	1.0	2	When switching to another antidepressant, be aware that the evidence for the relative advantage of switching either within or between classes is weak.	When switching to another antidepressant, be aware that the evidence for the relative advantage of switching either within or between classes is weak.	
relevant specialist	0	1.0	2	When assessing a person with suspected depression, be aware of any learning disabilities or acquired cognitive impairments, and if necessary consider consulting with a relevant specialist when developing treatment plans and strategies.	When assessing a person with suspected depression, be aware of any learning disabilities or acquired cognitive impairments, and if necessary consider consulting with a relevant specialist when developing treatment plans and strategies.	
routine activity	0	1.0	2	The teams should monitor risk as a high-priority routine activity in a way that allows people to continue their lives without disruption.	The teams should monitor risk as a high-priority routine activity in a way that allows people to continue their lives without disruption.	
social activities	0	1.0	2	For people with long-standing moderate or severe depression who would benefit from additional social or vocational support, consider: befriending as an adjunct to pharmacological or psychological treatments; befriending should be by trained volunteers providing, typically, at least weekly contact for between 2 and 6 months a rehabilitation programme if a person's depression has resulted in loss of work or disengagement from other social activities over a longer term.	For people with long-standing moderate or severe depression who would benefit from additional social or vocational support, consider: befriending as an adjunct to pharmacological or psychological treatments; befriending should be by trained volunteers providing, typically, at least weekly contact for between 2 and 6 months a rehabilitation programme if a person's depression has resulted in loss of work or disengagement from other social activities over a longer term.	
st john	0	1.0	2	Although there is evidence that St John's wort may be of benefit in mild or moderate depression, practitioners should: not prescribe or advise its use by people with depression because of uncertainty about appropriate doses, persistence of effect, variation in the nature of preparations and potential serious interactions with other drugs (including oral contraceptives, anticoagulants and anticonvulsants) advise people with depression of the different potencies of the preparations available and of the potential serious interactions of St John's wort with other drugs.	Although there is evidence that St John's wort may be of benefit in mild or moderate depression, practitioners should: not prescribe or advise its use by people with depression because of uncertainty about appropriate doses, persistence of effect, variation in the nature of preparations and potential serious interactions with other drugs (including oral contraceptives, anticoagulants and anticonvulsants) advise people with depression of the different potencies of the preparations available and of the potential serious interactions of St John's wort with other drugs.	
structured model	0	1.0	2	Group-based CBT for people with persistent subthreshold depressive symptoms or mild to moderate depression should: be based on a structured model such as 'Coping with Depression' be delivered by two trained and competent practitioners consist of 10 to 12 meetings of eight to ten participants normally take place over 12 to 16 weeks, including follow-up.	Group-based CBT for people with persistent subthreshold depressive symptoms or mild to moderate depression should: be based on a structured model such as 'Coping with Depression' be delivered by two trained and competent practitioners consist of 10 to 12 meetings of eight to ten participants normally take place over 12 to 16 weeks, including follow-up.	
symptoms previous	0	1.0	2	The choice of intervention should be influenced by the: duration of the episode of depression and the trajectory of symptoms previous course of depression and response to treatment likelihood of adherence to treatment and any potential adverse effects person's treatment preference and priorities.	The choice of intervention should be influenced by the: duration of the episode of depression and the trajectory of symptoms previous course of depression and response to treatment likelihood of adherence to treatment and any potential adverse effects person's treatment preference and priorities.	
trained volunteers	0	1.0	2	For people with long-standing moderate or severe depression who would benefit from additional social or vocational support, consider: befriending as an adjunct to pharmacological or psychological treatments; befriending should be by trained volunteers providing, typically, at least weekly contact for between 2 and 6 months a rehabilitation programme if a person's depression has resulted in loss of work or disengagement from other social activities over a longer term.	For people with long-standing moderate or severe depression who would benefit from additional social or vocational support, consider: befriending as an adjunct to pharmacological or psychological treatments; befriending should be by trained volunteers providing, typically, at least weekly contact for between 2 and 6 months a rehabilitation programme if a person's depression has resulted in loss of work or disengagement from other social activities over a longer term.	
treatment likelihood	0	1.0	2	The choice of intervention should be influenced by the: duration of the episode of depression and the trajectory of symptoms previous course of depression and response to treatment likelihood of adherence to treatment and any potential adverse effects person's treatment preference and priorities.	The choice of intervention should be influenced by the: duration of the episode of depression and the trajectory of symptoms previous course of depression and response to treatment likelihood of adherence to treatment and any potential adverse effects person's treatment preference and priorities.	
treatment preference	0	1.0	2	The choice of intervention should be influenced by the: duration of the episode of depression and the trajectory of symptoms previous course of depression and response to treatment likelihood of adherence to treatment and any potential adverse effects person's treatment preference and priorities.	The choice of intervention should be influenced by the: duration of the episode of depression and the trajectory of symptoms previous course of depression and response to treatment likelihood of adherence to treatment and any potential adverse effects person's treatment preference and priorities.	
uk marketing	0	1.0	4	This guideline recommends some drugs for indications for which they do not have a UK marketing authorisation at the date of publication, if they are already in use in the NHS for that indication, and there is good evidence to support that use	UK marketing authorisation for depression or the indication stated at the time of publication.	This guideline recommends some drugs for indications for which they do not have a UK marketing authorisation at the date of publication, if they are already in use in the NHS for that indication, and there is good evidence to support that use	UK marketing authorisation for depression or the indication stated at the time of publication.	
update information	0	1.0	2	The update information section has a list of recommendations for which the evidence has not been updated since the original guideline.	The update information section has a list of recommendations for which the evidence has not been updated since the original guideline.	
vocational support	0	1.0	2	For people with long-standing moderate or severe depression who would benefit from additional social or vocational support, consider: befriending as an adjunct to pharmacological or psychological treatments; befriending should be by trained volunteers providing, typically, at least weekly contact for between 2 and 6 months a rehabilitation programme if a person's depression has resulted in loss of work or disengagement from other social activities over a longer term.	For people with long-standing moderate or severe depression who would benefit from additional social or vocational support, consider: befriending as an adjunct to pharmacological or psychological treatments; befriending should be by trained volunteers providing, typically, at least weekly contact for between 2 and 6 months a rehabilitation programme if a person's depression has resulted in loss of work or disengagement from other social activities over a longer term.	
weekly contact	0	1.0	2	For people with long-standing moderate or severe depression who would benefit from additional social or vocational support, consider: befriending as an adjunct to pharmacological or psychological treatments; befriending should be by trained volunteers providing, typically, at least weekly contact for between 2 and 6 months a rehabilitation programme if a person's depression has resulted in loss of work or disengagement from other social activities over a longer term.	For people with long-standing moderate or severe depression who would benefit from additional social or vocational support, consider: befriending as an adjunct to pharmacological or psychological treatments; befriending should be by trained volunteers providing, typically, at least weekly contact for between 2 and 6 months a rehabilitation programme if a person's depression has resulted in loss of work or disengagement from other social activities over a longer term.	
written form	0	1.0	2	Ensure that consent to treatment is based on the provision of clear information (which should also be available in written form) about the intervention, covering: what it comprises what is expected of the person while having it likely outcomes (including any side effects).	Ensure that consent to treatment is based on the provision of clear information (which should also be available in written form) about the intervention, covering: what it comprises what is expected of the person while having it likely outcomes (including any side effects).	
communication difficulties	0	0.9928	2	For people with significant language or communication difficulties, for example people with sensory impairments or a learning disability, consider using the	For people with significant language or communication difficulties, for example people with sensory impairments or a learning disability, consider using the	
risk assessment	0	0.9928	2	Risk assessment and monitoring	Risk assessment and monitoring	
sensory impairments	0	0.9928	2	For people with significant language or communication difficulties, for example people with sensory impairments or a learning disability, consider using the	For people with significant language or communication difficulties, for example people with sensory impairments or a learning disability, consider using the	
significant language	0	0.9928	2	For people with significant language or communication difficulties, for example people with sensory impairments or a learning disability, consider using the	For people with significant language or communication difficulties, for example people with sensory impairments or a learning disability, consider using the	
account toxicity	0	0.9662	2	If a person with depression is assessed to be at risk of suicide: take into account toxicity in overdose if an antidepressant is prescribed or the person is taking other medication; if necessary, limit the amount of drug(s) available	If a person with depression is assessed to be at risk of suicide: take into account toxicity in overdose if an antidepressant is prescribed or the person is taking other medication; if necessary, limit the amount of drug(s) available	
frequent direct	0	0.9662	2	Last updated April 2018 consider increasing the level of support, such as more frequent direct or telephone contacts consider referral to specialist mental health services.	Last updated April 2018 consider increasing the level of support, such as more frequent direct or telephone contacts consider referral to specialist mental health services.	
telephone contacts	0	0.9662	2	Last updated April 2018 consider increasing the level of support, such as more frequent direct or telephone contacts consider referral to specialist mental health services.	Last updated April 2018 consider increasing the level of support, such as more frequent direct or telephone contacts consider referral to specialist mental health services.	
antipsychotic medication	0	0.9661	2	For people who have depression with psychotic symptoms, consider augmenting the current treatment plan with antipsychotic medication (although the optimum dose and duration of treatment are unknown).	For people who have depression with psychotic symptoms, consider augmenting the current treatment plan with antipsychotic medication (although the optimum dose and duration of treatment are unknown).	
current treatment	0	0.9661	2	For people who have depression with psychotic symptoms, consider augmenting the current treatment plan with antipsychotic medication (although the optimum dose and duration of treatment are unknown).	For people who have depression with psychotic symptoms, consider augmenting the current treatment plan with antipsychotic medication (although the optimum dose and duration of treatment are unknown).	
full range	0	0.9661	2	The full range of high-intensity psychological interventions should normally be offered in inpatient settings	The full range of high-intensity psychological interventions should normally be offered in inpatient settings	
inpatient settings	0	0.9661	2	The full range of high-intensity psychological interventions should normally be offered in inpatient settings	The full range of high-intensity psychological interventions should normally be offered in inpatient settings	
optimum dose	0	0.9661	2	For people who have depression with psychotic symptoms, consider augmenting the current treatment plan with antipsychotic medication (although the optimum dose and duration of treatment are unknown).	For people who have depression with psychotic symptoms, consider augmenting the current treatment plan with antipsychotic medication (although the optimum dose and duration of treatment are unknown).	
treatment plan	0	0.9661	6	Ensure competence in: culturally sensitive assessment using different explanatory models of depression addressing cultural and ethnic differences when developing and implementing treatment plans working with families from diverse ethnic and cultural backgrounds.	When assessing a person with suspected depression, be aware of any learning disabilities or acquired cognitive impairments, and if necessary consider consulting with a relevant specialist when developing treatment plans and strategies.	For people who have depression with psychotic symptoms, consider augmenting the current treatment plan with antipsychotic medication (although the optimum dose and duration of treatment are unknown).	Ensure competence in: culturally sensitive assessment using different explanatory models of depression addressing cultural and ethnic differences when developing and implementing treatment plans working with families from diverse ethnic and cultural backgrounds.	When assessing a person with suspected depression, be aware of any learning disabilities or acquired cognitive impairments, and if necessary consider consulting with a relevant specialist when developing treatment plans and strategies.	For people who have depression with psychotic symptoms, consider augmenting the current treatment plan with antipsychotic medication (although the optimum dose and duration of treatment are unknown).	
considerable time	0	0.9539	2	Symptoms are considered persistent if they continue despite active monitoring and or low-intensity intervention, or have been present for a considerable time, typically several months (For a diagnosis of dysthymia, symptoms should be present for at least 2 years .)	Symptoms are considered persistent if they continue despite active monitoring and or low-intensity intervention, or have been present for a considerable time, typically several months (For a diagnosis of dysthymia, symptoms should be present for at least 2 years .)	
day symptoms	0	0.9539	0	
low-intensity intervention	0	0.9539	2	Symptoms are considered persistent if they continue despite active monitoring and or low-intensity intervention, or have been present for a considerable time, typically several months (For a diagnosis of dysthymia, symptoms should be present for at least 2 years .)	Symptoms are considered persistent if they continue despite active monitoring and or low-intensity intervention, or have been present for a considerable time, typically several months (For a diagnosis of dysthymia, symptoms should be present for at least 2 years .)	
sufficient severity	0	0.9539	2	Symptoms should be present for at least 2 weeks and each symptom should be present at sufficient severity for most of every day	Symptoms should be present for at least 2 weeks and each symptom should be present at sufficient severity for most of every day	
other disorders	1	0.939	2	This guideline covers people whose depression occurs as the primary diagnosis; the relevant NICE guidelines should be consulted for depression occurring in the context of other disorders (see our topic page on depression).	This guideline covers people whose depression occurs as the primary diagnosis; the relevant NICE guidelines should be consulted for depression occurring in the context of other disorders (see our topic page on depression).	
primary diagnosis	0	0.939	2	This guideline covers people whose depression occurs as the primary diagnosis; the relevant NICE guidelines should be consulted for depression occurring in the context of other disorders (see our topic page on depression).	This guideline covers people whose depression occurs as the primary diagnosis; the relevant NICE guidelines should be consulted for depression occurring in the context of other disorders (see our topic page on depression).	
relevant nice	0	0.939	2	This guideline covers people whose depression occurs as the primary diagnosis; the relevant NICE guidelines should be consulted for depression occurring in the context of other disorders (see our topic page on depression).	This guideline covers people whose depression occurs as the primary diagnosis; the relevant NICE guidelines should be consulted for depression occurring in the context of other disorders (see our topic page on depression).	
topic page	0	0.939	2	This guideline covers people whose depression occurs as the primary diagnosis; the relevant NICE guidelines should be consulted for depression occurring in the context of other disorders (see our topic page on depression).	This guideline covers people whose depression occurs as the primary diagnosis; the relevant NICE guidelines should be consulted for depression occurring in the context of other disorders (see our topic page on depression).	
complex intervention	0	0.9389	2	It is likely to be effective only when provided as part of a more complex intervention.	It is likely to be effective only when provided as part of a more complex intervention.	
medication management	0	0.9389	2	Medication management as a separate intervention for people with depression should not be provided routinely by services	Medication management as a separate intervention for people with depression should not be provided routinely by services	
separate intervention	0	0.9389	2	Medication management as a separate intervention for people with depression should not be provided routinely by services	Medication management as a separate intervention for people with depression should not be provided routinely by services	
psychodynamic psychotherapy	0	0.9347	4	For people with depression who decline an antidepressant, CBT, IPT, behavioural activation and behavioural couples therapy, consider: counselling for people with persistent subthreshold depressive symptoms or mild to moderate depression short-term psychodynamic psychotherapy for people with mild to moderate depression.	For all people with mild to moderate depression having short-term psychodynamic psychotherapy, the duration of treatment should typically be in the range of 16 to 20 sessions over 4 to 6 months.	For people with depression who decline an antidepressant, CBT, IPT, behavioural activation and behavioural couples therapy, consider: counselling for people with persistent subthreshold depressive symptoms or mild to moderate depression short-term psychodynamic psychotherapy for people with mild to moderate depression.	For all people with mild to moderate depression having short-term psychodynamic psychotherapy, the duration of treatment should typically be in the range of 16 to 20 sessions over 4 to 6 months.	
short-term psychodynamic	0	0.9347	4	For people with depression who decline an antidepressant, CBT, IPT, behavioural activation and behavioural couples therapy, consider: counselling for people with persistent subthreshold depressive symptoms or mild to moderate depression short-term psychodynamic psychotherapy for people with mild to moderate depression.	For all people with mild to moderate depression having short-term psychodynamic psychotherapy, the duration of treatment should typically be in the range of 16 to 20 sessions over 4 to 6 months.	For people with depression who decline an antidepressant, CBT, IPT, behavioural activation and behavioural couples therapy, consider: counselling for people with persistent subthreshold depressive symptoms or mild to moderate depression short-term psychodynamic psychotherapy for people with mild to moderate depression.	For all people with mild to moderate depression having short-term psychodynamic psychotherapy, the duration of treatment should typically be in the range of 16 to 20 sessions over 4 to 6 months.	
relevant treatment	0	0.9158	8	Psychological and psychosocial interventions should be based on the relevant treatment manual(s), which should guide the structure and duration of the intervention	Practitioners should consider using competence frameworks developed from the relevant treatment manual(s) and for all interventions should: receive regular high-quality supervision use routine outcome measures and ensure that the person with depression is involved in reviewing the efficacy of the treatment engage in monitoring and evaluation of treatment adherence and practitioner competence  for example, by using video and audio tapes, and external audit and scrutiny where appropriate.	Psychological and psychosocial interventions should be based on the relevant treatment manual(s), which should guide the structure and duration of the intervention	Practitioners should consider using competence frameworks developed from the relevant treatment manual(s) and for all interventions should: receive regular high-quality supervision use routine outcome measures and ensure that the person with depression is involved in reviewing the efficacy of the treatment engage in monitoring and evaluation of treatment adherence and practitioner competence  for example, by using video and audio tapes, and external audit and scrutiny where appropriate.	Psychological and psychosocial interventions should be based on the relevant treatment manual(s), which should guide the structure and duration of the intervention	Practitioners should consider using competence frameworks developed from the relevant treatment manual(s) and for all interventions should: receive regular high-quality supervision use routine outcome measures and ensure that the person with depression is involved in reviewing the efficacy of the treatment engage in monitoring and evaluation of treatment adherence and practitioner competence  for example, by using video and audio tapes, and external audit and scrutiny where appropriate.	Psychological and psychosocial interventions should be based on the relevant treatment manual(s), which should guide the structure and duration of the intervention	Practitioners should consider using competence frameworks developed from the relevant treatment manual(s) and for all interventions should: receive regular high-quality supervision use routine outcome measures and ensure that the person with depression is involved in reviewing the efficacy of the treatment engage in monitoring and evaluation of treatment adherence and practitioner competence  for example, by using video and audio tapes, and external audit and scrutiny where appropriate.	
treatment manual(s)	0	0.9158	8	Psychological and psychosocial interventions should be based on the relevant treatment manual(s), which should guide the structure and duration of the intervention	Practitioners should consider using competence frameworks developed from the relevant treatment manual(s) and for all interventions should: receive regular high-quality supervision use routine outcome measures and ensure that the person with depression is involved in reviewing the efficacy of the treatment engage in monitoring and evaluation of treatment adherence and practitioner competence  for example, by using video and audio tapes, and external audit and scrutiny where appropriate.	Psychological and psychosocial interventions should be based on the relevant treatment manual(s), which should guide the structure and duration of the intervention	Practitioners should consider using competence frameworks developed from the relevant treatment manual(s) and for all interventions should: receive regular high-quality supervision use routine outcome measures and ensure that the person with depression is involved in reviewing the efficacy of the treatment engage in monitoring and evaluation of treatment adherence and practitioner competence  for example, by using video and audio tapes, and external audit and scrutiny where appropriate.	Psychological and psychosocial interventions should be based on the relevant treatment manual(s), which should guide the structure and duration of the intervention	Practitioners should consider using competence frameworks developed from the relevant treatment manual(s) and for all interventions should: receive regular high-quality supervision use routine outcome measures and ensure that the person with depression is involved in reviewing the efficacy of the treatment engage in monitoring and evaluation of treatment adherence and practitioner competence  for example, by using video and audio tapes, and external audit and scrutiny where appropriate.	Psychological and psychosocial interventions should be based on the relevant treatment manual(s), which should guide the structure and duration of the intervention	Practitioners should consider using competence frameworks developed from the relevant treatment manual(s) and for all interventions should: receive regular high-quality supervision use routine outcome measures and ensure that the person with depression is involved in reviewing the efficacy of the treatment engage in monitoring and evaluation of treatment adherence and practitioner competence  for example, by using video and audio tapes, and external audit and scrutiny where appropriate.	
behavioural principles	0	0.911	2	Behavioural couples therapy for depression should normally be based on behavioural principles, and an adequate course of therapy should be 15 to 20 sessions over 5 to 6 months.	Behavioural couples therapy for depression should normally be based on behavioural principles, and an adequate course of therapy should be 15 to 20 sessions over 5 to 6 months.	
collaborative care	0	0.8823	4	Medication, high-intensity psychological interventions, combined treatments, collaborative careb and referral for further assessment and interventions	For people with severe depression and those with moderate depression and complex problems, consider: referring to specialist mental health services for a programme of coordinated multiprofessional care providing collaborative care if the depression is in the context of a chronic physical health problem with associated functional impairment .	Medication, high-intensity psychological interventions, combined treatments, collaborative careb and referral for further assessment and interventions	For people with severe depression and those with moderate depression and complex problems, consider: referring to specialist mental health services for a programme of coordinated multiprofessional care providing collaborative care if the depression is in the context of a chronic physical health problem with associated functional impairment .	
complex problems	0	0.8823	2	For people with severe depression and those with moderate depression and complex problems, consider: referring to specialist mental health services for a programme of coordinated multiprofessional care providing collaborative care if the depression is in the context of a chronic physical health problem with associated functional impairment .	For people with severe depression and those with moderate depression and complex problems, consider: referring to specialist mental health services for a programme of coordinated multiprofessional care providing collaborative care if the depression is in the context of a chronic physical health problem with associated functional impairment .	
concomitant medication	0	0.8694	4	Discuss antidepressant treatment options with the person with depression, covering: the choice of antidepressant, including any anticipated adverse events, for example side effects and discontinuation symptoms (see recommendation ), and potential interactions with concomitant medication or physical health problems their perception of the efficacy and tolerability of any antidepressants they have previously taken.	When prescribing antidepressants for older people: prescribe at an age-appropriate dose taking into account the effect of general physical health and concomitant medication on pharmacokinetics and pharmacodynamics	Discuss antidepressant treatment options with the person with depression, covering: the choice of antidepressant, including any anticipated adverse events, for example side effects and discontinuation symptoms (see recommendation ), and potential interactions with concomitant medication or physical health problems their perception of the efficacy and tolerability of any antidepressants they have previously taken.	When prescribing antidepressants for older people: prescribe at an age-appropriate dose taking into account the effect of general physical health and concomitant medication on pharmacokinetics and pharmacodynamics	
group-based cbt	0	0.8694	4	Consider group-based CBT for people with persistent subthreshold depressive symptoms or mild to moderate depression who decline low-intensity psychosocial interventions (see recommendation ).	Group-based CBT for people with persistent subthreshold depressive symptoms or mild to moderate depression should: be based on a structured model such as 'Coping with Depression' be delivered by two trained and competent practitioners consist of 10 to 12 meetings of eight to ten participants normally take place over 12 to 16 weeks, including follow-up.	Consider group-based CBT for people with persistent subthreshold depressive symptoms or mild to moderate depression who decline low-intensity psychosocial interventions (see recommendation ).	Group-based CBT for people with persistent subthreshold depressive symptoms or mild to moderate depression should: be based on a structured model such as 'Coping with Depression' be delivered by two trained and competent practitioners consist of 10 to 12 meetings of eight to ten participants normally take place over 12 to 16 weeks, including follow-up.	
suspected depression	0	0.8694	4	When assessing a person with suspected depression, be aware of any learning disabilities or acquired cognitive impairments, and if necessary consider consulting with a relevant specialist when developing treatment plans and strategies.	When assessing a person with suspected depression, consider using a validated measure (for example, for symptoms, functions and or disability) to inform and evaluate treatment.	When assessing a person with suspected depression, be aware of any learning disabilities or acquired cognitive impairments, and if necessary consider consulting with a relevant specialist when developing treatment plans and strategies.	When assessing a person with suspected depression, consider using a validated measure (for example, for symptoms, functions and or disability) to inform and evaluate treatment.	
treatment options	0	0.8694	4	Last updated April 2018 explore treatment options in an atmosphere of hope and optimism, explaining the different courses of depression and that recovery is possible be aware that stigma and discrimination can be associated with a diagnosis of depression ensure that discussions take place in settings in which confidentiality, privacy and dignity are respected.	Discuss antidepressant treatment options with the person with depression, covering: the choice of antidepressant, including any anticipated adverse events, for example side effects and discontinuation symptoms (see recommendation ), and potential interactions with concomitant medication or physical health problems their perception of the efficacy and tolerability of any antidepressants they have previously taken.	Last updated April 2018 explore treatment options in an atmosphere of hope and optimism, explaining the different courses of depression and that recovery is possible be aware that stigma and discrimination can be associated with a diagnosis of depression ensure that discussions take place in settings in which confidentiality, privacy and dignity are respected.	Discuss antidepressant treatment options with the person with depression, covering: the choice of antidepressant, including any anticipated adverse events, for example side effects and discontinuation symptoms (see recommendation ), and potential interactions with concomitant medication or physical health problems their perception of the efficacy and tolerability of any antidepressants they have previously taken.	
identification treatment	0	0.8216	2	This guideline is published alongside 'Depression in adults with a chronic physical health problem: recognition and management' (NICE clinical guideline 91) which makes recommendations on the identification treatment and management of depression in adults aged 18 years and older who also have a chronic physical health problem.	This guideline is published alongside 'Depression in adults with a chronic physical health problem: recognition and management' (NICE clinical guideline 91) which makes recommendations on the identification treatment and management of depression in adults aged 18 years and older who also have a chronic physical health problem.	
multiprofessional care	0	0.8182	4	For people with severe depression and those with moderate depression and complex problems, consider: referring to specialist mental health services for a programme of coordinated multiprofessional care providing collaborative care if the depression is in the context of a chronic physical health problem with associated functional impairment .	Referral to specialist mental health services should normally be for people with depression who are at significant risk of self-harm, have psychotic symptoms, require complex multiprofessional care, or where an expert opinion on treatment and management is needed.	For people with severe depression and those with moderate depression and complex problems, consider: referring to specialist mental health services for a programme of coordinated multiprofessional care providing collaborative care if the depression is in the context of a chronic physical health problem with associated functional impairment .	Referral to specialist mental health services should normally be for people with depression who are at significant risk of self-harm, have psychotic symptoms, require complex multiprofessional care, or where an expert opinion on treatment and management is needed.	
previous treatments	0	0.8119	4	Last updated April 2018 outcome measure be aware that using a single antidepressant rather than combination medication or augmentation (see recommendations to ) is usually associated with a lower side-effect burden consider reintroducing previous treatments that have been inadequately delivered or adhered to, including increasing the dose consider switching to an alternative antidepressant.	In specialist mental health services, after thoroughly reviewing previous treatments for depression, consider reintroducing previous treatments that have been inadequately delivered or adhered to.	Last updated April 2018 outcome measure be aware that using a single antidepressant rather than combination medication or augmentation (see recommendations to ) is usually associated with a lower side-effect burden consider reintroducing previous treatments that have been inadequately delivered or adhered to, including increasing the dose consider switching to an alternative antidepressant.	In specialist mental health services, after thoroughly reviewing previous treatments for depression, consider reintroducing previous treatments that have been inadequately delivered or adhered to.	
residual symptoms	0	0.7781	6	Last updated April 2018 continue antidepressant treatment) or who have residual symptoms, should be offered one of the following psychological interventions: individual CBT for people who have relapsed despite antidepressant medication and for people with a significant history of depression and residual symptoms despite treatment mindfulness-based cognitive therapy for people who are currently well but have experienced three or more previous episodes of depression.	Treatment choice should be influenced by: previous treatment history, including the consequences of a relapse, residual symptoms, response to previous treatment and any discontinuation symptoms the person's preference.	People with depression who are considered to be at significant risk of relapse (including those who have relapsed despite antidepressant treatment or who are unable or choose not to continue antidepressant treatment) or who have residual symptoms, should be offered one of the following psychological interventions: individual CBT for people who have relapsed despite antidepressant medication and for people with a significant history of depression and residual symptoms despite treatment mindfulness-based cognitive therapy for people who are currently well but have experienced three or more previous episodes of depression.	Last updated April 2018 continue antidepressant treatment) or who have residual symptoms, should be offered one of the following psychological interventions: individual CBT for people who have relapsed despite antidepressant medication and for people with a significant history of depression and residual symptoms despite treatment mindfulness-based cognitive therapy for people who are currently well but have experienced three or more previous episodes of depression.	Treatment choice should be influenced by: previous treatment history, including the consequences of a relapse, residual symptoms, response to previous treatment and any discontinuation symptoms the person's preference.	People with depression who are considered to be at significant risk of relapse (including those who have relapsed despite antidepressant treatment or who are unable or choose not to continue antidepressant treatment) or who have residual symptoms, should be offered one of the following psychological interventions: individual CBT for people who have relapsed despite antidepressant medication and for people with a significant history of depression and residual symptoms despite treatment mindfulness-based cognitive therapy for people who are currently well but have experienced three or more previous episodes of depression.	
depression identification	0	0.7668	4	If a person answers 'yes' to either of the depression identification questions (see recommendation ) but the practitioner is not competent to perform a mental health assessment, they should refer the person to an appropriate professional	If a person answers 'yes' to either of the depression identification questions (see recommendation ), a practitioner who is competent to perform a mental health assessment should review the person's mental state and associated functional, interpersonal and social difficulties.	If a person answers 'yes' to either of the depression identification questions (see recommendation ) but the practitioner is not competent to perform a mental health assessment, they should refer the person to an appropriate professional	If a person answers 'yes' to either of the depression identification questions (see recommendation ), a practitioner who is competent to perform a mental health assessment should review the person's mental state and associated functional, interpersonal and social difficulties.	
health assessment	0	0.7668	4	If a person answers 'yes' to either of the depression identification questions (see recommendation ) but the practitioner is not competent to perform a mental health assessment, they should refer the person to an appropriate professional	If a person answers 'yes' to either of the depression identification questions (see recommendation ), a practitioner who is competent to perform a mental health assessment should review the person's mental state and associated functional, interpersonal and social difficulties.	If a person answers 'yes' to either of the depression identification questions (see recommendation ) but the practitioner is not competent to perform a mental health assessment, they should refer the person to an appropriate professional	If a person answers 'yes' to either of the depression identification questions (see recommendation ), a practitioner who is competent to perform a mental health assessment should review the person's mental state and associated functional, interpersonal and social difficulties.	
identification questions	0	0.7668	4	If a person answers 'yes' to either of the depression identification questions (see recommendation ) but the practitioner is not competent to perform a mental health assessment, they should refer the person to an appropriate professional	If a person answers 'yes' to either of the depression identification questions (see recommendation ), a practitioner who is competent to perform a mental health assessment should review the person's mental state and associated functional, interpersonal and social difficulties.	If a person answers 'yes' to either of the depression identification questions (see recommendation ) but the practitioner is not competent to perform a mental health assessment, they should refer the person to an appropriate professional	If a person answers 'yes' to either of the depression identification questions (see recommendation ), a practitioner who is competent to perform a mental health assessment should review the person's mental state and associated functional, interpersonal and social difficulties.	
person answers	0	0.7668	4	If a person answers 'yes' to either of the depression identification questions (see recommendation ) but the practitioner is not competent to perform a mental health assessment, they should refer the person to an appropriate professional	If a person answers 'yes' to either of the depression identification questions (see recommendation ), a practitioner who is competent to perform a mental health assessment should review the person's mental state and associated functional, interpersonal and social difficulties.	If a person answers 'yes' to either of the depression identification questions (see recommendation ) but the practitioner is not competent to perform a mental health assessment, they should refer the person to an appropriate professional	If a person answers 'yes' to either of the depression identification questions (see recommendation ), a practitioner who is competent to perform a mental health assessment should review the person's mental state and associated functional, interpersonal and social difficulties.	
cbt model	0	0.7546	2	CCBT for people with persistent subthreshold depressive symptoms or mild to moderate depression should: be provided via a stand-alone computer-based or web-based programme include an explanation of the CBT model, encourage tasks between sessions, and use thought-challenging and active monitoring of behaviour, thought patterns and	CCBT for people with persistent subthreshold depressive symptoms or mild to moderate depression should: be provided via a stand-alone computer-based or web-based programme include an explanation of the CBT model, encourage tasks between sessions, and use thought-challenging and active monitoring of behaviour, thought patterns and	
limited facilitation	0	0.7546	2	Last updated April 2018 outcomes be supported by a trained practitioner, who typically provides limited facilitation of the programme and reviews progress and outcome typically take place over 9 to 12 weeks, including follow-up.	Last updated April 2018 outcomes be supported by a trained practitioner, who typically provides limited facilitation of the programme and reviews progress and outcome typically take place over 9 to 12 weeks, including follow-up.	
significant side	0	0.7546	2	If response is absent or minimal after 3 to 4 weeks of treatment with a therapeutic dose of an antidepressant, increase the level of support (for example, by weekly face-to-face or telephone contact) and consider: increasing the dose in line with the SPC if there are no significant side effects or switching to another antidepressant as described in section if there are side effects or if the person prefers.	If response is absent or minimal after 3 to 4 weeks of treatment with a therapeutic dose of an antidepressant, increase the level of support (for example, by weekly face-to-face or telephone contact) and consider: increasing the dose in line with the SPC if there are no significant side effects or switching to another antidepressant as described in section if there are side effects or if the person prefers.	
stand-alone computer-based	0	0.7546	2	CCBT for people with persistent subthreshold depressive symptoms or mild to moderate depression should: be provided via a stand-alone computer-based or web-based programme include an explanation of the CBT model, encourage tasks between sessions, and use thought-challenging and active monitoring of behaviour, thought patterns and	CCBT for people with persistent subthreshold depressive symptoms or mild to moderate depression should: be provided via a stand-alone computer-based or web-based programme include an explanation of the CBT model, encourage tasks between sessions, and use thought-challenging and active monitoring of behaviour, thought patterns and	
telephone contact	0	0.7546	4	Last updated April 2018 consider increasing the level of support, such as more frequent direct or telephone contacts consider referral to specialist mental health services.	If response is absent or minimal after 3 to 4 weeks of treatment with a therapeutic dose of an antidepressant, increase the level of support (for example, by weekly face-to-face or telephone contact) and consider: increasing the dose in line with the SPC if there are no significant side effects or switching to another antidepressant as described in section if there are side effects or if the person prefers.	Last updated April 2018 consider increasing the level of support, such as more frequent direct or telephone contacts consider referral to specialist mental health services.	If response is absent or minimal after 3 to 4 weeks of treatment with a therapeutic dose of an antidepressant, increase the level of support (for example, by weekly face-to-face or telephone contact) and consider: increasing the dose in line with the SPC if there are no significant side effects or switching to another antidepressant as described in section if there are side effects or if the person prefers.	
therapeutic dose	0	0.7546	2	If response is absent or minimal after 3 to 4 weeks of treatment with a therapeutic dose of an antidepressant, increase the level of support (for example, by weekly face-to-face or telephone contact) and consider: increasing the dose in line with the SPC if there are no significant side effects or switching to another antidepressant as described in section if there are side effects or if the person prefers.	If response is absent or minimal after 3 to 4 weeks of treatment with a therapeutic dose of an antidepressant, increase the level of support (for example, by weekly face-to-face or telephone contact) and consider: increasing the dose in line with the SPC if there are no significant side effects or switching to another antidepressant as described in section if there are side effects or if the person prefers.	
web-based programme	0	0.7546	2	CCBT for people with persistent subthreshold depressive symptoms or mild to moderate depression should: be provided via a stand-alone computer-based or web-based programme include an explanation of the CBT model, encourage tasks between sessions, and use thought-challenging and active monitoring of behaviour, thought patterns and	CCBT for people with persistent subthreshold depressive symptoms or mild to moderate depression should: be provided via a stand-alone computer-based or web-based programme include an explanation of the CBT model, encourage tasks between sessions, and use thought-challenging and active monitoring of behaviour, thought patterns and	
weekly face-to-face	0	0.7546	2	If response is absent or minimal after 3 to 4 weeks of treatment with a therapeutic dose of an antidepressant, increase the level of support (for example, by weekly face-to-face or telephone contact) and consider: increasing the dose in line with the SPC if there are no significant side effects or switching to another antidepressant as described in section if there are side effects or if the person prefers.	If response is absent or minimal after 3 to 4 weeks of treatment with a therapeutic dose of an antidepressant, increase the level of support (for example, by weekly face-to-face or telephone contact) and consider: increasing the dose in line with the SPC if there are no significant side effects or switching to another antidepressant as described in section if there are side effects or if the person prefers.	
psychological intervention	0	0.7403	26	For people with moderate or severe depression, provide a combination of antidepressant medication and a high-intensity psychological intervention (CBT or IPT).	Psychological interventions for relapse prevention	Last updated April 2018 continue antidepressant treatment) or who have residual symptoms, should be offered one of the following psychological interventions: individual CBT for people who have relapsed despite antidepressant medication and for people with a significant history of depression and residual symptoms despite treatment mindfulness-based cognitive therapy for people who are currently well but have experienced three or more previous episodes of depression.	Medication, high-intensity psychological interventions, combined treatments, collaborative careb and referral for further assessment and interventions	Low-intensity psychosocial interventions, psychological interventions, medication and referral for further assessment and interventions	For people with persistent subthreshold depressive symptoms or mild to moderate depression who have not benefited from a low-intensity psychosocial intervention, discuss the relative merits of different interventions with the person and provide: an antidepressant (normally a selective serotonin reuptake inhibitor SSRI) or a high-intensity psychological intervention, normally one of the following options:	For people with moderate or severe depression, provide a combination of antidepressant medication and a high-intensity psychological intervention (CBT or IPT).	For all high-intensity psychological interventions, the duration of treatment should normally be within the limits indicated in this guideline	For a person whose depression has not responded to either pharmacological or psychological interventions, consider combining antidepressant medication with CBT.	Psychological interventions for relapse prevention	People with depression who are considered to be at significant risk of relapse (including those who have relapsed despite antidepressant treatment or who are unable or choose not to continue antidepressant treatment) or who have residual symptoms, should be offered one of the following psychological interventions: individual CBT for people who have relapsed despite antidepressant medication and for people with a significant history of depression and residual symptoms despite treatment mindfulness-based cognitive therapy for people who are currently well but have experienced three or more previous episodes of depression.	Delivering psychological interventions for relapse prevention	The full range of high-intensity psychological interventions should normally be offered in inpatient settings	For people with moderate or severe depression, provide a combination of antidepressant medication and a high-intensity psychological intervention (CBT or IPT).	Psychological interventions for relapse prevention	Last updated April 2018 continue antidepressant treatment) or who have residual symptoms, should be offered one of the following psychological interventions: individual CBT for people who have relapsed despite antidepressant medication and for people with a significant history of depression and residual symptoms despite treatment mindfulness-based cognitive therapy for people who are currently well but have experienced three or more previous episodes of depression.	Medication, high-intensity psychological interventions, combined treatments, collaborative careb and referral for further assessment and interventions	Low-intensity psychosocial interventions, psychological interventions, medication and referral for further assessment and interventions	For people with persistent subthreshold depressive symptoms or mild to moderate depression who have not benefited from a low-intensity psychosocial intervention, discuss the relative merits of different interventions with the person and provide: an antidepressant (normally a selective serotonin reuptake inhibitor SSRI) or a high-intensity psychological intervention, normally one of the following options:	For people with moderate or severe depression, provide a combination of antidepressant medication and a high-intensity psychological intervention (CBT or IPT).	For all high-intensity psychological interventions, the duration of treatment should normally be within the limits indicated in this guideline	For a person whose depression has not responded to either pharmacological or psychological interventions, consider combining antidepressant medication with CBT.	Psychological interventions for relapse prevention	People with depression who are considered to be at significant risk of relapse (including those who have relapsed despite antidepressant treatment or who are unable or choose not to continue antidepressant treatment) or who have residual symptoms, should be offered one of the following psychological interventions: individual CBT for people who have relapsed despite antidepressant medication and for people with a significant history of depression and residual symptoms despite treatment mindfulness-based cognitive therapy for people who are currently well but have experienced three or more previous episodes of depression.	Delivering psychological interventions for relapse prevention	The full range of high-intensity psychological interventions should normally be offered in inpatient settings	
antidepressant treatment	0	0.7343	10	People with depression who are considered to be at significant risk of relapse (including those who have relapsed despite antidepressant treatment or who are unable or choose not to	Last updated April 2018 continue antidepressant treatment) or who have residual symptoms, should be offered one of the following psychological interventions: individual CBT for people who have relapsed despite antidepressant medication and for people with a significant history of depression and residual symptoms despite treatment mindfulness-based cognitive therapy for people who are currently well but have experienced three or more previous episodes of depression.	Discuss antidepressant treatment options with the person with depression, covering: the choice of antidepressant, including any anticipated adverse events, for example side effects and discontinuation symptoms (see recommendation ), and potential interactions with concomitant medication or physical health problems their perception of the efficacy and tolerability of any antidepressants they have previously taken.	A person with depression started on antidepressants who is considered to present an increased suicide risk or is younger than 30 years (because of the potential increased prevalence of suicidal thoughts in the early stages of antidepressant treatment for this group) should normally be seen after 1 week and frequently thereafter as appropriate until the risk is no longer considered clinically important.	People with depression who are considered to be at significant risk of relapse (including those who have relapsed despite antidepressant treatment or who are unable or choose not to continue antidepressant treatment) or who have residual symptoms, should be offered one of the following psychological interventions: individual CBT for people who have relapsed despite antidepressant medication and for people with a significant history of depression and residual symptoms despite treatment mindfulness-based cognitive therapy for people who are currently well but have experienced three or more previous episodes of depression.	People with depression who are considered to be at significant risk of relapse (including those who have relapsed despite antidepressant treatment or who are unable or choose not to	Last updated April 2018 continue antidepressant treatment) or who have residual symptoms, should be offered one of the following psychological interventions: individual CBT for people who have relapsed despite antidepressant medication and for people with a significant history of depression and residual symptoms despite treatment mindfulness-based cognitive therapy for people who are currently well but have experienced three or more previous episodes of depression.	Discuss antidepressant treatment options with the person with depression, covering: the choice of antidepressant, including any anticipated adverse events, for example side effects and discontinuation symptoms (see recommendation ), and potential interactions with concomitant medication or physical health problems their perception of the efficacy and tolerability of any antidepressants they have previously taken.	A person with depression started on antidepressants who is considered to present an increased suicide risk or is younger than 30 years (because of the potential increased prevalence of suicidal thoughts in the early stages of antidepressant treatment for this group) should normally be seen after 1 week and frequently thereafter as appropriate until the risk is no longer considered clinically important.	People with depression who are considered to be at significant risk of relapse (including those who have relapsed despite antidepressant treatment or who are unable or choose not to continue antidepressant treatment) or who have residual symptoms, should be offered one of the following psychological interventions: individual CBT for people who have relapsed despite antidepressant medication and for people with a significant history of depression and residual symptoms despite treatment mindfulness-based cognitive therapy for people who are currently well but have experienced three or more previous episodes of depression.	
competent practitioners	0	0.7241	6	All interventions for depression should be delivered by competent practitioners	All interventions for depression should be delivered by competent practitioners.	Group-based CBT for people with persistent subthreshold depressive symptoms or mild to moderate depression should: be based on a structured model such as 'Coping with Depression' be delivered by two trained and competent practitioners consist of 10 to 12 meetings of eight to ten participants normally take place over 12 to 16 weeks, including follow-up.	All interventions for depression should be delivered by competent practitioners	All interventions for depression should be delivered by competent practitioners.	Group-based CBT for people with persistent subthreshold depressive symptoms or mild to moderate depression should: be based on a structured model such as 'Coping with Depression' be delivered by two trained and competent practitioners consist of 10 to 12 meetings of eight to ten participants normally take place over 12 to 16 weeks, including follow-up.	
atypical symptoms	0	0.7175	2	IV is used in nearly all the evidence reviewed and it provides definitions for atypical symptoms and seasonal depression	IV is used in nearly all the evidence reviewed and it provides definitions for atypical symptoms and seasonal depression	
careful review	0	0.7175	2	After careful review of the diagnostic criteria and the evidence, the	After careful review of the diagnostic criteria and the evidence, the	
classificatory systems	0	0.7175	2	It should be noted that classificatory systems are agreed conventions that seek to define different severities of depression in order to guide diagnosis and treatment, and their value is determined by how useful they are in practice	It should be noted that classificatory systems are agreed conventions that seek to define different severities of depression in order to guide diagnosis and treatment, and their value is determined by how useful they are in practice	
diagnostic assessment	0	0.7175	2	Therefore it is also important to consider both personal past history and family history of depression when undertaking a diagnostic assessment (see appendix for further details).	Therefore it is also important to consider both personal past history and family history of depression when undertaking a diagnostic assessment (see appendix for further details).	
diagnostic criteria	0	0.7175	2	After careful review of the diagnostic criteria and the evidence, the	After careful review of the diagnostic criteria and the evidence, the	
family history	0	0.7175	2	Therefore it is also important to consider both personal past history and family history of depression when undertaking a diagnostic assessment (see appendix for further details).	Therefore it is also important to consider both personal past history and family history of depression when undertaking a diagnostic assessment (see appendix for further details).	
personal past	0	0.7175	2	Therefore it is also important to consider both personal past history and family history of depression when undertaking a diagnostic assessment (see appendix for further details).	Therefore it is also important to consider both personal past history and family history of depression when undertaking a diagnostic assessment (see appendix for further details).	
practical terms	0	0.7175	2	In practical terms, clinicians are not expected to switch to DSM-IV but should be aware that the threshold for mild depression is higher than ICD-10 (five symptoms instead of four) and that degree of functional impairment should be routinely assessed before making a diagnosis	In practical terms, clinicians are not expected to switch to DSM-IV but should be aware that the threshold for mild depression is higher than ICD-10 (five symptoms instead of four) and that degree of functional impairment should be routinely assessed before making a diagnosis	
seasonal depression	0	0.7175	2	IV is used in nearly all the evidence reviewed and it provides definitions for atypical symptoms and seasonal depression	IV is used in nearly all the evidence reviewed and it provides definitions for atypical symptoms and seasonal depression	
alternative antidepressant	0	0.7174	2	Last updated April 2018 outcome measure be aware that using a single antidepressant rather than combination medication or augmentation (see recommendations to ) is usually associated with a lower side-effect burden consider reintroducing previous treatments that have been inadequately delivered or adhered to, including increasing the dose consider switching to an alternative antidepressant.	Last updated April 2018 outcome measure be aware that using a single antidepressant rather than combination medication or augmentation (see recommendations to ) is usually associated with a lower side-effect burden consider reintroducing previous treatments that have been inadequately delivered or adhered to, including increasing the dose consider switching to an alternative antidepressant.	
check adherence	0	0.7174	2	When reviewing drug treatment for a person with depression whose symptoms have not adequately responded to initial pharmacological interventions: check adherence to, and side effects from, initial treatment increase the frequency of appointments using outcome monitoring with a validated	When reviewing drug treatment for a person with depression whose symptoms have not adequately responded to initial pharmacological interventions: check adherence to, and side effects from, initial treatment increase the frequency of appointments using outcome monitoring with a validated	
chronic symptoms	0	0.7174	2	Last updated April 2018 treatment, provide appropriate information and consider one of the following strategies: monitor symptoms closely where side effects are mild and acceptable to the person or stop the antidepressant or change to a different antidepressant if the person prefers or in discussion with the person, consider short-term concomitant treatment with a benzodiazepine if anxiety, agitation and or insomnia are problematic (except in people with chronic symptoms of anxiety); this should usually be for no longer than 2 weeks in order to prevent the development of dependence.	Last updated April 2018 treatment, provide appropriate information and consider one of the following strategies: monitor symptoms closely where side effects are mild and acceptable to the person or stop the antidepressant or change to a different antidepressant if the person prefers or in discussion with the person, consider short-term concomitant treatment with a benzodiazepine if anxiety, agitation and or insomnia are problematic (except in people with chronic symptoms of anxiety); this should usually be for no longer than 2 weeks in order to prevent the development of dependence.	
combination medication	0	0.7174	2	Last updated April 2018 outcome measure be aware that using a single antidepressant rather than combination medication or augmentation (see recommendations to ) is usually associated with a lower side-effect burden consider reintroducing previous treatments that have been inadequately delivered or adhered to, including increasing the dose consider switching to an alternative antidepressant.	Last updated April 2018 outcome measure be aware that using a single antidepressant rather than combination medication or augmentation (see recommendations to ) is usually associated with a lower side-effect burden consider reintroducing previous treatments that have been inadequately delivered or adhered to, including increasing the dose consider switching to an alternative antidepressant.	
concomitant treatment	0	0.7174	2	Last updated April 2018 treatment, provide appropriate information and consider one of the following strategies: monitor symptoms closely where side effects are mild and acceptable to the person or stop the antidepressant or change to a different antidepressant if the person prefers or in discussion with the person, consider short-term concomitant treatment with a benzodiazepine if anxiety, agitation and or insomnia are problematic (except in people with chronic symptoms of anxiety); this should usually be for no longer than 2 weeks in order to prevent the development of dependence.	Last updated April 2018 treatment, provide appropriate information and consider one of the following strategies: monitor symptoms closely where side effects are mild and acceptable to the person or stop the antidepressant or change to a different antidepressant if the person prefers or in discussion with the person, consider short-term concomitant treatment with a benzodiazepine if anxiety, agitation and or insomnia are problematic (except in people with chronic symptoms of anxiety); this should usually be for no longer than 2 weeks in order to prevent the development of dependence.	
depression aspects	0	0.7174	2	The recommendations in this section update the depression aspects only of 'Guidance on the use of electroconvulsive therapy' (NICE technology appraisal guidance 59).	The recommendations in this section update the depression aspects only of 'Guidance on the use of electroconvulsive therapy' (NICE technology appraisal guidance 59).	
drug treatment	0	0.7174	26	For an adult with type 2 diabetes on antihypertensive drug treatment when diabetes is diagnosed, review blood pressure control and medications used.	First-line antihypertensive drug treatment should be a once-daily, generic angiotensin-converting enzyme (ACE) inhibitor	A calcium-channel blocker should be the first-line antihypertensive drug treatment for a woman for whom, after an informed discussion, it is agreed there is a possibility of her becoming pregnant.	Offer lifestyle advice and drug treatment to support adults with type 2 diabetes to achieve and maintain their HbA1c target (see section )	In adults with type 2 diabetes, if HbA1c levels are not adequately controlled by a single drug and rise to 58 mmol mol ( percent) or higher: reinforce advice about diet, lifestyle and adherence to drug treatment and support the person to aim for an HbA1c level of 53 mmol mol ( percent) and intensify drug treatment.	For adults with type 2 diabetes, discuss the benefits and risks of drug treatment, and the options available	Last updated May 2017 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost).	Offer standard-release metformin as the initial drug treatment for adults with type 2 diabetes.	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, consider initial drug treatment with: a dipeptidyl peptidase-4 (DPP-4) inhibitor or pioglitazone or a sulfonylurea.	In adults with type 2 diabetes, if initial drug treatment with metformin has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: metformin and a DPP-4 inhibitor or metformin and pioglitazone or metformin and a sulfonylurea.	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated and initial drug treatment has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: a DPP-4 inhibitor and pioglitazone or a DPP-4 inhibitor and a sulfonylurea or pioglitazone and a sulfonylurea.	For an adult with type 2 diabetes on antihypertensive drug treatment when diabetes is diagnosed, review blood pressure control and medications used.	First-line antihypertensive drug treatment should be a once-daily, generic angiotensin-converting enzyme (ACE) inhibitor	A calcium-channel blocker should be the first-line antihypertensive drug treatment for a woman for whom, after an informed discussion, it is agreed there is a possibility of her becoming pregnant.	Offer lifestyle advice and drug treatment to support adults with type 2 diabetes to achieve and maintain their HbA1c target (see section )	In adults with type 2 diabetes, if HbA1c levels are not adequately controlled by a single drug and rise to 58 mmol mol ( percent) or higher: reinforce advice about diet, lifestyle and adherence to drug treatment and support the person to aim for an HbA1c level of 53 mmol mol ( percent) and intensify drug treatment.	For adults with type 2 diabetes, discuss the benefits and risks of drug treatment, and the options available	Last updated May 2017 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost).	Offer standard-release metformin as the initial drug treatment for adults with type 2 diabetes.	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, consider initial drug treatment with: a dipeptidyl peptidase-4 (DPP-4) inhibitor or pioglitazone or a sulfonylurea.	In adults with type 2 diabetes, if initial drug treatment with metformin has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: metformin and a DPP-4 inhibitor or metformin and pioglitazone or metformin and a sulfonylurea.	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated and initial drug treatment has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: a DPP-4 inhibitor and pioglitazone or a DPP-4 inhibitor and a sulfonylurea or pioglitazone and a sulfonylurea.	When reviewing drug treatment for a person with depression whose symptoms have not adequately responded to initial pharmacological interventions: check adherence to, and side effects from, initial treatment increase the frequency of appointments using outcome monitoring with a validated	Do not use ECT routinely for people with moderate depression but consider it if their depression has not responded to multiple drug treatments and psychological treatment.	When reviewing drug treatment for a person with depression whose symptoms have not adequately responded to initial pharmacological interventions: check adherence to, and side effects from, initial treatment increase the frequency of appointments using outcome monitoring with a validated	Do not use ECT routinely for people with moderate depression but consider it if their depression has not responded to multiple drug treatments and psychological treatment.	
initial pharmacological	0	0.7174	2	When reviewing drug treatment for a person with depression whose symptoms have not adequately responded to initial pharmacological interventions: check adherence to, and side effects from, initial treatment increase the frequency of appointments using outcome monitoring with a validated	When reviewing drug treatment for a person with depression whose symptoms have not adequately responded to initial pharmacological interventions: check adherence to, and side effects from, initial treatment increase the frequency of appointments using outcome monitoring with a validated	
initial treatment	0	0.7174	2	When reviewing drug treatment for a person with depression whose symptoms have not adequately responded to initial pharmacological interventions: check adherence to, and side effects from, initial treatment increase the frequency of appointments using outcome monitoring with a validated	When reviewing drug treatment for a person with depression whose symptoms have not adequately responded to initial pharmacological interventions: check adherence to, and side effects from, initial treatment increase the frequency of appointments using outcome monitoring with a validated	
outcome measure	0	0.7174	6	Practitioners should consider using competence frameworks developed from the relevant treatment manual(s) and for all interventions should: receive regular high-quality supervision use routine outcome measures and ensure that the person with depression is involved in reviewing the efficacy of the treatment engage in monitoring and evaluation of treatment adherence and practitioner competence  for example, by using video and audio tapes, and external audit and scrutiny where appropriate.	Practitioners should consider using competence frameworks developed from the relevant treatment manual(s) and for all interventions should: receive regular high-quality supervision use routine outcome measures and ensure that the person with depression is involved in reviewing the efficacy of the treatment engage in monitoring and evaluation of treatment adherence and practitioner competence  for example, by using video and audio tapes, and external audit and scrutiny where appropriate.	Last updated April 2018 outcome measure be aware that using a single antidepressant rather than combination medication or augmentation (see recommendations to ) is usually associated with a lower side-effect burden consider reintroducing previous treatments that have been inadequately delivered or adhered to, including increasing the dose consider switching to an alternative antidepressant.	Practitioners should consider using competence frameworks developed from the relevant treatment manual(s) and for all interventions should: receive regular high-quality supervision use routine outcome measures and ensure that the person with depression is involved in reviewing the efficacy of the treatment engage in monitoring and evaluation of treatment adherence and practitioner competence  for example, by using video and audio tapes, and external audit and scrutiny where appropriate.	Practitioners should consider using competence frameworks developed from the relevant treatment manual(s) and for all interventions should: receive regular high-quality supervision use routine outcome measures and ensure that the person with depression is involved in reviewing the efficacy of the treatment engage in monitoring and evaluation of treatment adherence and practitioner competence  for example, by using video and audio tapes, and external audit and scrutiny where appropriate.	Last updated April 2018 outcome measure be aware that using a single antidepressant rather than combination medication or augmentation (see recommendations to ) is usually associated with a lower side-effect burden consider reintroducing previous treatments that have been inadequately delivered or adhered to, including increasing the dose consider switching to an alternative antidepressant.	
outcome monitoring	0	0.7174	2	When reviewing drug treatment for a person with depression whose symptoms have not adequately responded to initial pharmacological interventions: check adherence to, and side effects from, initial treatment increase the frequency of appointments using outcome monitoring with a validated	When reviewing drug treatment for a person with depression whose symptoms have not adequately responded to initial pharmacological interventions: check adherence to, and side effects from, initial treatment increase the frequency of appointments using outcome monitoring with a validated	
pharmacological interventions	0	0.7174	2	When reviewing drug treatment for a person with depression whose symptoms have not adequately responded to initial pharmacological interventions: check adherence to, and side effects from, initial treatment increase the frequency of appointments using outcome monitoring with a validated	When reviewing drug treatment for a person with depression whose symptoms have not adequately responded to initial pharmacological interventions: check adherence to, and side effects from, initial treatment increase the frequency of appointments using outcome monitoring with a validated	
short-term concomitant	0	0.7174	2	Last updated April 2018 treatment, provide appropriate information and consider one of the following strategies: monitor symptoms closely where side effects are mild and acceptable to the person or stop the antidepressant or change to a different antidepressant if the person prefers or in discussion with the person, consider short-term concomitant treatment with a benzodiazepine if anxiety, agitation and or insomnia are problematic (except in people with chronic symptoms of anxiety); this should usually be for no longer than 2 weeks in order to prevent the development of dependence.	Last updated April 2018 treatment, provide appropriate information and consider one of the following strategies: monitor symptoms closely where side effects are mild and acceptable to the person or stop the antidepressant or change to a different antidepressant if the person prefers or in discussion with the person, consider short-term concomitant treatment with a benzodiazepine if anxiety, agitation and or insomnia are problematic (except in people with chronic symptoms of anxiety); this should usually be for no longer than 2 weeks in order to prevent the development of dependence.	
single antidepressant	0	0.7174	2	Last updated April 2018 outcome measure be aware that using a single antidepressant rather than combination medication or augmentation (see recommendations to ) is usually associated with a lower side-effect burden consider reintroducing previous treatments that have been inadequately delivered or adhered to, including increasing the dose consider switching to an alternative antidepressant.	Last updated April 2018 outcome measure be aware that using a single antidepressant rather than combination medication or augmentation (see recommendations to ) is usually associated with a lower side-effect burden consider reintroducing previous treatments that have been inadequately delivered or adhered to, including increasing the dose consider switching to an alternative antidepressant.	
alternative media	0	0.6767	2	Individual guided self-help programmes based on the principles of CBT (and including behavioural activation and problem-solving techniques) for people with persistent subthreshold depressive symptoms or mild to moderate depression should: include the provision of written materials of an appropriate reading age (or alternative media to support access) be supported by a trained practitioner, who typically facilitates the self-help programme and reviews progress and outcome consist of up to six to eight sessions (face-to-face and via telephone) normally taking place over 9 to 12 weeks, including follow-up.	Individual guided self-help programmes based on the principles of CBT (and including behavioural activation and problem-solving techniques) for people with persistent subthreshold depressive symptoms or mild to moderate depression should: include the provision of written materials of an appropriate reading age (or alternative media to support access) be supported by a trained practitioner, who typically facilitates the self-help programme and reviews progress and outcome consist of up to six to eight sessions (face-to-face and via telephone) normally taking place over 9 to 12 weeks, including follow-up.	
cognitive impairment	1	0.6767	4	When assessing a person with suspected depression, be aware of any learning disabilities or acquired cognitive impairments, and if necessary consider consulting with a relevant specialist when developing treatment plans and strategies.	When providing interventions for people with a learning disability or acquired cognitive impairment who have a diagnosis of depression: where possible, provide the same interventions as for other people with depression if necessary, adjust the method of delivery or duration of the intervention to take account of the disability or impairment.	When assessing a person with suspected depression, be aware of any learning disabilities or acquired cognitive impairments, and if necessary consider consulting with a relevant specialist when developing treatment plans and strategies.	When providing interventions for people with a learning disability or acquired cognitive impairment who have a diagnosis of depression: where possible, provide the same interventions as for other people with depression if necessary, adjust the method of delivery or duration of the intervention to take account of the disability or impairment.	
inform people	0	0.6767	2	Inform people with depression about self-help groups, support groups and other local and national resources.	Inform people with depression about self-help groups, support groups and other local and national resources.	
national resources	1	0.6767	2	Inform people with depression about self-help groups, support groups and other local and national resources.	Inform people with depression about self-help groups, support groups and other local and national resources.	
reading age	0	0.6767	2	Individual guided self-help programmes based on the principles of CBT (and including behavioural activation and problem-solving techniques) for people with persistent subthreshold depressive symptoms or mild to moderate depression should: include the provision of written materials of an appropriate reading age (or alternative media to support access) be supported by a trained practitioner, who typically facilitates the self-help programme and reviews progress and outcome consist of up to six to eight sessions (face-to-face and via telephone) normally taking place over 9 to 12 weeks, including follow-up.	Individual guided self-help programmes based on the principles of CBT (and including behavioural activation and problem-solving techniques) for people with persistent subthreshold depressive symptoms or mild to moderate depression should: include the provision of written materials of an appropriate reading age (or alternative media to support access) be supported by a trained practitioner, who typically facilitates the self-help programme and reviews progress and outcome consist of up to six to eight sessions (face-to-face and via telephone) normally taking place over 9 to 12 weeks, including follow-up.	
self-help groups	0	0.6767	2	Inform people with depression about self-help groups, support groups and other local and national resources.	Inform people with depression about self-help groups, support groups and other local and national resources.	
self-help programme	0	0.6767	2	Individual guided self-help programmes based on the principles of CBT (and including behavioural activation and problem-solving techniques) for people with persistent subthreshold depressive symptoms or mild to moderate depression should: include the provision of written materials of an appropriate reading age (or alternative media to support access) be supported by a trained practitioner, who typically facilitates the self-help programme and reviews progress and outcome consist of up to six to eight sessions (face-to-face and via telephone) normally taking place over 9 to 12 weeks, including follow-up.	Individual guided self-help programmes based on the principles of CBT (and including behavioural activation and problem-solving techniques) for people with persistent subthreshold depressive symptoms or mild to moderate depression should: include the provision of written materials of an appropriate reading age (or alternative media to support access) be supported by a trained practitioner, who typically facilitates the self-help programme and reviews progress and outcome consist of up to six to eight sessions (face-to-face and via telephone) normally taking place over 9 to 12 weeks, including follow-up.	
self-help programmes	0	0.6767	2	Individual guided self-help programmes based on the principles of CBT (and including behavioural activation and problem-solving techniques) for people with persistent subthreshold depressive symptoms or mild to moderate depression should: include the provision of written materials of an appropriate reading age (or alternative media to support access) be supported by a trained practitioner, who typically facilitates the self-help programme and reviews progress and outcome consist of up to six to eight sessions (face-to-face and via telephone) normally taking place over 9 to 12 weeks, including follow-up.	Individual guided self-help programmes based on the principles of CBT (and including behavioural activation and problem-solving techniques) for people with persistent subthreshold depressive symptoms or mild to moderate depression should: include the provision of written materials of an appropriate reading age (or alternative media to support access) be supported by a trained practitioner, who typically facilitates the self-help programme and reviews progress and outcome consist of up to six to eight sessions (face-to-face and via telephone) normally taking place over 9 to 12 weeks, including follow-up.	
written materials	0	0.6767	2	Individual guided self-help programmes based on the principles of CBT (and including behavioural activation and problem-solving techniques) for people with persistent subthreshold depressive symptoms or mild to moderate depression should: include the provision of written materials of an appropriate reading age (or alternative media to support access) be supported by a trained practitioner, who typically facilitates the self-help programme and reviews progress and outcome consist of up to six to eight sessions (face-to-face and via telephone) normally taking place over 9 to 12 weeks, including follow-up.	Individual guided self-help programmes based on the principles of CBT (and including behavioural activation and problem-solving techniques) for people with persistent subthreshold depressive symptoms or mild to moderate depression should: include the provision of written materials of an appropriate reading age (or alternative media to support access) be supported by a trained practitioner, who typically facilitates the self-help programme and reviews progress and outcome consist of up to six to eight sessions (face-to-face and via telephone) normally taking place over 9 to 12 weeks, including follow-up.	
suicidal ideation	0	0.67	4	Advise people with depression of the potential for increased agitation, anxiety and suicidal ideation in the initial stages of treatment; actively seek out these symptoms and: ensure that the person knows how to seek help promptly review the person's treatment if they develop marked and or prolonged agitation.	Advise a person with depression and their family or carer to be vigilant for mood changes, negativity and hopelessness, and suicidal ideation, and to contact their practitioner if concerned	Advise people with depression of the potential for increased agitation, anxiety and suicidal ideation in the initial stages of treatment; actively seek out these symptoms and: ensure that the person knows how to seek help promptly review the person's treatment if they develop marked and or prolonged agitation.	Advise a person with depression and their family or carer to be vigilant for mood changes, negativity and hopelessness, and suicidal ideation, and to contact their practitioner if concerned	
early stages	0	0.6618	2	A person with depression started on antidepressants who is considered to present an increased suicide risk or is younger than 30 years (because of the potential increased prevalence of suicidal thoughts in the early stages of antidepressant treatment for this group) should normally be seen after 1 week and frequently thereafter as appropriate until the risk is no longer considered clinically important.	A person with depression started on antidepressants who is considered to present an increased suicide risk or is younger than 30 years (because of the potential increased prevalence of suicidal thoughts in the early stages of antidepressant treatment for this group) should normally be seen after 1 week and frequently thereafter as appropriate until the risk is no longer considered clinically important.	
suicidal thoughts	0	0.6618	2	A person with depression started on antidepressants who is considered to present an increased suicide risk or is younger than 30 years (because of the potential increased prevalence of suicidal thoughts in the early stages of antidepressant treatment for this group) should normally be seen after 1 week and frequently thereafter as appropriate until the risk is no longer considered clinically important.	A person with depression started on antidepressants who is considered to present an increased suicide risk or is younger than 30 years (because of the potential increased prevalence of suicidal thoughts in the early stages of antidepressant treatment for this group) should normally be seen after 1 week and frequently thereafter as appropriate until the risk is no longer considered clinically important.	
health services	1	0.6617	16	For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services.	For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services.	If a person with depression presents considerable immediate risk to themselves or others, refer them urgently to specialist mental health services.	Last updated April 2018 consider increasing the level of support, such as more frequent direct or telephone contacts consider referral to specialist mental health services.	For people with severe depression and those with moderate depression and complex problems, consider: referring to specialist mental health services for a programme of coordinated multiprofessional care providing collaborative care if the depression is in the context of a chronic physical health problem with associated functional impairment .	Referral to specialist mental health services should normally be for people with depression who are at significant risk of self-harm, have psychotic symptoms, require complex multiprofessional care, or where an expert opinion on treatment and management is needed.	The assessment of a person with depression referred to specialist mental health services should include: their symptom profile, suicide risk and, where appropriate, previous treatment history	In specialist mental health services, after thoroughly reviewing previous treatments for depression, consider reintroducing previous treatments that have been inadequately delivered or adhered to.	Medication in secondary care mental health services should be started under the supervision of a consultant psychiatrist.	If a person with depression presents considerable immediate risk to themselves or others, refer them urgently to specialist mental health services.	Last updated April 2018 consider increasing the level of support, such as more frequent direct or telephone contacts consider referral to specialist mental health services.	For people with severe depression and those with moderate depression and complex problems, consider: referring to specialist mental health services for a programme of coordinated multiprofessional care providing collaborative care if the depression is in the context of a chronic physical health problem with associated functional impairment .	Referral to specialist mental health services should normally be for people with depression who are at significant risk of self-harm, have psychotic symptoms, require complex multiprofessional care, or where an expert opinion on treatment and management is needed.	The assessment of a person with depression referred to specialist mental health services should include: their symptom profile, suicide risk and, where appropriate, previous treatment history	In specialist mental health services, after thoroughly reviewing previous treatments for depression, consider reintroducing previous treatments that have been inadequately delivered or adhered to.	Medication in secondary care mental health services should be started under the supervision of a consultant psychiatrist.	
specialist mental	0	0.6617	14	If a person with depression presents considerable immediate risk to themselves or others, refer them urgently to specialist mental health services.	Last updated April 2018 consider increasing the level of support, such as more frequent direct or telephone contacts consider referral to specialist mental health services.	Non-reversible monoamine oxidase inhibitors (MAOIs), such as phenelzine, should normally be prescribed only by specialist mental health professionals.	For people with severe depression and those with moderate depression and complex problems, consider: referring to specialist mental health services for a programme of coordinated multiprofessional care providing collaborative care if the depression is in the context of a chronic physical health problem with associated functional impairment .	Referral to specialist mental health services should normally be for people with depression who are at significant risk of self-harm, have psychotic symptoms, require complex multiprofessional care, or where an expert opinion on treatment and management is needed.	The assessment of a person with depression referred to specialist mental health services should include: their symptom profile, suicide risk and, where appropriate, previous treatment history	In specialist mental health services, after thoroughly reviewing previous treatments for depression, consider reintroducing previous treatments that have been inadequately delivered or adhered to.	If a person with depression presents considerable immediate risk to themselves or others, refer them urgently to specialist mental health services.	Last updated April 2018 consider increasing the level of support, such as more frequent direct or telephone contacts consider referral to specialist mental health services.	Non-reversible monoamine oxidase inhibitors (MAOIs), such as phenelzine, should normally be prescribed only by specialist mental health professionals.	For people with severe depression and those with moderate depression and complex problems, consider: referring to specialist mental health services for a programme of coordinated multiprofessional care providing collaborative care if the depression is in the context of a chronic physical health problem with associated functional impairment .	Referral to specialist mental health services should normally be for people with depression who are at significant risk of self-harm, have psychotic symptoms, require complex multiprofessional care, or where an expert opinion on treatment and management is needed.	The assessment of a person with depression referred to specialist mental health services should include: their symptom profile, suicide risk and, where appropriate, previous treatment history	In specialist mental health services, after thoroughly reviewing previous treatments for depression, consider reintroducing previous treatments that have been inadequately delivered or adhered to.	
nice guidelines	0	0.6581	8	For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services.	For guidance on the primary and secondary prevention of cardiovascular disease in adults with type 2 diabetes, see the NICE guidelines on cardiovascular disease and myocardial infarction.	For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services.	For guidance on the primary and secondary prevention of cardiovascular disease in adults with type 2 diabetes, see the NICE guidelines on cardiovascular disease and myocardial infarction.	This guideline covers people whose depression occurs as the primary diagnosis; the relevant NICE guidelines should be consulted for depression occurring in the context of other disorders (see our topic page on depression).	Making decisions using NICE guidelines explains how we use words to show the strength (or certainty) of our recommendations, and has information about prescribing medicines (including off-label use), professional guidelines, standards and laws (including on consent and mental capacity), and safeguarding.	This guideline covers people whose depression occurs as the primary diagnosis; the relevant NICE guidelines should be consulted for depression occurring in the context of other disorders (see our topic page on depression).	Making decisions using NICE guidelines explains how we use words to show the strength (or certainty) of our recommendations, and has information about prescribing medicines (including off-label use), professional guidelines, standards and laws (including on consent and mental capacity), and safeguarding.	
adverse effects	0	0.6521	4	The choice of intervention should be influenced by the: duration of the episode of depression and the trajectory of symptoms previous course of depression and response to treatment likelihood of adherence to treatment and any potential adverse effects person's treatment preference and priorities.	GMC guidance if off-label medication is prescribed, and monitor carefully for adverse effects be familiar with primary evidence and consider obtaining a second opinion when using unusual combinations, the evidence for the efficacy of a chosen strategy is limited or the riskbenefit ratio is unclear document the rationale for the chosen combination.	The choice of intervention should be influenced by the: duration of the episode of depression and the trajectory of symptoms previous course of depression and response to treatment likelihood of adherence to treatment and any potential adverse effects person's treatment preference and priorities.	GMC guidance if off-label medication is prescribed, and monitor carefully for adverse effects be familiar with primary evidence and consider obtaining a second opinion when using unusual combinations, the evidence for the efficacy of a chosen strategy is limited or the riskbenefit ratio is unclear document the rationale for the chosen combination.	
consultant psychiatrist	0	0.6521	4	When using combinations of medications (which should only normally be started in primary care in consultation with a consultant psychiatrist): select medications that are known to be safe when used together be aware of the increased side-effect burden this usually causes discuss the rationale for any combination with the person with depression, follow	Medication in secondary care mental health services should be started under the supervision of a consultant psychiatrist.	When using combinations of medications (which should only normally be started in primary care in consultation with a consultant psychiatrist): select medications that are known to be safe when used together be aware of the increased side-effect burden this usually causes discuss the rationale for any combination with the person with depression, follow	Medication in secondary care mental health services should be started under the supervision of a consultant psychiatrist.	
previous treatment	0	0.652	10	Last updated April 2018 outcome measure be aware that using a single antidepressant rather than combination medication or augmentation (see recommendations to ) is usually associated with a lower side-effect burden consider reintroducing previous treatments that have been inadequately delivered or adhered to, including increasing the dose consider switching to an alternative antidepressant.	Treatment choice should be influenced by: previous treatment history, including the consequences of a relapse, residual symptoms, response to previous treatment and any discontinuation symptoms the person's preference.	The assessment of a person with depression referred to specialist mental health services should include: their symptom profile, suicide risk and, where appropriate, previous treatment history	In specialist mental health services, after thoroughly reviewing previous treatments for depression, consider reintroducing previous treatments that have been inadequately delivered or adhered to.	ECT, consider a repeat trial of ECT only after: reviewing the adequacy of the previous treatment course and considering all other options and discussing the risks and benefits with the person and or, where appropriate, their advocate or carer.	Last updated April 2018 outcome measure be aware that using a single antidepressant rather than combination medication or augmentation (see recommendations to ) is usually associated with a lower side-effect burden consider reintroducing previous treatments that have been inadequately delivered or adhered to, including increasing the dose consider switching to an alternative antidepressant.	Treatment choice should be influenced by: previous treatment history, including the consequences of a relapse, residual symptoms, response to previous treatment and any discontinuation symptoms the person's preference.	The assessment of a person with depression referred to specialist mental health services should include: their symptom profile, suicide risk and, where appropriate, previous treatment history	In specialist mental health services, after thoroughly reviewing previous treatments for depression, consider reintroducing previous treatments that have been inadequately delivered or adhered to.	ECT, consider a repeat trial of ECT only after: reviewing the adequacy of the previous treatment course and considering all other options and discussing the risks and benefits with the person and or, where appropriate, their advocate or carer.	
treatment plans	0	0.652	4	Ensure competence in: culturally sensitive assessment using different explanatory models of depression addressing cultural and ethnic differences when developing and implementing treatment plans working with families from diverse ethnic and cultural backgrounds.	When assessing a person with suspected depression, be aware of any learning disabilities or acquired cognitive impairments, and if necessary consider consulting with a relevant specialist when developing treatment plans and strategies.	Ensure competence in: culturally sensitive assessment using different explanatory models of depression addressing cultural and ethnic differences when developing and implementing treatment plans working with families from diverse ethnic and cultural backgrounds.	When assessing a person with suspected depression, be aware of any learning disabilities or acquired cognitive impairments, and if necessary consider consulting with a relevant specialist when developing treatment plans and strategies.	
secondary care	0	0.6447	6	This guideline covers identifying and managing depression in adults aged 18 years and older, in primary and secondary care	This guideline makes recommendations on the identification, treatment and management of depression in adults aged 18 years and older, in primary and secondary care	Medication in secondary care mental health services should be started under the supervision of a consultant psychiatrist.	This guideline covers identifying and managing depression in adults aged 18 years and older, in primary and secondary care	This guideline makes recommendations on the identification, treatment and management of depression in adults aged 18 years and older, in primary and secondary care	Medication in secondary care mental health services should be started under the supervision of a consultant psychiatrist.	
mild depression	0	0.6429	6	In practical terms, clinicians are not expected to switch to DSM-IV but should be aware that the threshold for mild depression is higher than ICD-10 (five symptoms instead of four) and that degree of functional impairment should be routinely assessed before making a diagnosis	Do not use antidepressants routinely to treat persistent subthreshold depressive symptoms or mild depression because the riskbenefit ratio is poor, but consider them for people with: a past history of moderate or severe depression or initial presentation of subthreshold depressive symptoms that have been present for a long period (typically at least 2 years) or subthreshold depressive symptoms or mild depression that persist(s) after other interventions.	Do not use antidepressants routinely to treat persistent subthreshold depressive symptoms or mild depression because the riskbenefit ratio is poor, but consider them for people with: a past history of moderate or severe depression or initial presentation of subthreshold depressive symptoms that have been present for a long period (typically at least 2 years) or	In practical terms, clinicians are not expected to switch to DSM-IV but should be aware that the threshold for mild depression is higher than ICD-10 (five symptoms instead of four) and that degree of functional impairment should be routinely assessed before making a diagnosis	Do not use antidepressants routinely to treat persistent subthreshold depressive symptoms or mild depression because the riskbenefit ratio is poor, but consider them for people with: a past history of moderate or severe depression or initial presentation of subthreshold depressive symptoms that have been present for a long period (typically at least 2 years) or subthreshold depressive symptoms or mild depression that persist(s) after other interventions.	Do not use antidepressants routinely to treat persistent subthreshold depressive symptoms or mild depression because the riskbenefit ratio is poor, but consider them for people with: a past history of moderate or severe depression or initial presentation of subthreshold depressive symptoms that have been present for a long period (typically at least 2 years) or	
behavioural couples	0	0.6373	6	IPT) behavioural couples therapy for people who have a regular partner and where the relationship may contribute to the development or maintenance of depression, or where involving the partner is considered to be of potential therapeutic benefit.	For people with depression who decline an antidepressant, CBT, IPT, behavioural activation and behavioural couples therapy, consider: counselling for people with persistent subthreshold depressive symptoms or mild to moderate depression short-term psychodynamic psychotherapy for people with mild to moderate depression.	Behavioural couples therapy for depression should normally be based on behavioural principles, and an adequate course of therapy should be 15 to 20 sessions over 5 to 6 months.	IPT) behavioural couples therapy for people who have a regular partner and where the relationship may contribute to the development or maintenance of depression, or where involving the partner is considered to be of potential therapeutic benefit.	For people with depression who decline an antidepressant, CBT, IPT, behavioural activation and behavioural couples therapy, consider: counselling for people with persistent subthreshold depressive symptoms or mild to moderate depression short-term psychodynamic psychotherapy for people with mild to moderate depression.	Behavioural couples therapy for depression should normally be based on behavioural principles, and an adequate course of therapy should be 15 to 20 sessions over 5 to 6 months.	
couples therapy	0	0.6373	6	IPT) behavioural couples therapy for people who have a regular partner and where the relationship may contribute to the development or maintenance of depression, or where involving the partner is considered to be of potential therapeutic benefit.	For people with depression who decline an antidepressant, CBT, IPT, behavioural activation and behavioural couples therapy, consider: counselling for people with persistent subthreshold depressive symptoms or mild to moderate depression short-term psychodynamic psychotherapy for people with mild to moderate depression.	Behavioural couples therapy for depression should normally be based on behavioural principles, and an adequate course of therapy should be 15 to 20 sessions over 5 to 6 months.	IPT) behavioural couples therapy for people who have a regular partner and where the relationship may contribute to the development or maintenance of depression, or where involving the partner is considered to be of potential therapeutic benefit.	For people with depression who decline an antidepressant, CBT, IPT, behavioural activation and behavioural couples therapy, consider: counselling for people with persistent subthreshold depressive symptoms or mild to moderate depression short-term psychodynamic psychotherapy for people with mild to moderate depression.	Behavioural couples therapy for depression should normally be based on behavioural principles, and an adequate course of therapy should be 15 to 20 sessions over 5 to 6 months.	
appraisal guidance	0	0.6322	8	Section of this guideline updates recommendations made in 'Guidance on the use of electroconvulsive therapy' (NICE technology appraisal guidance 59) for the treatment of depression only	Recommendation of this guideline updates recommendations made in 'Computerised cognitive behaviour therapy for depression and anxiety' (NICE technology appraisal guidance 97) for the treatment of depression only	This recommendation (and recommendation in CG91) updates the recommendations on depression only in 'Computerised cognitive behaviour therapy for depression and anxiety' (NICE technology appraisal guidance 97).	The recommendations in this section update the depression aspects only of 'Guidance on the use of electroconvulsive therapy' (NICE technology appraisal guidance 59).	Section of this guideline updates recommendations made in 'Guidance on the use of electroconvulsive therapy' (NICE technology appraisal guidance 59) for the treatment of depression only	Recommendation of this guideline updates recommendations made in 'Computerised cognitive behaviour therapy for depression and anxiety' (NICE technology appraisal guidance 97) for the treatment of depression only	This recommendation (and recommendation in CG91) updates the recommendations on depression only in 'Computerised cognitive behaviour therapy for depression and anxiety' (NICE technology appraisal guidance 97).	The recommendations in this section update the depression aspects only of 'Guidance on the use of electroconvulsive therapy' (NICE technology appraisal guidance 59).	
nice technology	0	0.6322	8	Section of this guideline updates recommendations made in 'Guidance on the use of electroconvulsive therapy' (NICE technology appraisal guidance 59) for the treatment of depression only	Recommendation of this guideline updates recommendations made in 'Computerised cognitive behaviour therapy for depression and anxiety' (NICE technology appraisal guidance 97) for the treatment of depression only	This recommendation (and recommendation in CG91) updates the recommendations on depression only in 'Computerised cognitive behaviour therapy for depression and anxiety' (NICE technology appraisal guidance 97).	The recommendations in this section update the depression aspects only of 'Guidance on the use of electroconvulsive therapy' (NICE technology appraisal guidance 59).	Section of this guideline updates recommendations made in 'Guidance on the use of electroconvulsive therapy' (NICE technology appraisal guidance 59) for the treatment of depression only	Recommendation of this guideline updates recommendations made in 'Computerised cognitive behaviour therapy for depression and anxiety' (NICE technology appraisal guidance 97) for the treatment of depression only	This recommendation (and recommendation in CG91) updates the recommendations on depression only in 'Computerised cognitive behaviour therapy for depression and anxiety' (NICE technology appraisal guidance 97).	The recommendations in this section update the depression aspects only of 'Guidance on the use of electroconvulsive therapy' (NICE technology appraisal guidance 59).	
technology appraisal	0	0.6322	8	Section of this guideline updates recommendations made in 'Guidance on the use of electroconvulsive therapy' (NICE technology appraisal guidance 59) for the treatment of depression only	Recommendation of this guideline updates recommendations made in 'Computerised cognitive behaviour therapy for depression and anxiety' (NICE technology appraisal guidance 97) for the treatment of depression only	This recommendation (and recommendation in CG91) updates the recommendations on depression only in 'Computerised cognitive behaviour therapy for depression and anxiety' (NICE technology appraisal guidance 97).	The recommendations in this section update the depression aspects only of 'Guidance on the use of electroconvulsive therapy' (NICE technology appraisal guidance 59).	Section of this guideline updates recommendations made in 'Guidance on the use of electroconvulsive therapy' (NICE technology appraisal guidance 59) for the treatment of depression only	Recommendation of this guideline updates recommendations made in 'Computerised cognitive behaviour therapy for depression and anxiety' (NICE technology appraisal guidance 97) for the treatment of depression only	This recommendation (and recommendation in CG91) updates the recommendations on depression only in 'Computerised cognitive behaviour therapy for depression and anxiety' (NICE technology appraisal guidance 97).	The recommendations in this section update the depression aspects only of 'Guidance on the use of electroconvulsive therapy' (NICE technology appraisal guidance 59).	
2-week washout	0	0.6305	2	Last updated April 2018 from a non-reversible MAOI: a 2-week washout period is required (other antidepressants should not be prescribed routinely during this period).	Last updated April 2018 from a non-reversible MAOI: a 2-week washout period is required (other antidepressants should not be prescribed routinely during this period).	
non-reversible maoi	0	0.6305	2	Last updated April 2018 from a non-reversible MAOI: a 2-week washout period is required (other antidepressants should not be prescribed routinely during this period).	Last updated April 2018 from a non-reversible MAOI: a 2-week washout period is required (other antidepressants should not be prescribed routinely during this period).	
prevention depression	0	0.6305	0	
repeat trial	0	0.6305	2	ECT, consider a repeat trial of ECT only after: reviewing the adequacy of the previous treatment course and considering all other options and discussing the risks and benefits with the person and or, where appropriate, their advocate or carer.	ECT, consider a repeat trial of ECT only after: reviewing the adequacy of the previous treatment course and considering all other options and discussing the risks and benefits with the person and or, where appropriate, their advocate or carer.	
short half-life	0	0.6305	2	When switching to another antidepressant, which can normally be achieved within 1 week when switching from drugs with a short half-life, consider the potential for interactions in determining the choice of new drug and the nature and duration of the transition	When switching to another antidepressant, which can normally be achieved within 1 week when switching from drugs with a short half-life, consider the potential for interactions in determining the choice of new drug and the nature and duration of the transition	
transition depression	0	0.6305	0	
treatment choice	0	0.6305	4	Treatment choice should be influenced by: previous treatment history, including the consequences of a relapse, residual symptoms, response to previous treatment and any discontinuation symptoms the person's preference.	When considering ECT as a treatment choice, ensure that the person with depression is fully informed of the risks associated with ECT, and with the risks and benefits specific to them	Treatment choice should be influenced by: previous treatment history, including the consequences of a relapse, residual symptoms, response to previous treatment and any discontinuation symptoms the person's preference.	When considering ECT as a treatment choice, ensure that the person with depression is fully informed of the risks associated with ECT, and with the risks and benefits specific to them	
washout period	0	0.6305	2	Last updated April 2018 from a non-reversible MAOI: a 2-week washout period is required (other antidepressants should not be prescribed routinely during this period).	Last updated April 2018 from a non-reversible MAOI: a 2-week washout period is required (other antidepressants should not be prescribed routinely during this period).	
reviews progress	0	0.6222	4	Individual guided self-help programmes based on the principles of CBT (and including behavioural activation and problem-solving techniques) for people with persistent subthreshold depressive symptoms or mild to moderate depression should: include the provision of written materials of an appropriate reading age (or alternative media to support access) be supported by a trained practitioner, who typically facilitates the self-help programme and reviews progress and outcome consist of up to six to eight sessions (face-to-face and via telephone) normally taking place over 9 to 12 weeks, including follow-up.	Last updated April 2018 outcomes be supported by a trained practitioner, who typically provides limited facilitation of the programme and reviews progress and outcome typically take place over 9 to 12 weeks, including follow-up.	Individual guided self-help programmes based on the principles of CBT (and including behavioural activation and problem-solving techniques) for people with persistent subthreshold depressive symptoms or mild to moderate depression should: include the provision of written materials of an appropriate reading age (or alternative media to support access) be supported by a trained practitioner, who typically facilitates the self-help programme and reviews progress and outcome consist of up to six to eight sessions (face-to-face and via telephone) normally taking place over 9 to 12 weeks, including follow-up.	Last updated April 2018 outcomes be supported by a trained practitioner, who typically provides limited facilitation of the programme and reviews progress and outcome typically take place over 9 to 12 weeks, including follow-up.	
trained practitioner	0	0.6222	4	Individual guided self-help programmes based on the principles of CBT (and including behavioural activation and problem-solving techniques) for people with persistent subthreshold depressive symptoms or mild to moderate depression should: include the provision of written materials of an appropriate reading age (or alternative media to support access) be supported by a trained practitioner, who typically facilitates the self-help programme and reviews progress and outcome consist of up to six to eight sessions (face-to-face and via telephone) normally taking place over 9 to 12 weeks, including follow-up.	Last updated April 2018 outcomes be supported by a trained practitioner, who typically provides limited facilitation of the programme and reviews progress and outcome typically take place over 9 to 12 weeks, including follow-up.	Individual guided self-help programmes based on the principles of CBT (and including behavioural activation and problem-solving techniques) for people with persistent subthreshold depressive symptoms or mild to moderate depression should: include the provision of written materials of an appropriate reading age (or alternative media to support access) be supported by a trained practitioner, who typically facilitates the self-help programme and reviews progress and outcome consist of up to six to eight sessions (face-to-face and via telephone) normally taking place over 9 to 12 weeks, including follow-up.	Last updated April 2018 outcomes be supported by a trained practitioner, who typically provides limited facilitation of the programme and reviews progress and outcome typically take place over 9 to 12 weeks, including follow-up.	
antidepressant medication	0	0.6212	10	For people with moderate or severe depression, provide a combination of antidepressant medication and a high-intensity psychological intervention (CBT or IPT).	Last updated April 2018 continue antidepressant treatment) or who have residual symptoms, should be offered one of the following psychological interventions: individual CBT for people who have relapsed despite antidepressant medication and for people with a significant history of depression and residual symptoms despite treatment mindfulness-based cognitive therapy for people who are currently well but have experienced three or more previous episodes of depression.	For people with moderate or severe depression, provide a combination of antidepressant medication and a high-intensity psychological intervention (CBT or IPT).	For a person whose depression has not responded to either pharmacological or psychological interventions, consider combining antidepressant medication with CBT.	People with depression who are considered to be at significant risk of relapse (including those who have relapsed despite antidepressant treatment or who are unable or choose not to continue antidepressant treatment) or who have residual symptoms, should be offered one of the following psychological interventions: individual CBT for people who have relapsed despite antidepressant medication and for people with a significant history of depression and residual symptoms despite treatment mindfulness-based cognitive therapy for people who are currently well but have experienced three or more previous episodes of depression.	For people with moderate or severe depression, provide a combination of antidepressant medication and a high-intensity psychological intervention (CBT or IPT).	Last updated April 2018 continue antidepressant treatment) or who have residual symptoms, should be offered one of the following psychological interventions: individual CBT for people who have relapsed despite antidepressant medication and for people with a significant history of depression and residual symptoms despite treatment mindfulness-based cognitive therapy for people who are currently well but have experienced three or more previous episodes of depression.	For people with moderate or severe depression, provide a combination of antidepressant medication and a high-intensity psychological intervention (CBT or IPT).	For a person whose depression has not responded to either pharmacological or psychological interventions, consider combining antidepressant medication with CBT.	People with depression who are considered to be at significant risk of relapse (including those who have relapsed despite antidepressant treatment or who are unable or choose not to continue antidepressant treatment) or who have residual symptoms, should be offered one of the following psychological interventions: individual CBT for people who have relapsed despite antidepressant medication and for people with a significant history of depression and residual symptoms despite treatment mindfulness-based cognitive therapy for people who are currently well but have experienced three or more previous episodes of depression.	
side-effect burden	0	0.5862	6	Last updated April 2018 outcome measure be aware that using a single antidepressant rather than combination medication or augmentation (see recommendations to ) is usually associated with a lower side-effect burden consider reintroducing previous treatments that have been inadequately delivered or adhered to, including increasing the dose consider switching to an alternative antidepressant.	When using combinations of medications (which should only normally be started in primary care in consultation with a consultant psychiatrist): select medications that are known to be safe when used together be aware of the increased side-effect burden this usually causes discuss the rationale for any combination with the person with depression, follow	If a person with depression is informed about, and prepared to tolerate, the increased side-effect burden, consider combining or augmenting an antidepressant with: lithium or an antipsychotic such as aripiprazole , olanzapine , quetiapine or risperidone or another antidepressant such as mirtazapine or mianserin.	Last updated April 2018 outcome measure be aware that using a single antidepressant rather than combination medication or augmentation (see recommendations to ) is usually associated with a lower side-effect burden consider reintroducing previous treatments that have been inadequately delivered or adhered to, including increasing the dose consider switching to an alternative antidepressant.	When using combinations of medications (which should only normally be started in primary care in consultation with a consultant psychiatrist): select medications that are known to be safe when used together be aware of the increased side-effect burden this usually causes discuss the rationale for any combination with the person with depression, follow	If a person with depression is informed about, and prepared to tolerate, the increased side-effect burden, consider combining or augmenting an antidepressant with: lithium or an antipsychotic such as aripiprazole , olanzapine , quetiapine or risperidone or another antidepressant such as mirtazapine or mianserin.	
significant risk	0	0.5831	8	People with depression who are considered to be at significant risk of relapse (including those who have relapsed despite antidepressant treatment or who are unable or choose not to	People with depression who are considered to be at significant risk of relapse (including those who have relapsed despite antidepressant treatment or who are unable or choose not to continue antidepressant treatment) or who have residual symptoms, should be offered one of the following psychological interventions: individual CBT for people who have relapsed despite antidepressant medication and for people with a significant history of depression and residual symptoms despite treatment mindfulness-based cognitive therapy for people who are currently well but have experienced three or more previous episodes of depression.	Referral to specialist mental health services should normally be for people with depression who are at significant risk of self-harm, have psychotic symptoms, require complex multiprofessional care, or where an expert opinion on treatment and management is needed.	Consider inpatient treatment for people with depression who are at significant risk of suicide, self-harm or self-neglect.	People with depression who are considered to be at significant risk of relapse (including those who have relapsed despite antidepressant treatment or who are unable or choose not to	People with depression who are considered to be at significant risk of relapse (including those who have relapsed despite antidepressant treatment or who are unable or choose not to continue antidepressant treatment) or who have residual symptoms, should be offered one of the following psychological interventions: individual CBT for people who have relapsed despite antidepressant medication and for people with a significant history of depression and residual symptoms despite treatment mindfulness-based cognitive therapy for people who are currently well but have experienced three or more previous episodes of depression.	Referral to specialist mental health services should normally be for people with depression who are at significant risk of self-harm, have psychotic symptoms, require complex multiprofessional care, or where an expert opinion on treatment and management is needed.	Consider inpatient treatment for people with depression who are at significant risk of suicide, self-harm or self-neglect.	
adequate explanation	0	0.5751	2	When working with people with depression and their families or carers: provide information appropriate to their level of understanding about the nature of depression and the range of treatments available avoid clinical language without adequate explanation ensure that comprehensive written information is available in the appropriate language and in audio format if possible provide and work proficiently with independent interpreters (that is, someone who is not known to the person with depression) if needed.	When working with people with depression and their families or carers: provide information appropriate to their level of understanding about the nature of depression and the range of treatments available avoid clinical language without adequate explanation ensure that comprehensive written information is available in the appropriate language and in audio format if possible provide and work proficiently with independent interpreters (that is, someone who is not known to the person with depression) if needed.	
advise people	0	0.5751	4	Advise people with depression of the potential for increased agitation, anxiety and suicidal ideation in the initial stages of treatment; actively seek out these symptoms and: ensure that the person knows how to seek help promptly review the person's treatment if they develop marked and or prolonged agitation.	Although there is evidence that St John's wort may be of benefit in mild or moderate depression, practitioners should: not prescribe or advise its use by people with depression because of uncertainty about appropriate doses, persistence of effect, variation in the nature of preparations and potential serious interactions with other drugs (including oral contraceptives, anticoagulants and anticonvulsants) advise people with depression of the different potencies of the preparations available and of the potential serious interactions of St John's wort with other drugs.	Advise people with depression of the potential for increased agitation, anxiety and suicidal ideation in the initial stages of treatment; actively seek out these symptoms and: ensure that the person knows how to seek help promptly review the person's treatment if they develop marked and or prolonged agitation.	Although there is evidence that St John's wort may be of benefit in mild or moderate depression, practitioners should: not prescribe or advise its use by people with depression because of uncertainty about appropriate doses, persistence of effect, variation in the nature of preparations and potential serious interactions with other drugs (including oral contraceptives, anticoagulants and anticonvulsants) advise people with depression of the different potencies of the preparations available and of the potential serious interactions of St John's wort with other drugs.	
audio format	0	0.5751	2	When working with people with depression and their families or carers: provide information appropriate to their level of understanding about the nature of depression and the range of treatments available avoid clinical language without adequate explanation ensure that comprehensive written information is available in the appropriate language and in audio format if possible provide and work proficiently with independent interpreters (that is, someone who is not known to the person with depression) if needed.	When working with people with depression and their families or carers: provide information appropriate to their level of understanding about the nature of depression and the range of treatments available avoid clinical language without adequate explanation ensure that comprehensive written information is available in the appropriate language and in audio format if possible provide and work proficiently with independent interpreters (that is, someone who is not known to the person with depression) if needed.	
clinical language	0	0.5751	2	When working with people with depression and their families or carers: provide information appropriate to their level of understanding about the nature of depression and the range of treatments available avoid clinical language without adequate explanation ensure that comprehensive written information is available in the appropriate language and in audio format if possible provide and work proficiently with independent interpreters (that is, someone who is not known to the person with depression) if needed.	When working with people with depression and their families or carers: provide information appropriate to their level of understanding about the nature of depression and the range of treatments available avoid clinical language without adequate explanation ensure that comprehensive written information is available in the appropriate language and in audio format if possible provide and work proficiently with independent interpreters (that is, someone who is not known to the person with depression) if needed.	
combination treatments	0	0.5751	2	For a person whose depression has failed to respond to various strategies for augmentation and combination treatments, consider referral to a practitioner with a specialist interest in treating depression, or to a specialist service.	For a person whose depression has failed to respond to various strategies for augmentation and combination treatments, consider referral to a practitioner with a specialist interest in treating depression, or to a specialist service.	
comprehensive written	0	0.5751	2	When working with people with depression and their families or carers: provide information appropriate to their level of understanding about the nature of depression and the range of treatments available avoid clinical language without adequate explanation ensure that comprehensive written information is available in the appropriate language and in audio format if possible provide and work proficiently with independent interpreters (that is, someone who is not known to the person with depression) if needed.	When working with people with depression and their families or carers: provide information appropriate to their level of understanding about the nature of depression and the range of treatments available avoid clinical language without adequate explanation ensure that comprehensive written information is available in the appropriate language and in audio format if possible provide and work proficiently with independent interpreters (that is, someone who is not known to the person with depression) if needed.	
effective antidepressants	0	0.5751	2	Be aware that: compared with other equally effective antidepressants recommended for routine use in primary care, venlafaxine is associated with a greater risk of death from overdose tricyclic antidepressants (TCAs), except for lofepramine, are associated with the greatest risk in overdose.	Be aware that: compared with other equally effective antidepressants recommended for routine use in primary care, venlafaxine is associated with a greater risk of death from overdose tricyclic antidepressants (TCAs), except for lofepramine, are associated with the greatest risk in overdose.	
history depression	0	0.5751	0	
independent interpreters	0	0.5751	2	When working with people with depression and their families or carers: provide information appropriate to their level of understanding about the nature of depression and the range of treatments available avoid clinical language without adequate explanation ensure that comprehensive written information is available in the appropriate language and in audio format if possible provide and work proficiently with independent interpreters (that is, someone who is not known to the person with depression) if needed.	When working with people with depression and their families or carers: provide information appropriate to their level of understanding about the nature of depression and the range of treatments available avoid clinical language without adequate explanation ensure that comprehensive written information is available in the appropriate language and in audio format if possible provide and work proficiently with independent interpreters (that is, someone who is not known to the person with depression) if needed.	
initial stages	0	0.5751	2	Advise people with depression of the potential for increased agitation, anxiety and suicidal ideation in the initial stages of treatment; actively seek out these symptoms and: ensure that the person knows how to seek help promptly review the person's treatment if they develop marked and or prolonged agitation.	Advise people with depression of the potential for increased agitation, anxiety and suicidal ideation in the initial stages of treatment; actively seek out these symptoms and: ensure that the person knows how to seek help promptly review the person's treatment if they develop marked and or prolonged agitation.	
mental capacity	0	0.5751	2	Making decisions using NICE guidelines explains how we use words to show the strength (or certainty) of our recommendations, and has information about prescribing medicines (including off-label use), professional guidelines, standards and laws (including on consent and mental capacity), and safeguarding.	Making decisions using NICE guidelines explains how we use words to show the strength (or certainty) of our recommendations, and has information about prescribing medicines (including off-label use), professional guidelines, standards and laws (including on consent and mental capacity), and safeguarding.	
overdose tricyclic	0	0.5751	2	Be aware that: compared with other equally effective antidepressants recommended for routine use in primary care, venlafaxine is associated with a greater risk of death from overdose tricyclic antidepressants (TCAs), except for lofepramine, are associated with the greatest risk in overdose.	Be aware that: compared with other equally effective antidepressants recommended for routine use in primary care, venlafaxine is associated with a greater risk of death from overdose tricyclic antidepressants (TCAs), except for lofepramine, are associated with the greatest risk in overdose.	
professional guidelines	0	0.5751	2	Making decisions using NICE guidelines explains how we use words to show the strength (or certainty) of our recommendations, and has information about prescribing medicines (including off-label use), professional guidelines, standards and laws (including on consent and mental capacity), and safeguarding.	Making decisions using NICE guidelines explains how we use words to show the strength (or certainty) of our recommendations, and has information about prescribing medicines (including off-label use), professional guidelines, standards and laws (including on consent and mental capacity), and safeguarding.	
prolonged agitation	0	0.5751	2	Advise people with depression of the potential for increased agitation, anxiety and suicidal ideation in the initial stages of treatment; actively seek out these symptoms and: ensure that the person knows how to seek help promptly review the person's treatment if they develop marked and or prolonged agitation.	Advise people with depression of the potential for increased agitation, anxiety and suicidal ideation in the initial stages of treatment; actively seek out these symptoms and: ensure that the person knows how to seek help promptly review the person's treatment if they develop marked and or prolonged agitation.	
specialist interest	0	0.5751	2	For a person whose depression has failed to respond to various strategies for augmentation and combination treatments, consider referral to a practitioner with a specialist interest in treating depression, or to a specialist service.	For a person whose depression has failed to respond to various strategies for augmentation and combination treatments, consider referral to a practitioner with a specialist interest in treating depression, or to a specialist service.	
specialist service	0	0.5751	2	For a person whose depression has failed to respond to various strategies for augmentation and combination treatments, consider referral to a practitioner with a specialist interest in treating depression, or to a specialist service.	For a person whose depression has failed to respond to various strategies for augmentation and combination treatments, consider referral to a practitioner with a specialist interest in treating depression, or to a specialist service.	
symptom profile	0	0.5751	2	The assessment of a person with depression referred to specialist mental health services should include: their symptom profile, suicide risk and, where appropriate, previous treatment history	The assessment of a person with depression referred to specialist mental health services should include: their symptom profile, suicide risk and, where appropriate, previous treatment history	
tricyclic antidepressants	0	0.5751	2	Be aware that: compared with other equally effective antidepressants recommended for routine use in primary care, venlafaxine is associated with a greater risk of death from overdose tricyclic antidepressants (TCAs), except for lofepramine, are associated with the greatest risk in overdose.	Be aware that: compared with other equally effective antidepressants recommended for routine use in primary care, venlafaxine is associated with a greater risk of death from overdose tricyclic antidepressants (TCAs), except for lofepramine, are associated with the greatest risk in overdose.	
written information	0	0.5751	2	When working with people with depression and their families or carers: provide information appropriate to their level of understanding about the nature of depression and the range of treatments available avoid clinical language without adequate explanation ensure that comprehensive written information is available in the appropriate language and in audio format if possible provide and work proficiently with independent interpreters (that is, someone who is not known to the person with depression) if needed.	When working with people with depression and their families or carers: provide information appropriate to their level of understanding about the nature of depression and the range of treatments available avoid clinical language without adequate explanation ensure that comprehensive written information is available in the appropriate language and in audio format if possible provide and work proficiently with independent interpreters (that is, someone who is not known to the person with depression) if needed.	
physical activity	0	0.5684	8	For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services.	For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services.	Last updated April 2018 consider offering one or more of the following interventions, guided by the person's preference: individual guided self-help based on the principles of cognitive behavioural therapy (CBT) computerised cognitive behavioural therapy (CCBT) a structured group physical activity programme.	For people with persistent subthreshold depressive symptoms or mild to moderate depression, consider offering one or more of the following interventions, guided by the person's preference: individual guided self-help based on the principles of cognitive behavioural therapy (CBT) computerised cognitive behavioural therapy (CCBT) a structured group physical activity programme.	Physical activity programmes for people with persistent subthreshold depressive symptoms or mild to moderate depression should: be delivered in groups with support from a competent practitioner consist typically of three sessions per week of moderate duration (45 minutes to 1 hour) over 10 to 14 weeks (average 12 weeks).	Last updated April 2018 consider offering one or more of the following interventions, guided by the person's preference: individual guided self-help based on the principles of cognitive behavioural therapy (CBT) computerised cognitive behavioural therapy (CCBT) a structured group physical activity programme.	For people with persistent subthreshold depressive symptoms or mild to moderate depression, consider offering one or more of the following interventions, guided by the person's preference: individual guided self-help based on the principles of cognitive behavioural therapy (CBT) computerised cognitive behavioural therapy (CCBT) a structured group physical activity programme.	Physical activity programmes for people with persistent subthreshold depressive symptoms or mild to moderate depression should: be delivered in groups with support from a competent practitioner consist typically of three sessions per week of moderate duration (45 minutes to 1 hour) over 10 to 14 weeks (average 12 weeks).	
behavioural activation	0	0.5599	6	Individual guided self-help programmes based on the principles of CBT (and including behavioural activation and problem-solving techniques) for people with persistent subthreshold depressive symptoms or mild to moderate depression should: include the provision of written materials of an appropriate reading age (or alternative media to support access) be supported by a trained practitioner, who typically facilitates the self-help programme and reviews progress and outcome consist of up to six to eight sessions (face-to-face and via telephone) normally taking place over 9 to 12 weeks, including follow-up.	For people with depression who decline an antidepressant, CBT, IPT, behavioural activation and behavioural couples therapy, consider: counselling for people with persistent subthreshold depressive symptoms or mild to moderate depression short-term psychodynamic psychotherapy for people with mild to moderate depression.	For all people with depression having behavioural activation, the duration of treatment should typically be in the range of 16 to 20 sessions over 3 to 4 months	Individual guided self-help programmes based on the principles of CBT (and including behavioural activation and problem-solving techniques) for people with persistent subthreshold depressive symptoms or mild to moderate depression should: include the provision of written materials of an appropriate reading age (or alternative media to support access) be supported by a trained practitioner, who typically facilitates the self-help programme and reviews progress and outcome consist of up to six to eight sessions (face-to-face and via telephone) normally taking place over 9 to 12 weeks, including follow-up.	For people with depression who decline an antidepressant, CBT, IPT, behavioural activation and behavioural couples therapy, consider: counselling for people with persistent subthreshold depressive symptoms or mild to moderate depression short-term psychodynamic psychotherapy for people with mild to moderate depression.	For all people with depression having behavioural activation, the duration of treatment should typically be in the range of 16 to 20 sessions over 3 to 4 months	
chronic physical	0	0.5597	16	NICE has also produced a guideline on depression in adults with a chronic physical health problem (NICE guideline CG91).	This guideline is published alongside 'Depression in adults with a chronic physical health problem: recognition and management' (NICE clinical guideline 91) which makes recommendations on the identification treatment and management of depression in adults aged 18 years and older who also have a chronic physical health problem.	Be alert to possible depression (particularly in people with a past history of depression or a chronic physical health problem with associated functional impairment) and consider asking people who may have depression two questions, specifically:	This guideline is published alongside 'Depression in adults with a chronic physical health problem: recognition and management' (NICE clinical guideline 91), which makes recommendations on the identification, treatment and management of depression in adults aged 18 years and older who also have a chronic physical health problem.	Assessment, support, psychoeducation, active monitoring and referral for further assessment and interventions a Complex depression includes depression that shows an inadequate response to multiple treatments, is complicated by psychotic symptoms, and or is associated with significant psychiatric comorbidity or psychosocial factors. b Only for depression where the person also has a chronic physical health problem and associated functional impairment (see depression in adults with a chronic physical health problem: recognition and management NICE clinical guideline 91).	Be alert to possible depression (particularly in people with a past history of depression or a chronic physical health problem with associated functional impairment) and consider asking people who may have depression two questions, specifically:	Refer to 'Depression in adults with a chronic physical health problem: recognition and management' (NICE clinical guideline 91) for further information.	For people with severe depression and those with moderate depression and complex problems, consider: referring to specialist mental health services for a programme of coordinated multiprofessional care providing collaborative care if the depression is in the context of a chronic physical health problem with associated functional impairment .	NICE has also produced a guideline on depression in adults with a chronic physical health problem (NICE guideline CG91).	This guideline is published alongside 'Depression in adults with a chronic physical health problem: recognition and management' (NICE clinical guideline 91) which makes recommendations on the identification treatment and management of depression in adults aged 18 years and older who also have a chronic physical health problem.	Be alert to possible depression (particularly in people with a past history of depression or a chronic physical health problem with associated functional impairment) and consider asking people who may have depression two questions, specifically:	This guideline is published alongside 'Depression in adults with a chronic physical health problem: recognition and management' (NICE clinical guideline 91), which makes recommendations on the identification, treatment and management of depression in adults aged 18 years and older who also have a chronic physical health problem.	Assessment, support, psychoeducation, active monitoring and referral for further assessment and interventions a Complex depression includes depression that shows an inadequate response to multiple treatments, is complicated by psychotic symptoms, and or is associated with significant psychiatric comorbidity or psychosocial factors. b Only for depression where the person also has a chronic physical health problem and associated functional impairment (see depression in adults with a chronic physical health problem: recognition and management NICE clinical guideline 91).	Be alert to possible depression (particularly in people with a past history of depression or a chronic physical health problem with associated functional impairment) and consider asking people who may have depression two questions, specifically:	Refer to 'Depression in adults with a chronic physical health problem: recognition and management' (NICE clinical guideline 91) for further information.	For people with severe depression and those with moderate depression and complex problems, consider: referring to specialist mental health services for a programme of coordinated multiprofessional care providing collaborative care if the depression is in the context of a chronic physical health problem with associated functional impairment .	
health problem	0	0.5597	18	NICE has also produced a guideline on depression in adults with a chronic physical health problem (NICE guideline CG91).	This guideline is published alongside 'Depression in adults with a chronic physical health problem: recognition and management' (NICE clinical guideline 91) which makes recommendations on the identification treatment and management of depression in adults aged 18 years and older who also have a chronic physical health problem.	Be alert to possible depression (particularly in people with a past history of depression or a chronic physical health problem with associated functional impairment) and consider asking people who may have depression two questions, specifically:	This guideline is published alongside 'Depression in adults with a chronic physical health problem: recognition and management' (NICE clinical guideline 91), which makes recommendations on the identification, treatment and management of depression in adults aged 18 years and older who also have a chronic physical health problem.	Assessment, support, psychoeducation, active monitoring and referral for further assessment and interventions a Complex depression includes depression that shows an inadequate response to multiple treatments, is complicated by psychotic symptoms, and or is associated with significant psychiatric comorbidity or psychosocial factors. b Only for depression where the person also has a chronic physical health problem and associated functional impairment (see depression in adults with a chronic physical health problem: recognition and management NICE clinical guideline 91).	Be alert to possible depression (particularly in people with a past history of depression or a chronic physical health problem with associated functional impairment) and consider asking people who may have depression two questions, specifically:	Discuss antidepressant treatment options with the person with depression, covering: the choice of antidepressant, including any anticipated adverse events, for example side effects and discontinuation symptoms (see recommendation ), and potential interactions with concomitant medication or physical health problems their perception of the efficacy and tolerability of any antidepressants they have previously taken.	Refer to 'Depression in adults with a chronic physical health problem: recognition and management' (NICE clinical guideline 91) for further information.	For people with severe depression and those with moderate depression and complex problems, consider: referring to specialist mental health services for a programme of coordinated multiprofessional care providing collaborative care if the depression is in the context of a chronic physical health problem with associated functional impairment .	NICE has also produced a guideline on depression in adults with a chronic physical health problem (NICE guideline CG91).	This guideline is published alongside 'Depression in adults with a chronic physical health problem: recognition and management' (NICE clinical guideline 91) which makes recommendations on the identification treatment and management of depression in adults aged 18 years and older who also have a chronic physical health problem.	Be alert to possible depression (particularly in people with a past history of depression or a chronic physical health problem with associated functional impairment) and consider asking people who may have depression two questions, specifically:	This guideline is published alongside 'Depression in adults with a chronic physical health problem: recognition and management' (NICE clinical guideline 91), which makes recommendations on the identification, treatment and management of depression in adults aged 18 years and older who also have a chronic physical health problem.	Assessment, support, psychoeducation, active monitoring and referral for further assessment and interventions a Complex depression includes depression that shows an inadequate response to multiple treatments, is complicated by psychotic symptoms, and or is associated with significant psychiatric comorbidity or psychosocial factors. b Only for depression where the person also has a chronic physical health problem and associated functional impairment (see depression in adults with a chronic physical health problem: recognition and management NICE clinical guideline 91).	Be alert to possible depression (particularly in people with a past history of depression or a chronic physical health problem with associated functional impairment) and consider asking people who may have depression two questions, specifically:	Discuss antidepressant treatment options with the person with depression, covering: the choice of antidepressant, including any anticipated adverse events, for example side effects and discontinuation symptoms (see recommendation ), and potential interactions with concomitant medication or physical health problems their perception of the efficacy and tolerability of any antidepressants they have previously taken.	Refer to 'Depression in adults with a chronic physical health problem: recognition and management' (NICE clinical guideline 91) for further information.	For people with severe depression and those with moderate depression and complex problems, consider: referring to specialist mental health services for a programme of coordinated multiprofessional care providing collaborative care if the depression is in the context of a chronic physical health problem with associated functional impairment .	
clinical guideline	0	0.5557	8	This guideline is published alongside 'Depression in adults with a chronic physical health problem: recognition and management' (NICE clinical guideline 91) which makes recommendations on the identification treatment and management of depression in adults aged 18 years and older who also have a chronic physical health problem.	This guideline is published alongside 'Depression in adults with a chronic physical health problem: recognition and management' (NICE clinical guideline 91), which makes recommendations on the identification, treatment and management of depression in adults aged 18 years and older who also have a chronic physical health problem.	Assessment, support, psychoeducation, active monitoring and referral for further assessment and interventions a Complex depression includes depression that shows an inadequate response to multiple treatments, is complicated by psychotic symptoms, and or is associated with significant psychiatric comorbidity or psychosocial factors. b Only for depression where the person also has a chronic physical health problem and associated functional impairment (see depression in adults with a chronic physical health problem: recognition and management NICE clinical guideline 91).	Refer to 'Depression in adults with a chronic physical health problem: recognition and management' (NICE clinical guideline 91) for further information.	This guideline is published alongside 'Depression in adults with a chronic physical health problem: recognition and management' (NICE clinical guideline 91) which makes recommendations on the identification treatment and management of depression in adults aged 18 years and older who also have a chronic physical health problem.	This guideline is published alongside 'Depression in adults with a chronic physical health problem: recognition and management' (NICE clinical guideline 91), which makes recommendations on the identification, treatment and management of depression in adults aged 18 years and older who also have a chronic physical health problem.	Assessment, support, psychoeducation, active monitoring and referral for further assessment and interventions a Complex depression includes depression that shows an inadequate response to multiple treatments, is complicated by psychotic symptoms, and or is associated with significant psychiatric comorbidity or psychosocial factors. b Only for depression where the person also has a chronic physical health problem and associated functional impairment (see depression in adults with a chronic physical health problem: recognition and management NICE clinical guideline 91).	Refer to 'Depression in adults with a chronic physical health problem: recognition and management' (NICE clinical guideline 91) for further information.	
nice clinical	0	0.5557	8	This guideline is published alongside 'Depression in adults with a chronic physical health problem: recognition and management' (NICE clinical guideline 91) which makes recommendations on the identification treatment and management of depression in adults aged 18 years and older who also have a chronic physical health problem.	This guideline is published alongside 'Depression in adults with a chronic physical health problem: recognition and management' (NICE clinical guideline 91), which makes recommendations on the identification, treatment and management of depression in adults aged 18 years and older who also have a chronic physical health problem.	Assessment, support, psychoeducation, active monitoring and referral for further assessment and interventions a Complex depression includes depression that shows an inadequate response to multiple treatments, is complicated by psychotic symptoms, and or is associated with significant psychiatric comorbidity or psychosocial factors. b Only for depression where the person also has a chronic physical health problem and associated functional impairment (see depression in adults with a chronic physical health problem: recognition and management NICE clinical guideline 91).	Refer to 'Depression in adults with a chronic physical health problem: recognition and management' (NICE clinical guideline 91) for further information.	This guideline is published alongside 'Depression in adults with a chronic physical health problem: recognition and management' (NICE clinical guideline 91) which makes recommendations on the identification treatment and management of depression in adults aged 18 years and older who also have a chronic physical health problem.	This guideline is published alongside 'Depression in adults with a chronic physical health problem: recognition and management' (NICE clinical guideline 91), which makes recommendations on the identification, treatment and management of depression in adults aged 18 years and older who also have a chronic physical health problem.	Assessment, support, psychoeducation, active monitoring and referral for further assessment and interventions a Complex depression includes depression that shows an inadequate response to multiple treatments, is complicated by psychotic symptoms, and or is associated with significant psychiatric comorbidity or psychosocial factors. b Only for depression where the person also has a chronic physical health problem and associated functional impairment (see depression in adults with a chronic physical health problem: recognition and management NICE clinical guideline 91).	Refer to 'Depression in adults with a chronic physical health problem: recognition and management' (NICE clinical guideline 91) for further information.	
discontinuation symptoms	0	0.5533	10	Discuss antidepressant treatment options with the person with depression, covering: the choice of antidepressant, including any anticipated adverse events, for example side effects and discontinuation symptoms (see recommendation ), and potential interactions with concomitant medication or physical health problems their perception of the efficacy and tolerability of any antidepressants they have previously taken.	When prescribing antidepressants, explore any concerns the person with depression has about taking medication, explain fully the reasons for prescribing, and provide information about taking antidepressants, including: the gradual development of the full antidepressant effect the importance of taking medication as prescribed and the need to continue treatment after remission potential side effects the potential for interactions with other medications the risk and nature of discontinuation symptoms with all antidepressants, particularly with drugs with a shorter half-life (such as paroxetine and venlafaxine), and how these symptoms can be minimised the fact that addiction does not occur with antidepressants.	Treatment choice should be influenced by: previous treatment history, including the consequences of a relapse, residual symptoms, response to previous treatment and any discontinuation symptoms the person's preference.	Inform the person that they should seek advice from their practitioner if they experience significant discontinuation symptoms	If discontinuation symptoms occur: monitor symptoms and reassure the person if symptoms are mild consider reintroducing the original antidepressant at the dose that was effective (or another antidepressant with a longer half-life from the same class) if symptoms are severe, and reduce the dose gradually while monitoring symptoms.	Discuss antidepressant treatment options with the person with depression, covering: the choice of antidepressant, including any anticipated adverse events, for example side effects and discontinuation symptoms (see recommendation ), and potential interactions with concomitant medication or physical health problems their perception of the efficacy and tolerability of any antidepressants they have previously taken.	When prescribing antidepressants, explore any concerns the person with depression has about taking medication, explain fully the reasons for prescribing, and provide information about taking antidepressants, including: the gradual development of the full antidepressant effect the importance of taking medication as prescribed and the need to continue treatment after remission potential side effects the potential for interactions with other medications the risk and nature of discontinuation symptoms with all antidepressants, particularly with drugs with a shorter half-life (such as paroxetine and venlafaxine), and how these symptoms can be minimised the fact that addiction does not occur with antidepressants.	Treatment choice should be influenced by: previous treatment history, including the consequences of a relapse, residual symptoms, response to previous treatment and any discontinuation symptoms the person's preference.	Inform the person that they should seek advice from their practitioner if they experience significant discontinuation symptoms	If discontinuation symptoms occur: monitor symptoms and reassure the person if symptoms are mild consider reintroducing the original antidepressant at the dose that was effective (or another antidepressant with a longer half-life from the same class) if symptoms are severe, and reduce the dose gradually while monitoring symptoms.	
active monitoring	0	0.5481	6	Symptoms are considered persistent if they continue despite active monitoring and or low-intensity intervention, or have been present for a considerable time, typically several months (For a diagnosis of dysthymia, symptoms should be present for at least 2 years .)	Assessment, support, psychoeducation, active monitoring and referral for further assessment and interventions a Complex depression includes depression that shows an inadequate response to multiple treatments, is complicated by psychotic symptoms, and or is associated with significant psychiatric comorbidity or psychosocial factors. b Only for depression where the person also has a chronic physical health problem and associated functional impairment (see depression in adults with a chronic physical health problem: recognition and management NICE clinical guideline 91).	CCBT for people with persistent subthreshold depressive symptoms or mild to moderate depression should: be provided via a stand-alone computer-based or web-based programme include an explanation of the CBT model, encourage tasks between sessions, and use thought-challenging and active monitoring of behaviour, thought patterns and	Symptoms are considered persistent if they continue despite active monitoring and or low-intensity intervention, or have been present for a considerable time, typically several months (For a diagnosis of dysthymia, symptoms should be present for at least 2 years .)	Assessment, support, psychoeducation, active monitoring and referral for further assessment and interventions a Complex depression includes depression that shows an inadequate response to multiple treatments, is complicated by psychotic symptoms, and or is associated with significant psychiatric comorbidity or psychosocial factors. b Only for depression where the person also has a chronic physical health problem and associated functional impairment (see depression in adults with a chronic physical health problem: recognition and management NICE clinical guideline 91).	CCBT for people with persistent subthreshold depressive symptoms or mild to moderate depression should: be provided via a stand-alone computer-based or web-based programme include an explanation of the CBT model, encourage tasks between sessions, and use thought-challenging and active monitoring of behaviour, thought patterns and	
subthreshold depressive	0	0.5441	22	Do not use antidepressants routinely to treat persistent subthreshold depressive symptoms or mild depression because the riskbenefit ratio is poor, but consider them for people with: a past history of moderate or severe depression or initial presentation of subthreshold depressive symptoms that have been present for a long period (typically at least 2 years) or subthreshold depressive symptoms or mild depression that persist(s) after other interventions.	For people with persistent subthreshold depressive symptoms or mild to moderate depression, consider offering one or more of the following interventions, guided by the person's preference: individual guided self-help based on the principles of cognitive behavioural therapy (CBT) computerised cognitive behavioural therapy (CCBT) a structured group physical activity programme.	Individual guided self-help programmes based on the principles of CBT (and including behavioural activation and problem-solving techniques) for people with persistent subthreshold depressive symptoms or mild to moderate depression should: include the provision of written materials of an appropriate reading age (or alternative media to support access) be supported by a trained practitioner, who typically facilitates the self-help programme and reviews progress and outcome consist of up to six to eight sessions (face-to-face and via telephone) normally taking place over 9 to 12 weeks, including follow-up.	CCBT for people with persistent subthreshold depressive symptoms or mild to moderate depression should: be provided via a stand-alone computer-based or web-based programme include an explanation of the CBT model, encourage tasks between sessions, and use thought-challenging and active monitoring of behaviour, thought patterns and	Physical activity programmes for people with persistent subthreshold depressive symptoms or mild to moderate depression should: be delivered in groups with support from a competent practitioner consist typically of three sessions per week of moderate duration (45 minutes to 1 hour) over 10 to 14 weeks (average 12 weeks).	Consider group-based CBT for people with persistent subthreshold depressive symptoms or mild to moderate depression who decline low-intensity psychosocial interventions (see recommendation ).	Group-based CBT for people with persistent subthreshold depressive symptoms or mild to moderate depression should: be based on a structured model such as 'Coping with Depression' be delivered by two trained and competent practitioners consist of 10 to 12 meetings of eight to ten participants normally take place over 12 to 16 weeks, including follow-up.	Do not use antidepressants routinely to treat persistent subthreshold depressive symptoms or mild depression because the riskbenefit ratio is poor, but consider them for people with: a past history of moderate or severe depression or initial presentation of subthreshold depressive symptoms that have been present for a long period (typically at least 2 years) or	For people with persistent subthreshold depressive symptoms or mild to moderate depression who have not benefited from a low-intensity psychosocial intervention, discuss the relative merits of different interventions with the person and provide: an antidepressant (normally a selective serotonin reuptake inhibitor SSRI) or a high-intensity psychological intervention, normally one of the following options:	For people with depression who decline an antidepressant, CBT, IPT, behavioural activation and behavioural couples therapy, consider: counselling for people with persistent subthreshold depressive symptoms or mild to moderate depression short-term psychodynamic psychotherapy for people with mild to moderate depression.	For all people with persistent subthreshold depressive symptoms or mild to moderate depression having counselling, the duration of treatment should typically be in the range of six to ten sessions over 8 to 12 weeks.	Do not use antidepressants routinely to treat persistent subthreshold depressive symptoms or mild depression because the riskbenefit ratio is poor, but consider them for people with: a past history of moderate or severe depression or initial presentation of subthreshold depressive symptoms that have been present for a long period (typically at least 2 years) or subthreshold depressive symptoms or mild depression that persist(s) after other interventions.	For people with persistent subthreshold depressive symptoms or mild to moderate depression, consider offering one or more of the following interventions, guided by the person's preference: individual guided self-help based on the principles of cognitive behavioural therapy (CBT) computerised cognitive behavioural therapy (CCBT) a structured group physical activity programme.	Individual guided self-help programmes based on the principles of CBT (and including behavioural activation and problem-solving techniques) for people with persistent subthreshold depressive symptoms or mild to moderate depression should: include the provision of written materials of an appropriate reading age (or alternative media to support access) be supported by a trained practitioner, who typically facilitates the self-help programme and reviews progress and outcome consist of up to six to eight sessions (face-to-face and via telephone) normally taking place over 9 to 12 weeks, including follow-up.	CCBT for people with persistent subthreshold depressive symptoms or mild to moderate depression should: be provided via a stand-alone computer-based or web-based programme include an explanation of the CBT model, encourage tasks between sessions, and use thought-challenging and active monitoring of behaviour, thought patterns and	Physical activity programmes for people with persistent subthreshold depressive symptoms or mild to moderate depression should: be delivered in groups with support from a competent practitioner consist typically of three sessions per week of moderate duration (45 minutes to 1 hour) over 10 to 14 weeks (average 12 weeks).	Consider group-based CBT for people with persistent subthreshold depressive symptoms or mild to moderate depression who decline low-intensity psychosocial interventions (see recommendation ).	Group-based CBT for people with persistent subthreshold depressive symptoms or mild to moderate depression should: be based on a structured model such as 'Coping with Depression' be delivered by two trained and competent practitioners consist of 10 to 12 meetings of eight to ten participants normally take place over 12 to 16 weeks, including follow-up.	Do not use antidepressants routinely to treat persistent subthreshold depressive symptoms or mild depression because the riskbenefit ratio is poor, but consider them for people with: a past history of moderate or severe depression or initial presentation of subthreshold depressive symptoms that have been present for a long period (typically at least 2 years) or	For people with persistent subthreshold depressive symptoms or mild to moderate depression who have not benefited from a low-intensity psychosocial intervention, discuss the relative merits of different interventions with the person and provide: an antidepressant (normally a selective serotonin reuptake inhibitor SSRI) or a high-intensity psychological intervention, normally one of the following options:	For people with depression who decline an antidepressant, CBT, IPT, behavioural activation and behavioural couples therapy, consider: counselling for people with persistent subthreshold depressive symptoms or mild to moderate depression short-term psychodynamic psychotherapy for people with mild to moderate depression.	For all people with persistent subthreshold depressive symptoms or mild to moderate depression having counselling, the duration of treatment should typically be in the range of six to ten sessions over 8 to 12 weeks.	
suicide risk	0	0.5377	4	A person with depression started on antidepressants who is considered to present an increased suicide risk or is younger than 30 years (because of the potential increased prevalence of suicidal thoughts in the early stages of antidepressant treatment for this group) should normally be seen after 1 week and frequently thereafter as appropriate until the risk is no longer considered clinically important.	The assessment of a person with depression referred to specialist mental health services should include: their symptom profile, suicide risk and, where appropriate, previous treatment history	A person with depression started on antidepressants who is considered to present an increased suicide risk or is younger than 30 years (because of the potential increased prevalence of suicidal thoughts in the early stages of antidepressant treatment for this group) should normally be seen after 1 week and frequently thereafter as appropriate until the risk is no longer considered clinically important.	The assessment of a person with depression referred to specialist mental health services should include: their symptom profile, suicide risk and, where appropriate, previous treatment history	
physical health	0	0.5303	20	NICE has also produced a guideline on depression in adults with a chronic physical health problem (NICE guideline CG91).	This guideline is published alongside 'Depression in adults with a chronic physical health problem: recognition and management' (NICE clinical guideline 91) which makes recommendations on the identification treatment and management of depression in adults aged 18 years and older who also have a chronic physical health problem.	Be alert to possible depression (particularly in people with a past history of depression or a chronic physical health problem with associated functional impairment) and consider asking people who may have depression two questions, specifically:	This guideline is published alongside 'Depression in adults with a chronic physical health problem: recognition and management' (NICE clinical guideline 91), which makes recommendations on the identification, treatment and management of depression in adults aged 18 years and older who also have a chronic physical health problem.	Assessment, support, psychoeducation, active monitoring and referral for further assessment and interventions a Complex depression includes depression that shows an inadequate response to multiple treatments, is complicated by psychotic symptoms, and or is associated with significant psychiatric comorbidity or psychosocial factors. b Only for depression where the person also has a chronic physical health problem and associated functional impairment (see depression in adults with a chronic physical health problem: recognition and management NICE clinical guideline 91).	Be alert to possible depression (particularly in people with a past history of depression or a chronic physical health problem with associated functional impairment) and consider asking people who may have depression two questions, specifically:	Discuss antidepressant treatment options with the person with depression, covering: the choice of antidepressant, including any anticipated adverse events, for example side effects and discontinuation symptoms (see recommendation ), and potential interactions with concomitant medication or physical health problems their perception of the efficacy and tolerability of any antidepressants they have previously taken.	Refer to 'Depression in adults with a chronic physical health problem: recognition and management' (NICE clinical guideline 91) for further information.	When prescribing antidepressants for older people: prescribe at an age-appropriate dose taking into account the effect of general physical health and concomitant medication on pharmacokinetics and pharmacodynamics	For people with severe depression and those with moderate depression and complex problems, consider: referring to specialist mental health services for a programme of coordinated multiprofessional care providing collaborative care if the depression is in the context of a chronic physical health problem with associated functional impairment .	NICE has also produced a guideline on depression in adults with a chronic physical health problem (NICE guideline CG91).	This guideline is published alongside 'Depression in adults with a chronic physical health problem: recognition and management' (NICE clinical guideline 91) which makes recommendations on the identification treatment and management of depression in adults aged 18 years and older who also have a chronic physical health problem.	Be alert to possible depression (particularly in people with a past history of depression or a chronic physical health problem with associated functional impairment) and consider asking people who may have depression two questions, specifically:	This guideline is published alongside 'Depression in adults with a chronic physical health problem: recognition and management' (NICE clinical guideline 91), which makes recommendations on the identification, treatment and management of depression in adults aged 18 years and older who also have a chronic physical health problem.	Assessment, support, psychoeducation, active monitoring and referral for further assessment and interventions a Complex depression includes depression that shows an inadequate response to multiple treatments, is complicated by psychotic symptoms, and or is associated with significant psychiatric comorbidity or psychosocial factors. b Only for depression where the person also has a chronic physical health problem and associated functional impairment (see depression in adults with a chronic physical health problem: recognition and management NICE clinical guideline 91).	Be alert to possible depression (particularly in people with a past history of depression or a chronic physical health problem with associated functional impairment) and consider asking people who may have depression two questions, specifically:	Discuss antidepressant treatment options with the person with depression, covering: the choice of antidepressant, including any anticipated adverse events, for example side effects and discontinuation symptoms (see recommendation ), and potential interactions with concomitant medication or physical health problems their perception of the efficacy and tolerability of any antidepressants they have previously taken.	Refer to 'Depression in adults with a chronic physical health problem: recognition and management' (NICE clinical guideline 91) for further information.	When prescribing antidepressants for older people: prescribe at an age-appropriate dose taking into account the effect of general physical health and concomitant medication on pharmacokinetics and pharmacodynamics	For people with severe depression and those with moderate depression and complex problems, consider: referring to specialist mental health services for a programme of coordinated multiprofessional care providing collaborative care if the depression is in the context of a chronic physical health problem with associated functional impairment .	
prevention psychological	0	0.5261	0	
psychological interventions	0	0.5253	20	Psychological interventions for relapse prevention	Last updated April 2018 continue antidepressant treatment) or who have residual symptoms, should be offered one of the following psychological interventions: individual CBT for people who have relapsed despite antidepressant medication and for people with a significant history of depression and residual symptoms despite treatment mindfulness-based cognitive therapy for people who are currently well but have experienced three or more previous episodes of depression.	Medication, high-intensity psychological interventions, combined treatments, collaborative careb and referral for further assessment and interventions	Low-intensity psychosocial interventions, psychological interventions, medication and referral for further assessment and interventions	For all high-intensity psychological interventions, the duration of treatment should normally be within the limits indicated in this guideline	For a person whose depression has not responded to either pharmacological or psychological interventions, consider combining antidepressant medication with CBT.	Psychological interventions for relapse prevention	People with depression who are considered to be at significant risk of relapse (including those who have relapsed despite antidepressant treatment or who are unable or choose not to continue antidepressant treatment) or who have residual symptoms, should be offered one of the following psychological interventions: individual CBT for people who have relapsed despite antidepressant medication and for people with a significant history of depression and residual symptoms despite treatment mindfulness-based cognitive therapy for people who are currently well but have experienced three or more previous episodes of depression.	Delivering psychological interventions for relapse prevention	The full range of high-intensity psychological interventions should normally be offered in inpatient settings	Psychological interventions for relapse prevention	Last updated April 2018 continue antidepressant treatment) or who have residual symptoms, should be offered one of the following psychological interventions: individual CBT for people who have relapsed despite antidepressant medication and for people with a significant history of depression and residual symptoms despite treatment mindfulness-based cognitive therapy for people who are currently well but have experienced three or more previous episodes of depression.	Medication, high-intensity psychological interventions, combined treatments, collaborative careb and referral for further assessment and interventions	Low-intensity psychosocial interventions, psychological interventions, medication and referral for further assessment and interventions	For all high-intensity psychological interventions, the duration of treatment should normally be within the limits indicated in this guideline	For a person whose depression has not responded to either pharmacological or psychological interventions, consider combining antidepressant medication with CBT.	Psychological interventions for relapse prevention	People with depression who are considered to be at significant risk of relapse (including those who have relapsed despite antidepressant treatment or who are unable or choose not to continue antidepressant treatment) or who have residual symptoms, should be offered one of the following psychological interventions: individual CBT for people who have relapsed despite antidepressant medication and for people with a significant history of depression and residual symptoms despite treatment mindfulness-based cognitive therapy for people who are currently well but have experienced three or more previous episodes of depression.	Delivering psychological interventions for relapse prevention	The full range of high-intensity psychological interventions should normally be offered in inpatient settings	
treatment history	0	0.5241	4	Treatment choice should be influenced by: previous treatment history, including the consequences of a relapse, residual symptoms, response to previous treatment and any discontinuation symptoms the person's preference.	The assessment of a person with depression referred to specialist mental health services should include: their symptom profile, suicide risk and, where appropriate, previous treatment history	Treatment choice should be influenced by: previous treatment history, including the consequences of a relapse, residual symptoms, response to previous treatment and any discontinuation symptoms the person's preference.	The assessment of a person with depression referred to specialist mental health services should include: their symptom profile, suicide risk and, where appropriate, previous treatment history	
comprehensive assessment	0	0.5229	6	When assessing a person who may have depression, conduct a comprehensive assessment that does not rely simply on a symptom count	Note that a comprehensive assessment of depression should not rely simply on a symptom count, but should take into account the degree of functional impairment and or disability (see section ).	When assessing a person who may have depression, conduct a comprehensive assessment that does not rely simply on a symptom count	When assessing a person who may have depression, conduct a comprehensive assessment that does not rely simply on a symptom count	Note that a comprehensive assessment of depression should not rely simply on a symptom count, but should take into account the degree of functional impairment and or disability (see section ).	When assessing a person who may have depression, conduct a comprehensive assessment that does not rely simply on a symptom count	
symptom count	0	0.5229	6	When assessing a person who may have depression, conduct a comprehensive assessment that does not rely simply on a symptom count	Note that a comprehensive assessment of depression should not rely simply on a symptom count, but should take into account the degree of functional impairment and or disability (see section ).	When assessing a person who may have depression, conduct a comprehensive assessment that does not rely simply on a symptom count	When assessing a person who may have depression, conduct a comprehensive assessment that does not rely simply on a symptom count	Note that a comprehensive assessment of depression should not rely simply on a symptom count, but should take into account the degree of functional impairment and or disability (see section ).	When assessing a person who may have depression, conduct a comprehensive assessment that does not rely simply on a symptom count	
behaviour therapy	0	0.5198	4	Recommendation of this guideline updates recommendations made in 'Computerised cognitive behaviour therapy for depression and anxiety' (NICE technology appraisal guidance 97) for the treatment of depression only	This recommendation (and recommendation in CG91) updates the recommendations on depression only in 'Computerised cognitive behaviour therapy for depression and anxiety' (NICE technology appraisal guidance 97).	Recommendation of this guideline updates recommendations made in 'Computerised cognitive behaviour therapy for depression and anxiety' (NICE technology appraisal guidance 97) for the treatment of depression only	This recommendation (and recommendation in CG91) updates the recommendations on depression only in 'Computerised cognitive behaviour therapy for depression and anxiety' (NICE technology appraisal guidance 97).	
cognitive behaviour	0	0.5198	8	Recommendation of this guideline updates recommendations made in 'Computerised cognitive behaviour therapy for depression and anxiety' (NICE technology appraisal guidance 97) for the treatment of depression only	Last updated April 2018 consider offering one or more of the following interventions, guided by the person's preference: individual guided self-help based on the principles of cognitive behavioural therapy (CBT) computerised cognitive behavioural therapy (CCBT) a structured group physical activity programme.	This recommendation (and recommendation in CG91) updates the recommendations on depression only in 'Computerised cognitive behaviour therapy for depression and anxiety' (NICE technology appraisal guidance 97).	For people with persistent subthreshold depressive symptoms or mild to moderate depression, consider offering one or more of the following interventions, guided by the person's preference: individual guided self-help based on the principles of cognitive behavioural therapy (CBT) computerised cognitive behavioural therapy (CCBT) a structured group physical activity programme.	Recommendation of this guideline updates recommendations made in 'Computerised cognitive behaviour therapy for depression and anxiety' (NICE technology appraisal guidance 97) for the treatment of depression only	Last updated April 2018 consider offering one or more of the following interventions, guided by the person's preference: individual guided self-help based on the principles of cognitive behavioural therapy (CBT) computerised cognitive behavioural therapy (CCBT) a structured group physical activity programme.	This recommendation (and recommendation in CG91) updates the recommendations on depression only in 'Computerised cognitive behaviour therapy for depression and anxiety' (NICE technology appraisal guidance 97).	For people with persistent subthreshold depressive symptoms or mild to moderate depression, consider offering one or more of the following interventions, guided by the person's preference: individual guided self-help based on the principles of cognitive behavioural therapy (CBT) computerised cognitive behavioural therapy (CCBT) a structured group physical activity programme.	
computerised cognitive	0	0.5198	8	Recommendation of this guideline updates recommendations made in 'Computerised cognitive behaviour therapy for depression and anxiety' (NICE technology appraisal guidance 97) for the treatment of depression only	Last updated April 2018 consider offering one or more of the following interventions, guided by the person's preference: individual guided self-help based on the principles of cognitive behavioural therapy (CBT) computerised cognitive behavioural therapy (CCBT) a structured group physical activity programme.	This recommendation (and recommendation in CG91) updates the recommendations on depression only in 'Computerised cognitive behaviour therapy for depression and anxiety' (NICE technology appraisal guidance 97).	For people with persistent subthreshold depressive symptoms or mild to moderate depression, consider offering one or more of the following interventions, guided by the person's preference: individual guided self-help based on the principles of cognitive behavioural therapy (CBT) computerised cognitive behavioural therapy (CCBT) a structured group physical activity programme.	Recommendation of this guideline updates recommendations made in 'Computerised cognitive behaviour therapy for depression and anxiety' (NICE technology appraisal guidance 97) for the treatment of depression only	Last updated April 2018 consider offering one or more of the following interventions, guided by the person's preference: individual guided self-help based on the principles of cognitive behavioural therapy (CBT) computerised cognitive behavioural therapy (CCBT) a structured group physical activity programme.	This recommendation (and recommendation in CG91) updates the recommendations on depression only in 'Computerised cognitive behaviour therapy for depression and anxiety' (NICE technology appraisal guidance 97).	For people with persistent subthreshold depressive symptoms or mild to moderate depression, consider offering one or more of the following interventions, guided by the person's preference: individual guided self-help based on the principles of cognitive behavioural therapy (CBT) computerised cognitive behavioural therapy (CCBT) a structured group physical activity programme.	
electroconvulsive therapy	0	0.5198	4	Section of this guideline updates recommendations made in 'Guidance on the use of electroconvulsive therapy' (NICE technology appraisal guidance 59) for the treatment of depression only	The recommendations in this section update the depression aspects only of 'Guidance on the use of electroconvulsive therapy' (NICE technology appraisal guidance 59).	Section of this guideline updates recommendations made in 'Guidance on the use of electroconvulsive therapy' (NICE technology appraisal guidance 59) for the treatment of depression only	The recommendations in this section update the depression aspects only of 'Guidance on the use of electroconvulsive therapy' (NICE technology appraisal guidance 59).	
side effects	0	0.5149	18	Gradually increase the dose of standard-release metformin over several weeks to minimise the risk of gastrointestinal side effects in adults with type 2 diabetes.	If an adult with type 2 diabetes experiences gastrointestinal side effects with standard-release metformin, consider a trial of modified-release metformin.	Gradually increase the dose of standard-release metformin over several weeks to minimise the risk of gastrointestinal side effects in adults with type 2 diabetes.	If an adult with type 2 diabetes experiences gastrointestinal side effects with standard-release metformin, consider a trial of modified-release metformin.	Ensure that consent to treatment is based on the provision of clear information (which should also be available in written form) about the intervention, covering: what it comprises what is expected of the person while having it likely outcomes (including any side effects).	Discuss antidepressant treatment options with the person with depression, covering: the choice of antidepressant, including any anticipated adverse events, for example side effects and discontinuation symptoms (see recommendation ), and potential interactions with concomitant medication or physical health problems their perception of the efficacy and tolerability of any antidepressants they have previously taken.	When prescribing antidepressants, explore any concerns the person with depression has about taking medication, explain fully the reasons for prescribing, and provide information about taking antidepressants, including: the gradual development of the full antidepressant effect the importance of taking medication as prescribed and the need to continue treatment after remission potential side effects the potential for interactions with other medications the risk and nature of discontinuation symptoms with all antidepressants, particularly with drugs with a shorter half-life (such as paroxetine and venlafaxine), and how these symptoms can be minimised the fact that addiction does not occur with antidepressants.	Last updated April 2018 treatment, provide appropriate information and consider one of the following strategies: monitor symptoms closely where side effects are mild and acceptable to the person or stop the antidepressant or change to a different antidepressant if the person prefers or in discussion with the person, consider short-term concomitant treatment with a benzodiazepine if anxiety, agitation and or insomnia are problematic (except in people with chronic symptoms of anxiety); this should usually be for no longer than 2 weeks in order to prevent the development of dependence.	If response is absent or minimal after 3 to 4 weeks of treatment with a therapeutic dose of an antidepressant, increase the level of support (for example, by weekly face-to-face or telephone contact) and consider: increasing the dose in line with the SPC if there are no significant side effects or switching to another antidepressant as described in section if there are side effects or if the person prefers.	When reviewing drug treatment for a person with depression whose symptoms have not adequately responded to initial pharmacological interventions: check adherence to, and side effects from, initial treatment increase the frequency of appointments using outcome monitoring with a validated	People who have had multiple episodes of depression, and who have had a good response to treatment with an antidepressant and an augmenting agent, should remain on this combination after remission if they find the side effects tolerable and acceptable	Ensure that consent to treatment is based on the provision of clear information (which should also be available in written form) about the intervention, covering: what it comprises what is expected of the person while having it likely outcomes (including any side effects).	Discuss antidepressant treatment options with the person with depression, covering: the choice of antidepressant, including any anticipated adverse events, for example side effects and discontinuation symptoms (see recommendation ), and potential interactions with concomitant medication or physical health problems their perception of the efficacy and tolerability of any antidepressants they have previously taken.	When prescribing antidepressants, explore any concerns the person with depression has about taking medication, explain fully the reasons for prescribing, and provide information about taking antidepressants, including: the gradual development of the full antidepressant effect the importance of taking medication as prescribed and the need to continue treatment after remission potential side effects the potential for interactions with other medications the risk and nature of discontinuation symptoms with all antidepressants, particularly with drugs with a shorter half-life (such as paroxetine and venlafaxine), and how these symptoms can be minimised the fact that addiction does not occur with antidepressants.	Last updated April 2018 treatment, provide appropriate information and consider one of the following strategies: monitor symptoms closely where side effects are mild and acceptable to the person or stop the antidepressant or change to a different antidepressant if the person prefers or in discussion with the person, consider short-term concomitant treatment with a benzodiazepine if anxiety, agitation and or insomnia are problematic (except in people with chronic symptoms of anxiety); this should usually be for no longer than 2 weeks in order to prevent the development of dependence.	If response is absent or minimal after 3 to 4 weeks of treatment with a therapeutic dose of an antidepressant, increase the level of support (for example, by weekly face-to-face or telephone contact) and consider: increasing the dose in line with the SPC if there are no significant side effects or switching to another antidepressant as described in section if there are side effects or if the person prefers.	When reviewing drug treatment for a person with depression whose symptoms have not adequately responded to initial pharmacological interventions: check adherence to, and side effects from, initial treatment increase the frequency of appointments using outcome monitoring with a validated	People who have had multiple episodes of depression, and who have had a good response to treatment with an antidepressant and an augmenting agent, should remain on this combination after remission if they find the side effects tolerable and acceptable	
mental health	1	0.5114	28	For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services.	For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services.	For people with recurrent severe depression or depression with psychotic symptoms and for those who have been treated under the Mental Health Act, consider developing advance decisions and advance statements collaboratively with the person	When families or carers are involved in supporting a person with severe or chronic depression, consider: providing written and verbal information on depression and its management, including how families or carers can support the person offering a carer's assessment of their caring, physical and mental health needs if necessary providing information about local family or carer support groups and voluntary organisations, and helping families or carers to access these negotiating between the person and their family or carer about confidentiality and the sharing of information.	In addition to assessing symptoms and associated functional impairment, consider how the following factors may have affected the development, course and severity of a person's depression: any history of depression and comorbid mental health or physical disorders any past history of mood elevation (to determine if the depression may be part of bipolar disorder )	If a person answers 'yes' to either of the depression identification questions (see recommendation ) but the practitioner is not competent to perform a mental health assessment, they should refer the person to an appropriate professional	If a person answers 'yes' to either of the depression identification questions (see recommendation ), a practitioner who is competent to perform a mental health assessment should review the person's mental state and associated functional, interpersonal and social difficulties.	If a person with depression presents considerable immediate risk to themselves or others, refer them urgently to specialist mental health services.	Last updated April 2018 consider increasing the level of support, such as more frequent direct or telephone contacts consider referral to specialist mental health services.	Non-reversible monoamine oxidase inhibitors (MAOIs), such as phenelzine, should normally be prescribed only by specialist mental health professionals.	For people with severe depression and those with moderate depression and complex problems, consider: referring to specialist mental health services for a programme of coordinated multiprofessional care providing collaborative care if the depression is in the context of a chronic physical health problem with associated functional impairment .	Referral to specialist mental health services should normally be for people with depression who are at significant risk of self-harm, have psychotic symptoms, require complex multiprofessional care, or where an expert opinion on treatment and management is needed.	The assessment of a person with depression referred to specialist mental health services should include: their symptom profile, suicide risk and, where appropriate, previous treatment history	In specialist mental health services, after thoroughly reviewing previous treatments for depression, consider reintroducing previous treatments that have been inadequately delivered or adhered to.	Medication in secondary care mental health services should be started under the supervision of a consultant psychiatrist.	For people with recurrent severe depression or depression with psychotic symptoms and for those who have been treated under the Mental Health Act, consider developing advance decisions and advance statements collaboratively with the person	When families or carers are involved in supporting a person with severe or chronic depression, consider: providing written and verbal information on depression and its management, including how families or carers can support the person offering a carer's assessment of their caring, physical and mental health needs if necessary providing information about local family or carer support groups and voluntary organisations, and helping families or carers to access these negotiating between the person and their family or carer about confidentiality and the sharing of information.	In addition to assessing symptoms and associated functional impairment, consider how the following factors may have affected the development, course and severity of a person's depression: any history of depression and comorbid mental health or physical disorders any past history of mood elevation (to determine if the depression may be part of bipolar disorder )	If a person answers 'yes' to either of the depression identification questions (see recommendation ) but the practitioner is not competent to perform a mental health assessment, they should refer the person to an appropriate professional	If a person answers 'yes' to either of the depression identification questions (see recommendation ), a practitioner who is competent to perform a mental health assessment should review the person's mental state and associated functional, interpersonal and social difficulties.	If a person with depression presents considerable immediate risk to themselves or others, refer them urgently to specialist mental health services.	Last updated April 2018 consider increasing the level of support, such as more frequent direct or telephone contacts consider referral to specialist mental health services.	Non-reversible monoamine oxidase inhibitors (MAOIs), such as phenelzine, should normally be prescribed only by specialist mental health professionals.	For people with severe depression and those with moderate depression and complex problems, consider: referring to specialist mental health services for a programme of coordinated multiprofessional care providing collaborative care if the depression is in the context of a chronic physical health problem with associated functional impairment .	Referral to specialist mental health services should normally be for people with depression who are at significant risk of self-harm, have psychotic symptoms, require complex multiprofessional care, or where an expert opinion on treatment and management is needed.	The assessment of a person with depression referred to specialist mental health services should include: their symptom profile, suicide risk and, where appropriate, previous treatment history	In specialist mental health services, after thoroughly reviewing previous treatments for depression, consider reintroducing previous treatments that have been inadequately delivered or adhered to.	Medication in secondary care mental health services should be started under the supervision of a consultant psychiatrist.	
depressive symptoms	0	0.5062	24	Do not use antidepressants routinely to treat persistent subthreshold depressive symptoms or mild depression because the riskbenefit ratio is poor, but consider them for people with: a past history of moderate or severe depression or initial presentation of subthreshold depressive symptoms that have been present for a long period (typically at least 2 years) or subthreshold depressive symptoms or mild depression that persist(s) after other interventions.	When the person has an anxiety disorder and comorbid depression or depressive symptoms, consult the NICE guideline for the relevant anxiety disorder (see find guidance) and consider treating the anxiety disorder first (since effective treatment of the anxiety disorder will often improve the depression or the depressive symptoms).	For people with persistent subthreshold depressive symptoms or mild to moderate depression, consider offering one or more of the following interventions, guided by the person's preference: individual guided self-help based on the principles of cognitive behavioural therapy (CBT) computerised cognitive behavioural therapy (CCBT) a structured group physical activity programme.	Individual guided self-help programmes based on the principles of CBT (and including behavioural activation and problem-solving techniques) for people with persistent subthreshold depressive symptoms or mild to moderate depression should: include the provision of written materials of an appropriate reading age (or alternative media to support access) be supported by a trained practitioner, who typically facilitates the self-help programme and reviews progress and outcome consist of up to six to eight sessions (face-to-face and via telephone) normally taking place over 9 to 12 weeks, including follow-up.	CCBT for people with persistent subthreshold depressive symptoms or mild to moderate depression should: be provided via a stand-alone computer-based or web-based programme include an explanation of the CBT model, encourage tasks between sessions, and use thought-challenging and active monitoring of behaviour, thought patterns and	Physical activity programmes for people with persistent subthreshold depressive symptoms or mild to moderate depression should: be delivered in groups with support from a competent practitioner consist typically of three sessions per week of moderate duration (45 minutes to 1 hour) over 10 to 14 weeks (average 12 weeks).	Consider group-based CBT for people with persistent subthreshold depressive symptoms or mild to moderate depression who decline low-intensity psychosocial interventions (see recommendation ).	Group-based CBT for people with persistent subthreshold depressive symptoms or mild to moderate depression should: be based on a structured model such as 'Coping with Depression' be delivered by two trained and competent practitioners consist of 10 to 12 meetings of eight to ten participants normally take place over 12 to 16 weeks, including follow-up.	Do not use antidepressants routinely to treat persistent subthreshold depressive symptoms or mild depression because the riskbenefit ratio is poor, but consider them for people with: a past history of moderate or severe depression or initial presentation of subthreshold depressive symptoms that have been present for a long period (typically at least 2 years) or	For people with persistent subthreshold depressive symptoms or mild to moderate depression who have not benefited from a low-intensity psychosocial intervention, discuss the relative merits of different interventions with the person and provide: an antidepressant (normally a selective serotonin reuptake inhibitor SSRI) or a high-intensity psychological intervention, normally one of the following options:	For people with depression who decline an antidepressant, CBT, IPT, behavioural activation and behavioural couples therapy, consider: counselling for people with persistent subthreshold depressive symptoms or mild to moderate depression short-term psychodynamic psychotherapy for people with mild to moderate depression.	For all people with persistent subthreshold depressive symptoms or mild to moderate depression having counselling, the duration of treatment should typically be in the range of six to ten sessions over 8 to 12 weeks.	Do not use antidepressants routinely to treat persistent subthreshold depressive symptoms or mild depression because the riskbenefit ratio is poor, but consider them for people with: a past history of moderate or severe depression or initial presentation of subthreshold depressive symptoms that have been present for a long period (typically at least 2 years) or subthreshold depressive symptoms or mild depression that persist(s) after other interventions.	When the person has an anxiety disorder and comorbid depression or depressive symptoms, consult the NICE guideline for the relevant anxiety disorder (see find guidance) and consider treating the anxiety disorder first (since effective treatment of the anxiety disorder will often improve the depression or the depressive symptoms).	For people with persistent subthreshold depressive symptoms or mild to moderate depression, consider offering one or more of the following interventions, guided by the person's preference: individual guided self-help based on the principles of cognitive behavioural therapy (CBT) computerised cognitive behavioural therapy (CCBT) a structured group physical activity programme.	Individual guided self-help programmes based on the principles of CBT (and including behavioural activation and problem-solving techniques) for people with persistent subthreshold depressive symptoms or mild to moderate depression should: include the provision of written materials of an appropriate reading age (or alternative media to support access) be supported by a trained practitioner, who typically facilitates the self-help programme and reviews progress and outcome consist of up to six to eight sessions (face-to-face and via telephone) normally taking place over 9 to 12 weeks, including follow-up.	CCBT for people with persistent subthreshold depressive symptoms or mild to moderate depression should: be provided via a stand-alone computer-based or web-based programme include an explanation of the CBT model, encourage tasks between sessions, and use thought-challenging and active monitoring of behaviour, thought patterns and	Physical activity programmes for people with persistent subthreshold depressive symptoms or mild to moderate depression should: be delivered in groups with support from a competent practitioner consist typically of three sessions per week of moderate duration (45 minutes to 1 hour) over 10 to 14 weeks (average 12 weeks).	Consider group-based CBT for people with persistent subthreshold depressive symptoms or mild to moderate depression who decline low-intensity psychosocial interventions (see recommendation ).	Group-based CBT for people with persistent subthreshold depressive symptoms or mild to moderate depression should: be based on a structured model such as 'Coping with Depression' be delivered by two trained and competent practitioners consist of 10 to 12 meetings of eight to ten participants normally take place over 12 to 16 weeks, including follow-up.	Do not use antidepressants routinely to treat persistent subthreshold depressive symptoms or mild depression because the riskbenefit ratio is poor, but consider them for people with: a past history of moderate or severe depression or initial presentation of subthreshold depressive symptoms that have been present for a long period (typically at least 2 years) or	For people with persistent subthreshold depressive symptoms or mild to moderate depression who have not benefited from a low-intensity psychosocial intervention, discuss the relative merits of different interventions with the person and provide: an antidepressant (normally a selective serotonin reuptake inhibitor SSRI) or a high-intensity psychological intervention, normally one of the following options:	For people with depression who decline an antidepressant, CBT, IPT, behavioural activation and behavioural couples therapy, consider: counselling for people with persistent subthreshold depressive symptoms or mild to moderate depression short-term psychodynamic psychotherapy for people with mild to moderate depression.	For all people with persistent subthreshold depressive symptoms or mild to moderate depression having counselling, the duration of treatment should typically be in the range of six to ten sessions over 8 to 12 weeks.	
high-intensity psychological	0	0.505	12	For people with moderate or severe depression, provide a combination of antidepressant medication and a high-intensity psychological intervention (CBT or IPT).	Medication, high-intensity psychological interventions, combined treatments, collaborative careb and referral for further assessment and interventions	For people with persistent subthreshold depressive symptoms or mild to moderate depression who have not benefited from a low-intensity psychosocial intervention, discuss the relative merits of different interventions with the person and provide: an antidepressant (normally a selective serotonin reuptake inhibitor SSRI) or a high-intensity psychological intervention, normally one of the following options:	For people with moderate or severe depression, provide a combination of antidepressant medication and a high-intensity psychological intervention (CBT or IPT).	For all high-intensity psychological interventions, the duration of treatment should normally be within the limits indicated in this guideline	The full range of high-intensity psychological interventions should normally be offered in inpatient settings	For people with moderate or severe depression, provide a combination of antidepressant medication and a high-intensity psychological intervention (CBT or IPT).	Medication, high-intensity psychological interventions, combined treatments, collaborative careb and referral for further assessment and interventions	For people with persistent subthreshold depressive symptoms or mild to moderate depression who have not benefited from a low-intensity psychosocial intervention, discuss the relative merits of different interventions with the person and provide: an antidepressant (normally a selective serotonin reuptake inhibitor SSRI) or a high-intensity psychological intervention, normally one of the following options:	For people with moderate or severe depression, provide a combination of antidepressant medication and a high-intensity psychological intervention (CBT or IPT).	For all high-intensity psychological interventions, the duration of treatment should normally be within the limits indicated in this guideline	The full range of high-intensity psychological interventions should normally be offered in inpatient settings	
previous episodes	0	0.5027	4	Last updated April 2018 continue antidepressant treatment) or who have residual symptoms, should be offered one of the following psychological interventions: individual CBT for people who have relapsed despite antidepressant medication and for people with a significant history of depression and residual symptoms despite treatment mindfulness-based cognitive therapy for people who are currently well but have experienced three or more previous episodes of depression.	People with depression who are considered to be at significant risk of relapse (including those who have relapsed despite antidepressant treatment or who are unable or choose not to continue antidepressant treatment) or who have residual symptoms, should be offered one of the following psychological interventions: individual CBT for people who have relapsed despite antidepressant medication and for people with a significant history of depression and residual symptoms despite treatment mindfulness-based cognitive therapy for people who are currently well but have experienced three or more previous episodes of depression.	Last updated April 2018 continue antidepressant treatment) or who have residual symptoms, should be offered one of the following psychological interventions: individual CBT for people who have relapsed despite antidepressant medication and for people with a significant history of depression and residual symptoms despite treatment mindfulness-based cognitive therapy for people who are currently well but have experienced three or more previous episodes of depression.	People with depression who are considered to be at significant risk of relapse (including those who have relapsed despite antidepressant treatment or who are unable or choose not to continue antidepressant treatment) or who have residual symptoms, should be offered one of the following psychological interventions: individual CBT for people who have relapsed despite antidepressant medication and for people with a significant history of depression and residual symptoms despite treatment mindfulness-based cognitive therapy for people who are currently well but have experienced three or more previous episodes of depression.	
significant history	0	0.5027	4	Last updated April 2018 continue antidepressant treatment) or who have residual symptoms, should be offered one of the following psychological interventions: individual CBT for people who have relapsed despite antidepressant medication and for people with a significant history of depression and residual symptoms despite treatment mindfulness-based cognitive therapy for people who are currently well but have experienced three or more previous episodes of depression.	People with depression who are considered to be at significant risk of relapse (including those who have relapsed despite antidepressant treatment or who are unable or choose not to continue antidepressant treatment) or who have residual symptoms, should be offered one of the following psychological interventions: individual CBT for people who have relapsed despite antidepressant medication and for people with a significant history of depression and residual symptoms despite treatment mindfulness-based cognitive therapy for people who are currently well but have experienced three or more previous episodes of depression.	Last updated April 2018 continue antidepressant treatment) or who have residual symptoms, should be offered one of the following psychological interventions: individual CBT for people who have relapsed despite antidepressant medication and for people with a significant history of depression and residual symptoms despite treatment mindfulness-based cognitive therapy for people who are currently well but have experienced three or more previous episodes of depression.	People with depression who are considered to be at significant risk of relapse (including those who have relapsed despite antidepressant treatment or who are unable or choose not to continue antidepressant treatment) or who have residual symptoms, should be offered one of the following psychological interventions: individual CBT for people who have relapsed despite antidepressant medication and for people with a significant history of depression and residual symptoms despite treatment mindfulness-based cognitive therapy for people who are currently well but have experienced three or more previous episodes of depression.	
treatment mindfulness-based	0	0.5027	4	Last updated April 2018 continue antidepressant treatment) or who have residual symptoms, should be offered one of the following psychological interventions: individual CBT for people who have relapsed despite antidepressant medication and for people with a significant history of depression and residual symptoms despite treatment mindfulness-based cognitive therapy for people who are currently well but have experienced three or more previous episodes of depression.	People with depression who are considered to be at significant risk of relapse (including those who have relapsed despite antidepressant treatment or who are unable or choose not to continue antidepressant treatment) or who have residual symptoms, should be offered one of the following psychological interventions: individual CBT for people who have relapsed despite antidepressant medication and for people with a significant history of depression and residual symptoms despite treatment mindfulness-based cognitive therapy for people who are currently well but have experienced three or more previous episodes of depression.	Last updated April 2018 continue antidepressant treatment) or who have residual symptoms, should be offered one of the following psychological interventions: individual CBT for people who have relapsed despite antidepressant medication and for people with a significant history of depression and residual symptoms despite treatment mindfulness-based cognitive therapy for people who are currently well but have experienced three or more previous episodes of depression.	People with depression who are considered to be at significant risk of relapse (including those who have relapsed despite antidepressant treatment or who are unable or choose not to continue antidepressant treatment) or who have residual symptoms, should be offered one of the following psychological interventions: individual CBT for people who have relapsed despite antidepressant medication and for people with a significant history of depression and residual symptoms despite treatment mindfulness-based cognitive therapy for people who are currently well but have experienced three or more previous episodes of depression.	
psychotic symptoms	0	0.5014	8	For people with recurrent severe depression or depression with psychotic symptoms and for those who have been treated under the Mental Health Act, consider developing advance decisions and advance statements collaboratively with the person	Assessment, support, psychoeducation, active monitoring and referral for further assessment and interventions a Complex depression includes depression that shows an inadequate response to multiple treatments, is complicated by psychotic symptoms, and or is associated with significant psychiatric comorbidity or psychosocial factors. b Only for depression where the person also has a chronic physical health problem and associated functional impairment (see depression in adults with a chronic physical health problem: recognition and management NICE clinical guideline 91).	Referral to specialist mental health services should normally be for people with depression who are at significant risk of self-harm, have psychotic symptoms, require complex multiprofessional care, or where an expert opinion on treatment and management is needed.	For people who have depression with psychotic symptoms, consider augmenting the current treatment plan with antipsychotic medication (although the optimum dose and duration of treatment are unknown).	For people with recurrent severe depression or depression with psychotic symptoms and for those who have been treated under the Mental Health Act, consider developing advance decisions and advance statements collaboratively with the person	Assessment, support, psychoeducation, active monitoring and referral for further assessment and interventions a Complex depression includes depression that shows an inadequate response to multiple treatments, is complicated by psychotic symptoms, and or is associated with significant psychiatric comorbidity or psychosocial factors. b Only for depression where the person also has a chronic physical health problem and associated functional impairment (see depression in adults with a chronic physical health problem: recognition and management NICE clinical guideline 91).	Referral to specialist mental health services should normally be for people with depression who are at significant risk of self-harm, have psychotic symptoms, require complex multiprofessional care, or where an expert opinion on treatment and management is needed.	For people who have depression with psychotic symptoms, consider augmenting the current treatment plan with antipsychotic medication (although the optimum dose and duration of treatment are unknown).	
activity programme	0	0.5	6	Last updated April 2018 consider offering one or more of the following interventions, guided by the person's preference: individual guided self-help based on the principles of cognitive behavioural therapy (CBT) computerised cognitive behavioural therapy (CCBT) a structured group physical activity programme.	For people with persistent subthreshold depressive symptoms or mild to moderate depression, consider offering one or more of the following interventions, guided by the person's preference: individual guided self-help based on the principles of cognitive behavioural therapy (CBT) computerised cognitive behavioural therapy (CCBT) a structured group physical activity programme.	Physical activity programmes for people with persistent subthreshold depressive symptoms or mild to moderate depression should: be delivered in groups with support from a competent practitioner consist typically of three sessions per week of moderate duration (45 minutes to 1 hour) over 10 to 14 weeks (average 12 weeks).	Last updated April 2018 consider offering one or more of the following interventions, guided by the person's preference: individual guided self-help based on the principles of cognitive behavioural therapy (CBT) computerised cognitive behavioural therapy (CCBT) a structured group physical activity programme.	For people with persistent subthreshold depressive symptoms or mild to moderate depression, consider offering one or more of the following interventions, guided by the person's preference: individual guided self-help based on the principles of cognitive behavioural therapy (CBT) computerised cognitive behavioural therapy (CCBT) a structured group physical activity programme.	Physical activity programmes for people with persistent subthreshold depressive symptoms or mild to moderate depression should: be delivered in groups with support from a competent practitioner consist typically of three sessions per week of moderate duration (45 minutes to 1 hour) over 10 to 14 weeks (average 12 weeks).	
blood pressure	0	0.5	8	Measure blood pressure at least annually in an adult with type 2 diabetes without previously diagnosed hypertension or renal disease	For an adult with type 2 diabetes on antihypertensive drug treatment when diabetes is diagnosed, review blood pressure control and medications used.	Repeat blood pressure measurements within: 1 month if blood pressure is higher than 150 90 mmHg 2 months if blood pressure is higher than 140 80 mmHg 2 months if blood pressure is higher than 130 80 mmHg and there is kidney, eye or cerebrovascular damage.	Measure blood pressure at least annually in an adult with type 2 diabetes without previously diagnosed hypertension or renal disease	For an adult with type 2 diabetes on antihypertensive drug treatment when diabetes is diagnosed, review blood pressure control and medications used.	Repeat blood pressure measurements within: 1 month if blood pressure is higher than 150 90 mmHg 2 months if blood pressure is higher than 140 80 mmHg 2 months if blood pressure is higher than 130 80 mmHg and there is kidney, eye or cerebrovascular damage.	For example: the potential for higher doses of venlafaxine to exacerbate cardiac arrhythmias and the need to monitor the person's blood pressure the possible exacerbation of hypertension with venlafaxine and duloxetine the potential for postural hypotension and arrhythmias with TCAs the need for haematological monitoring with mianserin in elderly people.	For example: the potential for higher doses of venlafaxine to exacerbate cardiac arrhythmias and the need to monitor the person's blood pressure the possible exacerbation of hypertension with venlafaxine and duloxetine the potential for postural hypotension and arrhythmias with TCAs the need for haematological monitoring with mianserin in elderly people.	
cardiac arrhythmias	0	0.5	2	For example: the potential for higher doses of venlafaxine to exacerbate cardiac arrhythmias and the need to monitor the person's blood pressure the possible exacerbation of hypertension with venlafaxine and duloxetine the potential for postural hypotension and arrhythmias with TCAs the need for haematological monitoring with mianserin in elderly people.	For example: the potential for higher doses of venlafaxine to exacerbate cardiac arrhythmias and the need to monitor the person's blood pressure the possible exacerbation of hypertension with venlafaxine and duloxetine the potential for postural hypotension and arrhythmias with TCAs the need for haematological monitoring with mianserin in elderly people.	
care mhra	0	0.5	0	
elderly people	0	0.5	2	For example: the potential for higher doses of venlafaxine to exacerbate cardiac arrhythmias and the need to monitor the person's blood pressure the possible exacerbation of hypertension with venlafaxine and duloxetine the potential for postural hypotension and arrhythmias with TCAs the need for haematological monitoring with mianserin in elderly people.	For example: the potential for higher doses of venlafaxine to exacerbate cardiac arrhythmias and the need to monitor the person's blood pressure the possible exacerbation of hypertension with venlafaxine and duloxetine the potential for postural hypotension and arrhythmias with TCAs the need for haematological monitoring with mianserin in elderly people.	
gmc guidance	0	0.5	2	GMC guidance if off-label medication is prescribed, and monitor carefully for adverse effects be familiar with primary evidence and consider obtaining a second opinion when using unusual combinations, the evidence for the efficacy of a chosen strategy is limited or the riskbenefit ratio is unclear document the rationale for the chosen combination.	GMC guidance if off-label medication is prescribed, and monitor carefully for adverse effects be familiar with primary evidence and consider obtaining a second opinion when using unusual combinations, the evidence for the efficacy of a chosen strategy is limited or the riskbenefit ratio is unclear document the rationale for the chosen combination.	
good evidence	0	0.5	2	This guideline recommends some drugs for indications for which they do not have a UK marketing authorisation at the date of publication, if they are already in use in the NHS for that indication, and there is good evidence to support that use	This guideline recommends some drugs for indications for which they do not have a UK marketing authorisation at the date of publication, if they are already in use in the NHS for that indication, and there is good evidence to support that use	
group physical	0	0.5	4	Last updated April 2018 consider offering one or more of the following interventions, guided by the person's preference: individual guided self-help based on the principles of cognitive behavioural therapy (CBT) computerised cognitive behavioural therapy (CCBT) a structured group physical activity programme.	For people with persistent subthreshold depressive symptoms or mild to moderate depression, consider offering one or more of the following interventions, guided by the person's preference: individual guided self-help based on the principles of cognitive behavioural therapy (CBT) computerised cognitive behavioural therapy (CCBT) a structured group physical activity programme.	Last updated April 2018 consider offering one or more of the following interventions, guided by the person's preference: individual guided self-help based on the principles of cognitive behavioural therapy (CBT) computerised cognitive behavioural therapy (CCBT) a structured group physical activity programme.	For people with persistent subthreshold depressive symptoms or mild to moderate depression, consider offering one or more of the following interventions, guided by the person's preference: individual guided self-help based on the principles of cognitive behavioural therapy (CBT) computerised cognitive behavioural therapy (CCBT) a structured group physical activity programme.	
guideline cg91	0	0.5	2	NICE has also produced a guideline on depression in adults with a chronic physical health problem (NICE guideline CG91).	NICE has also produced a guideline on depression in adults with a chronic physical health problem (NICE guideline CG91).	
haematological monitoring	0	0.5	2	For example: the potential for higher doses of venlafaxine to exacerbate cardiac arrhythmias and the need to monitor the person's blood pressure the possible exacerbation of hypertension with venlafaxine and duloxetine the potential for postural hypotension and arrhythmias with TCAs the need for haematological monitoring with mianserin in elderly people.	For example: the potential for higher doses of venlafaxine to exacerbate cardiac arrhythmias and the need to monitor the person's blood pressure the possible exacerbation of hypertension with venlafaxine and duloxetine the potential for postural hypotension and arrhythmias with TCAs the need for haematological monitoring with mianserin in elderly people.	
inhibitor ssri	0	0.5	2	For people with persistent subthreshold depressive symptoms or mild to moderate depression who have not benefited from a low-intensity psychosocial intervention, discuss the relative merits of different interventions with the person and provide: an antidepressant (normally a selective serotonin reuptake inhibitor SSRI) or a high-intensity psychological intervention, normally one of the following options:	For people with persistent subthreshold depressive symptoms or mild to moderate depression who have not benefited from a low-intensity psychosocial intervention, discuss the relative merits of different interventions with the person and provide: an antidepressant (normally a selective serotonin reuptake inhibitor SSRI) or a high-intensity psychological intervention, normally one of the following options:	
maintenance ect	0	0.5	2	The effectiveness of maintenance ECT for relapse prevention in people with severe and recurring	The effectiveness of maintenance ECT for relapse prevention in people with severe and recurring	
mhra advice	0	0.5	2	MHRA advice on valproate: In April 2018, we added warnings that valproate must not be used in pregnancy, and only used in girls and women when there is no alternative and a pregnancy prevention plan is in place	MHRA advice on valproate: In April 2018, we added warnings that valproate must not be used in pregnancy, and only used in girls and women when there is no alternative and a pregnancy prevention plan is in place	
off-label medication	0	0.5	2	GMC guidance if off-label medication is prescribed, and monitor carefully for adverse effects be familiar with primary evidence and consider obtaining a second opinion when using unusual combinations, the evidence for the efficacy of a chosen strategy is limited or the riskbenefit ratio is unclear document the rationale for the chosen combination.	GMC guidance if off-label medication is prescribed, and monitor carefully for adverse effects be familiar with primary evidence and consider obtaining a second opinion when using unusual combinations, the evidence for the efficacy of a chosen strategy is limited or the riskbenefit ratio is unclear document the rationale for the chosen combination.	
oral contraceptives	0	0.5	2	Although there is evidence that St John's wort may be of benefit in mild or moderate depression, practitioners should: not prescribe or advise its use by people with depression because of uncertainty about appropriate doses, persistence of effect, variation in the nature of preparations and potential serious interactions with other drugs (including oral contraceptives, anticoagulants and anticonvulsants) advise people with depression of the different potencies of the preparations available and of the potential serious interactions of St John's wort with other drugs.	Although there is evidence that St John's wort may be of benefit in mild or moderate depression, practitioners should: not prescribe or advise its use by people with depression because of uncertainty about appropriate doses, persistence of effect, variation in the nature of preparations and potential serious interactions with other drugs (including oral contraceptives, anticoagulants and anticonvulsants) advise people with depression of the different potencies of the preparations available and of the potential serious interactions of St John's wort with other drugs.	
place nice	0	0.5	0	
postural hypotension	0	0.5	2	For example: the potential for higher doses of venlafaxine to exacerbate cardiac arrhythmias and the need to monitor the person's blood pressure the possible exacerbation of hypertension with venlafaxine and duloxetine the potential for postural hypotension and arrhythmias with TCAs the need for haematological monitoring with mianserin in elderly people.	For example: the potential for higher doses of venlafaxine to exacerbate cardiac arrhythmias and the need to monitor the person's blood pressure the possible exacerbation of hypertension with venlafaxine and duloxetine the potential for postural hypotension and arrhythmias with TCAs the need for haematological monitoring with mianserin in elderly people.	
potential therapeutic	0	0.5	2	IPT) behavioural couples therapy for people who have a regular partner and where the relationship may contribute to the development or maintenance of depression, or where involving the partner is considered to be of potential therapeutic benefit.	IPT) behavioural couples therapy for people who have a regular partner and where the relationship may contribute to the development or maintenance of depression, or where involving the partner is considered to be of potential therapeutic benefit.	
pregnancy prevention	0	0.5	2	MHRA advice on valproate: In April 2018, we added warnings that valproate must not be used in pregnancy, and only used in girls and women when there is no alternative and a pregnancy prevention plan is in place	MHRA advice on valproate: In April 2018, we added warnings that valproate must not be used in pregnancy, and only used in girls and women when there is no alternative and a pregnancy prevention plan is in place	
prevention plan	0	0.5	2	MHRA advice on valproate: In April 2018, we added warnings that valproate must not be used in pregnancy, and only used in girls and women when there is no alternative and a pregnancy prevention plan is in place	MHRA advice on valproate: In April 2018, we added warnings that valproate must not be used in pregnancy, and only used in girls and women when there is no alternative and a pregnancy prevention plan is in place	
primary evidence	0	0.5	2	GMC guidance if off-label medication is prescribed, and monitor carefully for adverse effects be familiar with primary evidence and consider obtaining a second opinion when using unusual combinations, the evidence for the efficacy of a chosen strategy is limited or the riskbenefit ratio is unclear document the rationale for the chosen combination.	GMC guidance if off-label medication is prescribed, and monitor carefully for adverse effects be familiar with primary evidence and consider obtaining a second opinion when using unusual combinations, the evidence for the efficacy of a chosen strategy is limited or the riskbenefit ratio is unclear document the rationale for the chosen combination.	
psychosocial intervention	0	0.5	10	Psychological and psychosocial interventions should be based on the relevant treatment manual(s), which should guide the structure and duration of the intervention	Psychological and psychosocial interventions should be based on the relevant treatment manual(s), which should guide the structure and duration of the intervention	Low-intensity psychosocial interventions, psychological interventions, medication and referral for further assessment and interventions	Consider group-based CBT for people with persistent subthreshold depressive symptoms or mild to moderate depression who decline low-intensity psychosocial interventions (see recommendation ).	For people with persistent subthreshold depressive symptoms or mild to moderate depression who have not benefited from a low-intensity psychosocial intervention, discuss the relative merits of different interventions with the person and provide: an antidepressant (normally a selective serotonin reuptake inhibitor SSRI) or a high-intensity psychological intervention, normally one of the following options:	Psychological and psychosocial interventions should be based on the relevant treatment manual(s), which should guide the structure and duration of the intervention	Psychological and psychosocial interventions should be based on the relevant treatment manual(s), which should guide the structure and duration of the intervention	Low-intensity psychosocial interventions, psychological interventions, medication and referral for further assessment and interventions	Consider group-based CBT for people with persistent subthreshold depressive symptoms or mild to moderate depression who decline low-intensity psychosocial interventions (see recommendation ).	For people with persistent subthreshold depressive symptoms or mild to moderate depression who have not benefited from a low-intensity psychosocial intervention, discuss the relative merits of different interventions with the person and provide: an antidepressant (normally a selective serotonin reuptake inhibitor SSRI) or a high-intensity psychological intervention, normally one of the following options:	
regular partner	0	0.5	2	IPT) behavioural couples therapy for people who have a regular partner and where the relationship may contribute to the development or maintenance of depression, or where involving the partner is considered to be of potential therapeutic benefit.	IPT) behavioural couples therapy for people who have a regular partner and where the relationship may contribute to the development or maintenance of depression, or where involving the partner is considered to be of potential therapeutic benefit.	
relative merits	0	0.5	2	For people with persistent subthreshold depressive symptoms or mild to moderate depression who have not benefited from a low-intensity psychosocial intervention, discuss the relative merits of different interventions with the person and provide: an antidepressant (normally a selective serotonin reuptake inhibitor SSRI) or a high-intensity psychological intervention, normally one of the following options:	For people with persistent subthreshold depressive symptoms or mild to moderate depression who have not benefited from a low-intensity psychosocial intervention, discuss the relative merits of different interventions with the person and provide: an antidepressant (normally a selective serotonin reuptake inhibitor SSRI) or a high-intensity psychological intervention, normally one of the following options:	
reuptake inhibitor	0	0.5	2	For people with persistent subthreshold depressive symptoms or mild to moderate depression who have not benefited from a low-intensity psychosocial intervention, discuss the relative merits of different interventions with the person and provide: an antidepressant (normally a selective serotonin reuptake inhibitor SSRI) or a high-intensity psychological intervention, normally one of the following options:	For people with persistent subthreshold depressive symptoms or mild to moderate depression who have not benefited from a low-intensity psychosocial intervention, discuss the relative merits of different interventions with the person and provide: an antidepressant (normally a selective serotonin reuptake inhibitor SSRI) or a high-intensity psychological intervention, normally one of the following options:	
selective serotonin	0	0.5	2	For people with persistent subthreshold depressive symptoms or mild to moderate depression who have not benefited from a low-intensity psychosocial intervention, discuss the relative merits of different interventions with the person and provide: an antidepressant (normally a selective serotonin reuptake inhibitor SSRI) or a high-intensity psychological intervention, normally one of the following options:	For people with persistent subthreshold depressive symptoms or mild to moderate depression who have not benefited from a low-intensity psychosocial intervention, discuss the relative merits of different interventions with the person and provide: an antidepressant (normally a selective serotonin reuptake inhibitor SSRI) or a high-intensity psychological intervention, normally one of the following options:	
serotonin reuptake	0	0.5	2	For people with persistent subthreshold depressive symptoms or mild to moderate depression who have not benefited from a low-intensity psychosocial intervention, discuss the relative merits of different interventions with the person and provide: an antidepressant (normally a selective serotonin reuptake inhibitor SSRI) or a high-intensity psychological intervention, normally one of the following options:	For people with persistent subthreshold depressive symptoms or mild to moderate depression who have not benefited from a low-intensity psychosocial intervention, discuss the relative merits of different interventions with the person and provide: an antidepressant (normally a selective serotonin reuptake inhibitor SSRI) or a high-intensity psychological intervention, normally one of the following options:	
structured group	0	0.5	4	Last updated April 2018 consider offering one or more of the following interventions, guided by the person's preference: individual guided self-help based on the principles of cognitive behavioural therapy (CBT) computerised cognitive behavioural therapy (CCBT) a structured group physical activity programme.	For people with persistent subthreshold depressive symptoms or mild to moderate depression, consider offering one or more of the following interventions, guided by the person's preference: individual guided self-help based on the principles of cognitive behavioural therapy (CBT) computerised cognitive behavioural therapy (CCBT) a structured group physical activity programme.	Last updated April 2018 consider offering one or more of the following interventions, guided by the person's preference: individual guided self-help based on the principles of cognitive behavioural therapy (CBT) computerised cognitive behavioural therapy (CCBT) a structured group physical activity programme.	For people with persistent subthreshold depressive symptoms or mild to moderate depression, consider offering one or more of the following interventions, guided by the person's preference: individual guided self-help based on the principles of cognitive behavioural therapy (CBT) computerised cognitive behavioural therapy (CCBT) a structured group physical activity programme.	
therapeutic benefit	0	0.5	2	IPT) behavioural couples therapy for people who have a regular partner and where the relationship may contribute to the development or maintenance of depression, or where involving the partner is considered to be of potential therapeutic benefit.	IPT) behavioural couples therapy for people who have a regular partner and where the relationship may contribute to the development or maintenance of depression, or where involving the partner is considered to be of potential therapeutic benefit.	
unclear document	0	0.5	2	GMC guidance if off-label medication is prescribed, and monitor carefully for adverse effects be familiar with primary evidence and consider obtaining a second opinion when using unusual combinations, the evidence for the efficacy of a chosen strategy is limited or the riskbenefit ratio is unclear document the rationale for the chosen combination.	GMC guidance if off-label medication is prescribed, and monitor carefully for adverse effects be familiar with primary evidence and consider obtaining a second opinion when using unusual combinations, the evidence for the efficacy of a chosen strategy is limited or the riskbenefit ratio is unclear document the rationale for the chosen combination.	
unusual combinations	0	0.5	2	GMC guidance if off-label medication is prescribed, and monitor carefully for adverse effects be familiar with primary evidence and consider obtaining a second opinion when using unusual combinations, the evidence for the efficacy of a chosen strategy is limited or the riskbenefit ratio is unclear document the rationale for the chosen combination.	GMC guidance if off-label medication is prescribed, and monitor carefully for adverse effects be familiar with primary evidence and consider obtaining a second opinion when using unusual combinations, the evidence for the efficacy of a chosen strategy is limited or the riskbenefit ratio is unclear document the rationale for the chosen combination.	
bipolar disorder	0	0.4999	2	In addition to assessing symptoms and associated functional impairment, consider how the following factors may have affected the development, course and severity of a person's depression: any history of depression and comorbid mental health or physical disorders any past history of mood elevation (to determine if the depression may be part of bipolar disorder )	In addition to assessing symptoms and associated functional impairment, consider how the following factors may have affected the development, course and severity of a person's depression: any history of depression and comorbid mental health or physical disorders any past history of mood elevation (to determine if the depression may be part of bipolar disorder )	
choosing treatments	0	0.4999	2	Principles for assessment, coordination of care and choosing treatments	Principles for assessment, coordination of care and choosing treatments	
comorbid mental	0	0.4999	2	In addition to assessing symptoms and associated functional impairment, consider how the following factors may have affected the development, course and severity of a person's depression: any history of depression and comorbid mental health or physical disorders any past history of mood elevation (to determine if the depression may be part of bipolar disorder )	In addition to assessing symptoms and associated functional impairment, consider how the following factors may have affected the development, course and severity of a person's depression: any history of depression and comorbid mental health or physical disorders any past history of mood elevation (to determine if the depression may be part of bipolar disorder )	
cultural backgrounds	0	0.4999	2	Ensure competence in: culturally sensitive assessment using different explanatory models of depression addressing cultural and ethnic differences when developing and implementing treatment plans working with families from diverse ethnic and cultural backgrounds.	Ensure competence in: culturally sensitive assessment using different explanatory models of depression addressing cultural and ethnic differences when developing and implementing treatment plans working with families from diverse ethnic and cultural backgrounds.	
depression ensure	0	0.4999	2	Last updated April 2018 explore treatment options in an atmosphere of hope and optimism, explaining the different courses of depression and that recovery is possible be aware that stigma and discrimination can be associated with a diagnosis of depression ensure that discussions take place in settings in which confidentiality, privacy and dignity are respected.	Last updated April 2018 explore treatment options in an atmosphere of hope and optimism, explaining the different courses of depression and that recovery is possible be aware that stigma and discrimination can be associated with a diagnosis of depression ensure that discussions take place in settings in which confidentiality, privacy and dignity are respected.	
diverse cultural	0	0.4999	2	Be respectful of, and sensitive to, diverse cultural, ethnic and religious backgrounds when working with people with depression, and be aware of the possible variations in the presentation of depression	Be respectful of, and sensitive to, diverse cultural, ethnic and religious backgrounds when working with people with depression, and be aware of the possible variations in the presentation of depression	
diverse ethnic	0	0.4999	2	Ensure competence in: culturally sensitive assessment using different explanatory models of depression addressing cultural and ethnic differences when developing and implementing treatment plans working with families from diverse ethnic and cultural backgrounds.	Ensure competence in: culturally sensitive assessment using different explanatory models of depression addressing cultural and ethnic differences when developing and implementing treatment plans working with families from diverse ethnic and cultural backgrounds.	
ensure competence	0	0.4999	2	Ensure competence in: culturally sensitive assessment using different explanatory models of depression addressing cultural and ethnic differences when developing and implementing treatment plans working with families from diverse ethnic and cultural backgrounds.	Ensure competence in: culturally sensitive assessment using different explanatory models of depression addressing cultural and ethnic differences when developing and implementing treatment plans working with families from diverse ethnic and cultural backgrounds.	
ethnic differences	0	0.4999	2	Ensure competence in: culturally sensitive assessment using different explanatory models of depression addressing cultural and ethnic differences when developing and implementing treatment plans working with families from diverse ethnic and cultural backgrounds.	Ensure competence in: culturally sensitive assessment using different explanatory models of depression addressing cultural and ethnic differences when developing and implementing treatment plans working with families from diverse ethnic and cultural backgrounds.	
explanatory models	0	0.4999	2	Ensure competence in: culturally sensitive assessment using different explanatory models of depression addressing cultural and ethnic differences when developing and implementing treatment plans working with families from diverse ethnic and cultural backgrounds.	Ensure competence in: culturally sensitive assessment using different explanatory models of depression addressing cultural and ethnic differences when developing and implementing treatment plans working with families from diverse ethnic and cultural backgrounds.	
mood elevation	0	0.4999	2	In addition to assessing symptoms and associated functional impairment, consider how the following factors may have affected the development, course and severity of a person's depression: any history of depression and comorbid mental health or physical disorders any past history of mood elevation (to determine if the depression may be part of bipolar disorder )	In addition to assessing symptoms and associated functional impairment, consider how the following factors may have affected the development, course and severity of a person's depression: any history of depression and comorbid mental health or physical disorders any past history of mood elevation (to determine if the depression may be part of bipolar disorder )	
physical disorders	0	0.4999	2	In addition to assessing symptoms and associated functional impairment, consider how the following factors may have affected the development, course and severity of a person's depression: any history of depression and comorbid mental health or physical disorders any past history of mood elevation (to determine if the depression may be part of bipolar disorder )	In addition to assessing symptoms and associated functional impairment, consider how the following factors may have affected the development, course and severity of a person's depression: any history of depression and comorbid mental health or physical disorders any past history of mood elevation (to determine if the depression may be part of bipolar disorder )	
religious backgrounds	0	0.4999	2	Be respectful of, and sensitive to, diverse cultural, ethnic and religious backgrounds when working with people with depression, and be aware of the possible variations in the presentation of depression	Be respectful of, and sensitive to, diverse cultural, ethnic and religious backgrounds when working with people with depression, and be aware of the possible variations in the presentation of depression	
sensitive assessment	0	0.4999	2	Ensure competence in: culturally sensitive assessment using different explanatory models of depression addressing cultural and ethnic differences when developing and implementing treatment plans working with families from diverse ethnic and cultural backgrounds.	Ensure competence in: culturally sensitive assessment using different explanatory models of depression addressing cultural and ethnic differences when developing and implementing treatment plans working with families from diverse ethnic and cultural backgrounds.	
low-intensity psychosocial	0	0.493	6	Low-intensity psychosocial interventions, psychological interventions, medication and referral for further assessment and interventions	Consider group-based CBT for people with persistent subthreshold depressive symptoms or mild to moderate depression who decline low-intensity psychosocial interventions (see recommendation ).	For people with persistent subthreshold depressive symptoms or mild to moderate depression who have not benefited from a low-intensity psychosocial intervention, discuss the relative merits of different interventions with the person and provide: an antidepressant (normally a selective serotonin reuptake inhibitor SSRI) or a high-intensity psychological intervention, normally one of the following options:	Low-intensity psychosocial interventions, psychological interventions, medication and referral for further assessment and interventions	Consider group-based CBT for people with persistent subthreshold depressive symptoms or mild to moderate depression who decline low-intensity psychosocial interventions (see recommendation ).	For people with persistent subthreshold depressive symptoms or mild to moderate depression who have not benefited from a low-intensity psychosocial intervention, discuss the relative merits of different interventions with the person and provide: an antidepressant (normally a selective serotonin reuptake inhibitor SSRI) or a high-intensity psychological intervention, normally one of the following options:	
initial presentation	0	0.4814	4	Do not use antidepressants routinely to treat persistent subthreshold depressive symptoms or mild depression because the riskbenefit ratio is poor, but consider them for people with: a past history of moderate or severe depression or initial presentation of subthreshold depressive symptoms that have been present for a long period (typically at least 2 years) or subthreshold depressive symptoms or mild depression that persist(s) after other interventions.	Do not use antidepressants routinely to treat persistent subthreshold depressive symptoms or mild depression because the riskbenefit ratio is poor, but consider them for people with: a past history of moderate or severe depression or initial presentation of subthreshold depressive symptoms that have been present for a long period (typically at least 2 years) or	Do not use antidepressants routinely to treat persistent subthreshold depressive symptoms or mild depression because the riskbenefit ratio is poor, but consider them for people with: a past history of moderate or severe depression or initial presentation of subthreshold depressive symptoms that have been present for a long period (typically at least 2 years) or subthreshold depressive symptoms or mild depression that persist(s) after other interventions.	Do not use antidepressants routinely to treat persistent subthreshold depressive symptoms or mild depression because the riskbenefit ratio is poor, but consider them for people with: a past history of moderate or severe depression or initial presentation of subthreshold depressive symptoms that have been present for a long period (typically at least 2 years) or	
long period	0	0.4814	4	Do not use antidepressants routinely to treat persistent subthreshold depressive symptoms or mild depression because the riskbenefit ratio is poor, but consider them for people with: a past history of moderate or severe depression or initial presentation of subthreshold depressive symptoms that have been present for a long period (typically at least 2 years) or subthreshold depressive symptoms or mild depression that persist(s) after other interventions.	Do not use antidepressants routinely to treat persistent subthreshold depressive symptoms or mild depression because the riskbenefit ratio is poor, but consider them for people with: a past history of moderate or severe depression or initial presentation of subthreshold depressive symptoms that have been present for a long period (typically at least 2 years) or	Do not use antidepressants routinely to treat persistent subthreshold depressive symptoms or mild depression because the riskbenefit ratio is poor, but consider them for people with: a past history of moderate or severe depression or initial presentation of subthreshold depressive symptoms that have been present for a long period (typically at least 2 years) or subthreshold depressive symptoms or mild depression that persist(s) after other interventions.	Do not use antidepressants routinely to treat persistent subthreshold depressive symptoms or mild depression because the riskbenefit ratio is poor, but consider them for people with: a past history of moderate or severe depression or initial presentation of subthreshold depressive symptoms that have been present for a long period (typically at least 2 years) or	
practitioners psychological	0	0.4782	0	
original antidepressant	0	0.477	2	If discontinuation symptoms occur: monitor symptoms and reassure the person if symptoms are mild consider reintroducing the original antidepressant at the dose that was effective (or another antidepressant with a longer half-life from the same class) if symptoms are severe, and reduce the dose gradually while monitoring symptoms.	If discontinuation symptoms occur: monitor symptoms and reassure the person if symptoms are mild consider reintroducing the original antidepressant at the dose that was effective (or another antidepressant with a longer half-life from the same class) if symptoms are severe, and reduce the dose gradually while monitoring symptoms.	
significant discontinuation	0	0.477	2	Inform the person that they should seek advice from their practitioner if they experience significant discontinuation symptoms	Inform the person that they should seek advice from their practitioner if they experience significant discontinuation symptoms	
effective intervention	0	0.4695	4	The stepped-care model provides a framework in which to organise the provision of services, and supports patients, carers and practitioners in identifying and accessing the most effective interventions (see figure 1)	In stepped care the least intrusive, most effective intervention is provided first; if a person does not benefit from the intervention initially offered, or declines an intervention, they should be offered an appropriate intervention from the next step.	The stepped-care model provides a framework in which to organise the provision of services, and supports patients, carers and practitioners in identifying and accessing the most effective interventions (see figure 1)	In stepped care the least intrusive, most effective intervention is provided first; if a person does not benefit from the intervention initially offered, or declines an intervention, they should be offered an appropriate intervention from the next step.	
effective interventions	0	0.4695	2	The stepped-care model provides a framework in which to organise the provision of services, and supports patients, carers and practitioners in identifying and accessing the most effective interventions (see figure 1)	The stepped-care model provides a framework in which to organise the provision of services, and supports patients, carers and practitioners in identifying and accessing the most effective interventions (see figure 1)	
stepped-care model	0	0.4695	2	The stepped-care model provides a framework in which to organise the provision of services, and supports patients, carers and practitioners in identifying and accessing the most effective interventions (see figure 1)	The stepped-care model provides a framework in which to organise the provision of services, and supports patients, carers and practitioners in identifying and accessing the most effective interventions (see figure 1)	
primary care	1	0.4674	4	Be aware that: compared with other equally effective antidepressants recommended for routine use in primary care, venlafaxine is associated with a greater risk of death from overdose tricyclic antidepressants (TCAs), except for lofepramine, are associated with the greatest risk in overdose.	When using combinations of medications (which should only normally be started in primary care in consultation with a consultant psychiatrist): select medications that are known to be safe when used together be aware of the increased side-effect burden this usually causes discuss the rationale for any combination with the person with depression, follow	Be aware that: compared with other equally effective antidepressants recommended for routine use in primary care, venlafaxine is associated with a greater risk of death from overdose tricyclic antidepressants (TCAs), except for lofepramine, are associated with the greatest risk in overdose.	When using combinations of medications (which should only normally be started in primary care in consultation with a consultant psychiatrist): select medications that are known to be safe when used together be aware of the increased side-effect burden this usually causes discuss the rationale for any combination with the person with depression, follow	
moderate depression	0	0.4625	26	For people with persistent subthreshold depressive symptoms or mild to moderate depression, consider offering one or more of the following interventions, guided by the person's preference: individual guided self-help based on the principles of cognitive behavioural therapy (CBT) computerised cognitive behavioural therapy (CCBT) a structured group physical activity programme.	Individual guided self-help programmes based on the principles of CBT (and including behavioural activation and problem-solving techniques) for people with persistent subthreshold depressive symptoms or mild to moderate depression should: include the provision of written materials of an appropriate reading age (or alternative media to support access) be supported by a trained practitioner, who typically facilitates the self-help programme and reviews progress and outcome consist of up to six to eight sessions (face-to-face and via telephone) normally taking place over 9 to 12 weeks, including follow-up.	CCBT for people with persistent subthreshold depressive symptoms or mild to moderate depression should: be provided via a stand-alone computer-based or web-based programme include an explanation of the CBT model, encourage tasks between sessions, and use thought-challenging and active monitoring of behaviour, thought patterns and	Physical activity programmes for people with persistent subthreshold depressive symptoms or mild to moderate depression should: be delivered in groups with support from a competent practitioner consist typically of three sessions per week of moderate duration (45 minutes to 1 hour) over 10 to 14 weeks (average 12 weeks).	Consider group-based CBT for people with persistent subthreshold depressive symptoms or mild to moderate depression who decline low-intensity psychosocial interventions (see recommendation ).	Group-based CBT for people with persistent subthreshold depressive symptoms or mild to moderate depression should: be based on a structured model such as 'Coping with Depression' be delivered by two trained and competent practitioners consist of 10 to 12 meetings of eight to ten participants normally take place over 12 to 16 weeks, including follow-up.	Although there is evidence that St John's wort may be of benefit in mild or moderate depression, practitioners should: not prescribe or advise its use by people with depression because of uncertainty about appropriate doses, persistence of effect, variation in the nature of preparations and potential serious interactions with other drugs (including oral contraceptives, anticoagulants and anticonvulsants) advise people with depression of the different potencies of the preparations available and of the potential serious interactions of St John's wort with other drugs.	For people with persistent subthreshold depressive symptoms or mild to moderate depression who have not benefited from a low-intensity psychosocial intervention, discuss the relative merits of different interventions with the person and provide: an antidepressant (normally a selective serotonin reuptake inhibitor SSRI) or a high-intensity psychological intervention, normally one of the following options:	For people with depression who decline an antidepressant, CBT, IPT, behavioural activation and behavioural couples therapy, consider: counselling for people with persistent subthreshold depressive symptoms or mild to moderate depression short-term psychodynamic psychotherapy for people with mild to moderate depression.	For all people with persistent subthreshold depressive symptoms or mild to moderate depression having counselling, the duration of treatment should typically be in the range of six to ten sessions over 8 to 12 weeks.	For all people with mild to moderate depression having short-term psychodynamic psychotherapy, the duration of treatment should typically be in the range of 16 to 20 sessions over 4 to 6 months.	For people with severe depression and those with moderate depression and complex problems, consider: referring to specialist mental health services for a programme of coordinated multiprofessional care providing collaborative care if the depression is in the context of a chronic physical health problem with associated functional impairment .	Do not use ECT routinely for people with moderate depression but consider it if their depression has not responded to multiple drug treatments and psychological treatment.	For people with persistent subthreshold depressive symptoms or mild to moderate depression, consider offering one or more of the following interventions, guided by the person's preference: individual guided self-help based on the principles of cognitive behavioural therapy (CBT) computerised cognitive behavioural therapy (CCBT) a structured group physical activity programme.	Individual guided self-help programmes based on the principles of CBT (and including behavioural activation and problem-solving techniques) for people with persistent subthreshold depressive symptoms or mild to moderate depression should: include the provision of written materials of an appropriate reading age (or alternative media to support access) be supported by a trained practitioner, who typically facilitates the self-help programme and reviews progress and outcome consist of up to six to eight sessions (face-to-face and via telephone) normally taking place over 9 to 12 weeks, including follow-up.	CCBT for people with persistent subthreshold depressive symptoms or mild to moderate depression should: be provided via a stand-alone computer-based or web-based programme include an explanation of the CBT model, encourage tasks between sessions, and use thought-challenging and active monitoring of behaviour, thought patterns and	Physical activity programmes for people with persistent subthreshold depressive symptoms or mild to moderate depression should: be delivered in groups with support from a competent practitioner consist typically of three sessions per week of moderate duration (45 minutes to 1 hour) over 10 to 14 weeks (average 12 weeks).	Consider group-based CBT for people with persistent subthreshold depressive symptoms or mild to moderate depression who decline low-intensity psychosocial interventions (see recommendation ).	Group-based CBT for people with persistent subthreshold depressive symptoms or mild to moderate depression should: be based on a structured model such as 'Coping with Depression' be delivered by two trained and competent practitioners consist of 10 to 12 meetings of eight to ten participants normally take place over 12 to 16 weeks, including follow-up.	Although there is evidence that St John's wort may be of benefit in mild or moderate depression, practitioners should: not prescribe or advise its use by people with depression because of uncertainty about appropriate doses, persistence of effect, variation in the nature of preparations and potential serious interactions with other drugs (including oral contraceptives, anticoagulants and anticonvulsants) advise people with depression of the different potencies of the preparations available and of the potential serious interactions of St John's wort with other drugs.	For people with persistent subthreshold depressive symptoms or mild to moderate depression who have not benefited from a low-intensity psychosocial intervention, discuss the relative merits of different interventions with the person and provide: an antidepressant (normally a selective serotonin reuptake inhibitor SSRI) or a high-intensity psychological intervention, normally one of the following options:	For people with depression who decline an antidepressant, CBT, IPT, behavioural activation and behavioural couples therapy, consider: counselling for people with persistent subthreshold depressive symptoms or mild to moderate depression short-term psychodynamic psychotherapy for people with mild to moderate depression.	For all people with persistent subthreshold depressive symptoms or mild to moderate depression having counselling, the duration of treatment should typically be in the range of six to ten sessions over 8 to 12 weeks.	For all people with mild to moderate depression having short-term psychodynamic psychotherapy, the duration of treatment should typically be in the range of 16 to 20 sessions over 4 to 6 months.	For people with severe depression and those with moderate depression and complex problems, consider: referring to specialist mental health services for a programme of coordinated multiprofessional care providing collaborative care if the depression is in the context of a chronic physical health problem with associated functional impairment .	Do not use ECT routinely for people with moderate depression but consider it if their depression has not responded to multiple drug treatments and psychological treatment.	
support groups	0	0.4608	4	Inform people with depression about self-help groups, support groups and other local and national resources.	When families or carers are involved in supporting a person with severe or chronic depression, consider: providing written and verbal information on depression and its management, including how families or carers can support the person offering a carer's assessment of their caring, physical and mental health needs if necessary providing information about local family or carer support groups and voluntary organisations, and helping families or carers to access these negotiating between the person and their family or carer about confidentiality and the sharing of information.	Inform people with depression about self-help groups, support groups and other local and national resources.	When families or carers are involved in supporting a person with severe or chronic depression, consider: providing written and verbal information on depression and its management, including how families or carers can support the person offering a carer's assessment of their caring, physical and mental health needs if necessary providing information about local family or carer support groups and voluntary organisations, and helping families or carers to access these negotiating between the person and their family or carer about confidentiality and the sharing of information.	
persistent subthreshold	0	0.4586	22	Do not use antidepressants routinely to treat persistent subthreshold depressive symptoms or mild depression because the riskbenefit ratio is poor, but consider them for people with: a past history of moderate or severe depression or initial presentation of subthreshold depressive symptoms that have been present for a long period (typically at least 2 years) or subthreshold depressive symptoms or mild depression that persist(s) after other interventions.	For people with persistent subthreshold depressive symptoms or mild to moderate depression, consider offering one or more of the following interventions, guided by the person's preference: individual guided self-help based on the principles of cognitive behavioural therapy (CBT) computerised cognitive behavioural therapy (CCBT) a structured group physical activity programme.	Individual guided self-help programmes based on the principles of CBT (and including behavioural activation and problem-solving techniques) for people with persistent subthreshold depressive symptoms or mild to moderate depression should: include the provision of written materials of an appropriate reading age (or alternative media to support access) be supported by a trained practitioner, who typically facilitates the self-help programme and reviews progress and outcome consist of up to six to eight sessions (face-to-face and via telephone) normally taking place over 9 to 12 weeks, including follow-up.	CCBT for people with persistent subthreshold depressive symptoms or mild to moderate depression should: be provided via a stand-alone computer-based or web-based programme include an explanation of the CBT model, encourage tasks between sessions, and use thought-challenging and active monitoring of behaviour, thought patterns and	Physical activity programmes for people with persistent subthreshold depressive symptoms or mild to moderate depression should: be delivered in groups with support from a competent practitioner consist typically of three sessions per week of moderate duration (45 minutes to 1 hour) over 10 to 14 weeks (average 12 weeks).	Consider group-based CBT for people with persistent subthreshold depressive symptoms or mild to moderate depression who decline low-intensity psychosocial interventions (see recommendation ).	Group-based CBT for people with persistent subthreshold depressive symptoms or mild to moderate depression should: be based on a structured model such as 'Coping with Depression' be delivered by two trained and competent practitioners consist of 10 to 12 meetings of eight to ten participants normally take place over 12 to 16 weeks, including follow-up.	Do not use antidepressants routinely to treat persistent subthreshold depressive symptoms or mild depression because the riskbenefit ratio is poor, but consider them for people with: a past history of moderate or severe depression or initial presentation of subthreshold depressive symptoms that have been present for a long period (typically at least 2 years) or	For people with persistent subthreshold depressive symptoms or mild to moderate depression who have not benefited from a low-intensity psychosocial intervention, discuss the relative merits of different interventions with the person and provide: an antidepressant (normally a selective serotonin reuptake inhibitor SSRI) or a high-intensity psychological intervention, normally one of the following options:	For people with depression who decline an antidepressant, CBT, IPT, behavioural activation and behavioural couples therapy, consider: counselling for people with persistent subthreshold depressive symptoms or mild to moderate depression short-term psychodynamic psychotherapy for people with mild to moderate depression.	For all people with persistent subthreshold depressive symptoms or mild to moderate depression having counselling, the duration of treatment should typically be in the range of six to ten sessions over 8 to 12 weeks.	Do not use antidepressants routinely to treat persistent subthreshold depressive symptoms or mild depression because the riskbenefit ratio is poor, but consider them for people with: a past history of moderate or severe depression or initial presentation of subthreshold depressive symptoms that have been present for a long period (typically at least 2 years) or subthreshold depressive symptoms or mild depression that persist(s) after other interventions.	For people with persistent subthreshold depressive symptoms or mild to moderate depression, consider offering one or more of the following interventions, guided by the person's preference: individual guided self-help based on the principles of cognitive behavioural therapy (CBT) computerised cognitive behavioural therapy (CCBT) a structured group physical activity programme.	Individual guided self-help programmes based on the principles of CBT (and including behavioural activation and problem-solving techniques) for people with persistent subthreshold depressive symptoms or mild to moderate depression should: include the provision of written materials of an appropriate reading age (or alternative media to support access) be supported by a trained practitioner, who typically facilitates the self-help programme and reviews progress and outcome consist of up to six to eight sessions (face-to-face and via telephone) normally taking place over 9 to 12 weeks, including follow-up.	CCBT for people with persistent subthreshold depressive symptoms or mild to moderate depression should: be provided via a stand-alone computer-based or web-based programme include an explanation of the CBT model, encourage tasks between sessions, and use thought-challenging and active monitoring of behaviour, thought patterns and	Physical activity programmes for people with persistent subthreshold depressive symptoms or mild to moderate depression should: be delivered in groups with support from a competent practitioner consist typically of three sessions per week of moderate duration (45 minutes to 1 hour) over 10 to 14 weeks (average 12 weeks).	Consider group-based CBT for people with persistent subthreshold depressive symptoms or mild to moderate depression who decline low-intensity psychosocial interventions (see recommendation ).	Group-based CBT for people with persistent subthreshold depressive symptoms or mild to moderate depression should: be based on a structured model such as 'Coping with Depression' be delivered by two trained and competent practitioners consist of 10 to 12 meetings of eight to ten participants normally take place over 12 to 16 weeks, including follow-up.	Do not use antidepressants routinely to treat persistent subthreshold depressive symptoms or mild depression because the riskbenefit ratio is poor, but consider them for people with: a past history of moderate or severe depression or initial presentation of subthreshold depressive symptoms that have been present for a long period (typically at least 2 years) or	For people with persistent subthreshold depressive symptoms or mild to moderate depression who have not benefited from a low-intensity psychosocial intervention, discuss the relative merits of different interventions with the person and provide: an antidepressant (normally a selective serotonin reuptake inhibitor SSRI) or a high-intensity psychological intervention, normally one of the following options:	For people with depression who decline an antidepressant, CBT, IPT, behavioural activation and behavioural couples therapy, consider: counselling for people with persistent subthreshold depressive symptoms or mild to moderate depression short-term psychodynamic psychotherapy for people with mild to moderate depression.	For all people with persistent subthreshold depressive symptoms or mild to moderate depression having counselling, the duration of treatment should typically be in the range of six to ten sessions over 8 to 12 weeks.	
audio tapes	0	0.4579	4	Practitioners should consider using competence frameworks developed from the relevant treatment manual(s) and for all interventions should: receive regular high-quality supervision use routine outcome measures and ensure that the person with depression is involved in reviewing the efficacy of the treatment engage in monitoring and evaluation of treatment adherence and practitioner competence  for example, by using video and audio tapes, and external audit and scrutiny where appropriate.	Practitioners should consider using competence frameworks developed from the relevant treatment manual(s) and for all interventions should: receive regular high-quality supervision use routine outcome measures and ensure that the person with depression is involved in reviewing the efficacy of the treatment engage in monitoring and evaluation of treatment adherence and practitioner competence  for example, by using video and audio tapes, and external audit and scrutiny where appropriate.	Practitioners should consider using competence frameworks developed from the relevant treatment manual(s) and for all interventions should: receive regular high-quality supervision use routine outcome measures and ensure that the person with depression is involved in reviewing the efficacy of the treatment engage in monitoring and evaluation of treatment adherence and practitioner competence  for example, by using video and audio tapes, and external audit and scrutiny where appropriate.	Practitioners should consider using competence frameworks developed from the relevant treatment manual(s) and for all interventions should: receive regular high-quality supervision use routine outcome measures and ensure that the person with depression is involved in reviewing the efficacy of the treatment engage in monitoring and evaluation of treatment adherence and practitioner competence  for example, by using video and audio tapes, and external audit and scrutiny where appropriate.	
competence frameworks	0	0.4579	4	Practitioners should consider using competence frameworks developed from the relevant treatment manual(s) and for all interventions should: receive regular high-quality supervision use routine outcome measures and ensure that the person with depression is involved in reviewing the efficacy of the treatment engage in monitoring and evaluation of treatment adherence and practitioner competence  for example, by using video and audio tapes, and external audit and scrutiny where appropriate.	Practitioners should consider using competence frameworks developed from the relevant treatment manual(s) and for all interventions should: receive regular high-quality supervision use routine outcome measures and ensure that the person with depression is involved in reviewing the efficacy of the treatment engage in monitoring and evaluation of treatment adherence and practitioner competence  for example, by using video and audio tapes, and external audit and scrutiny where appropriate.	Practitioners should consider using competence frameworks developed from the relevant treatment manual(s) and for all interventions should: receive regular high-quality supervision use routine outcome measures and ensure that the person with depression is involved in reviewing the efficacy of the treatment engage in monitoring and evaluation of treatment adherence and practitioner competence  for example, by using video and audio tapes, and external audit and scrutiny where appropriate.	Practitioners should consider using competence frameworks developed from the relevant treatment manual(s) and for all interventions should: receive regular high-quality supervision use routine outcome measures and ensure that the person with depression is involved in reviewing the efficacy of the treatment engage in monitoring and evaluation of treatment adherence and practitioner competence  for example, by using video and audio tapes, and external audit and scrutiny where appropriate.	
external audit	0	0.4579	4	Practitioners should consider using competence frameworks developed from the relevant treatment manual(s) and for all interventions should: receive regular high-quality supervision use routine outcome measures and ensure that the person with depression is involved in reviewing the efficacy of the treatment engage in monitoring and evaluation of treatment adherence and practitioner competence  for example, by using video and audio tapes, and external audit and scrutiny where appropriate.	Practitioners should consider using competence frameworks developed from the relevant treatment manual(s) and for all interventions should: receive regular high-quality supervision use routine outcome measures and ensure that the person with depression is involved in reviewing the efficacy of the treatment engage in monitoring and evaluation of treatment adherence and practitioner competence  for example, by using video and audio tapes, and external audit and scrutiny where appropriate.	Practitioners should consider using competence frameworks developed from the relevant treatment manual(s) and for all interventions should: receive regular high-quality supervision use routine outcome measures and ensure that the person with depression is involved in reviewing the efficacy of the treatment engage in monitoring and evaluation of treatment adherence and practitioner competence  for example, by using video and audio tapes, and external audit and scrutiny where appropriate.	Practitioners should consider using competence frameworks developed from the relevant treatment manual(s) and for all interventions should: receive regular high-quality supervision use routine outcome measures and ensure that the person with depression is involved in reviewing the efficacy of the treatment engage in monitoring and evaluation of treatment adherence and practitioner competence  for example, by using video and audio tapes, and external audit and scrutiny where appropriate.	
high-quality supervision	0	0.4579	4	Practitioners should consider using competence frameworks developed from the relevant treatment manual(s) and for all interventions should: receive regular high-quality supervision use routine outcome measures and ensure that the person with depression is involved in reviewing the efficacy of the treatment engage in monitoring and evaluation of treatment adherence and practitioner competence  for example, by using video and audio tapes, and external audit and scrutiny where appropriate.	Practitioners should consider using competence frameworks developed from the relevant treatment manual(s) and for all interventions should: receive regular high-quality supervision use routine outcome measures and ensure that the person with depression is involved in reviewing the efficacy of the treatment engage in monitoring and evaluation of treatment adherence and practitioner competence  for example, by using video and audio tapes, and external audit and scrutiny where appropriate.	Practitioners should consider using competence frameworks developed from the relevant treatment manual(s) and for all interventions should: receive regular high-quality supervision use routine outcome measures and ensure that the person with depression is involved in reviewing the efficacy of the treatment engage in monitoring and evaluation of treatment adherence and practitioner competence  for example, by using video and audio tapes, and external audit and scrutiny where appropriate.	Practitioners should consider using competence frameworks developed from the relevant treatment manual(s) and for all interventions should: receive regular high-quality supervision use routine outcome measures and ensure that the person with depression is involved in reviewing the efficacy of the treatment engage in monitoring and evaluation of treatment adherence and practitioner competence  for example, by using video and audio tapes, and external audit and scrutiny where appropriate.	
intervention practitioners	0	0.4579	0	
outcome measures	0	0.4579	4	Practitioners should consider using competence frameworks developed from the relevant treatment manual(s) and for all interventions should: receive regular high-quality supervision use routine outcome measures and ensure that the person with depression is involved in reviewing the efficacy of the treatment engage in monitoring and evaluation of treatment adherence and practitioner competence  for example, by using video and audio tapes, and external audit and scrutiny where appropriate.	Practitioners should consider using competence frameworks developed from the relevant treatment manual(s) and for all interventions should: receive regular high-quality supervision use routine outcome measures and ensure that the person with depression is involved in reviewing the efficacy of the treatment engage in monitoring and evaluation of treatment adherence and practitioner competence  for example, by using video and audio tapes, and external audit and scrutiny where appropriate.	Practitioners should consider using competence frameworks developed from the relevant treatment manual(s) and for all interventions should: receive regular high-quality supervision use routine outcome measures and ensure that the person with depression is involved in reviewing the efficacy of the treatment engage in monitoring and evaluation of treatment adherence and practitioner competence  for example, by using video and audio tapes, and external audit and scrutiny where appropriate.	Practitioners should consider using competence frameworks developed from the relevant treatment manual(s) and for all interventions should: receive regular high-quality supervision use routine outcome measures and ensure that the person with depression is involved in reviewing the efficacy of the treatment engage in monitoring and evaluation of treatment adherence and practitioner competence  for example, by using video and audio tapes, and external audit and scrutiny where appropriate.	
practitioner competence	0	0.4579	4	Practitioners should consider using competence frameworks developed from the relevant treatment manual(s) and for all interventions should: receive regular high-quality supervision use routine outcome measures and ensure that the person with depression is involved in reviewing the efficacy of the treatment engage in monitoring and evaluation of treatment adherence and practitioner competence  for example, by using video and audio tapes, and external audit and scrutiny where appropriate.	Practitioners should consider using competence frameworks developed from the relevant treatment manual(s) and for all interventions should: receive regular high-quality supervision use routine outcome measures and ensure that the person with depression is involved in reviewing the efficacy of the treatment engage in monitoring and evaluation of treatment adherence and practitioner competence  for example, by using video and audio tapes, and external audit and scrutiny where appropriate.	Practitioners should consider using competence frameworks developed from the relevant treatment manual(s) and for all interventions should: receive regular high-quality supervision use routine outcome measures and ensure that the person with depression is involved in reviewing the efficacy of the treatment engage in monitoring and evaluation of treatment adherence and practitioner competence  for example, by using video and audio tapes, and external audit and scrutiny where appropriate.	Practitioners should consider using competence frameworks developed from the relevant treatment manual(s) and for all interventions should: receive regular high-quality supervision use routine outcome measures and ensure that the person with depression is involved in reviewing the efficacy of the treatment engage in monitoring and evaluation of treatment adherence and practitioner competence  for example, by using video and audio tapes, and external audit and scrutiny where appropriate.	
regular high-quality	0	0.4579	4	Practitioners should consider using competence frameworks developed from the relevant treatment manual(s) and for all interventions should: receive regular high-quality supervision use routine outcome measures and ensure that the person with depression is involved in reviewing the efficacy of the treatment engage in monitoring and evaluation of treatment adherence and practitioner competence  for example, by using video and audio tapes, and external audit and scrutiny where appropriate.	Practitioners should consider using competence frameworks developed from the relevant treatment manual(s) and for all interventions should: receive regular high-quality supervision use routine outcome measures and ensure that the person with depression is involved in reviewing the efficacy of the treatment engage in monitoring and evaluation of treatment adherence and practitioner competence  for example, by using video and audio tapes, and external audit and scrutiny where appropriate.	Practitioners should consider using competence frameworks developed from the relevant treatment manual(s) and for all interventions should: receive regular high-quality supervision use routine outcome measures and ensure that the person with depression is involved in reviewing the efficacy of the treatment engage in monitoring and evaluation of treatment adherence and practitioner competence  for example, by using video and audio tapes, and external audit and scrutiny where appropriate.	Practitioners should consider using competence frameworks developed from the relevant treatment manual(s) and for all interventions should: receive regular high-quality supervision use routine outcome measures and ensure that the person with depression is involved in reviewing the efficacy of the treatment engage in monitoring and evaluation of treatment adherence and practitioner competence  for example, by using video and audio tapes, and external audit and scrutiny where appropriate.	
routine outcome	0	0.4579	4	Practitioners should consider using competence frameworks developed from the relevant treatment manual(s) and for all interventions should: receive regular high-quality supervision use routine outcome measures and ensure that the person with depression is involved in reviewing the efficacy of the treatment engage in monitoring and evaluation of treatment adherence and practitioner competence  for example, by using video and audio tapes, and external audit and scrutiny where appropriate.	Practitioners should consider using competence frameworks developed from the relevant treatment manual(s) and for all interventions should: receive regular high-quality supervision use routine outcome measures and ensure that the person with depression is involved in reviewing the efficacy of the treatment engage in monitoring and evaluation of treatment adherence and practitioner competence  for example, by using video and audio tapes, and external audit and scrutiny where appropriate.	Practitioners should consider using competence frameworks developed from the relevant treatment manual(s) and for all interventions should: receive regular high-quality supervision use routine outcome measures and ensure that the person with depression is involved in reviewing the efficacy of the treatment engage in monitoring and evaluation of treatment adherence and practitioner competence  for example, by using video and audio tapes, and external audit and scrutiny where appropriate.	Practitioners should consider using competence frameworks developed from the relevant treatment manual(s) and for all interventions should: receive regular high-quality supervision use routine outcome measures and ensure that the person with depression is involved in reviewing the efficacy of the treatment engage in monitoring and evaluation of treatment adherence and practitioner competence  for example, by using video and audio tapes, and external audit and scrutiny where appropriate.	
treatment adherence	0	0.4579	4	Practitioners should consider using competence frameworks developed from the relevant treatment manual(s) and for all interventions should: receive regular high-quality supervision use routine outcome measures and ensure that the person with depression is involved in reviewing the efficacy of the treatment engage in monitoring and evaluation of treatment adherence and practitioner competence  for example, by using video and audio tapes, and external audit and scrutiny where appropriate.	Practitioners should consider using competence frameworks developed from the relevant treatment manual(s) and for all interventions should: receive regular high-quality supervision use routine outcome measures and ensure that the person with depression is involved in reviewing the efficacy of the treatment engage in monitoring and evaluation of treatment adherence and practitioner competence  for example, by using video and audio tapes, and external audit and scrutiny where appropriate.	Practitioners should consider using competence frameworks developed from the relevant treatment manual(s) and for all interventions should: receive regular high-quality supervision use routine outcome measures and ensure that the person with depression is involved in reviewing the efficacy of the treatment engage in monitoring and evaluation of treatment adherence and practitioner competence  for example, by using video and audio tapes, and external audit and scrutiny where appropriate.	Practitioners should consider using competence frameworks developed from the relevant treatment manual(s) and for all interventions should: receive regular high-quality supervision use routine outcome measures and ensure that the person with depression is involved in reviewing the efficacy of the treatment engage in monitoring and evaluation of treatment adherence and practitioner competence  for example, by using video and audio tapes, and external audit and scrutiny where appropriate.	
psychosocial interventions	0	0.4467	8	Psychological and psychosocial interventions should be based on the relevant treatment manual(s), which should guide the structure and duration of the intervention	Psychological and psychosocial interventions should be based on the relevant treatment manual(s), which should guide the structure and duration of the intervention	Low-intensity psychosocial interventions, psychological interventions, medication and referral for further assessment and interventions	Consider group-based CBT for people with persistent subthreshold depressive symptoms or mild to moderate depression who decline low-intensity psychosocial interventions (see recommendation ).	Psychological and psychosocial interventions should be based on the relevant treatment manual(s), which should guide the structure and duration of the intervention	Psychological and psychosocial interventions should be based on the relevant treatment manual(s), which should guide the structure and duration of the intervention	Low-intensity psychosocial interventions, psychological interventions, medication and referral for further assessment and interventions	Consider group-based CBT for people with persistent subthreshold depressive symptoms or mild to moderate depression who decline low-intensity psychosocial interventions (see recommendation ).	
care plan	0	0.4412	4	Teams working with people with complex and severe depression should develop comprehensive multidisciplinary care plans in collaboration with the person with depression (and their family or carer, if agreed with the person)	The care plan should: identify clearly the roles and responsibilities of all health and social care professionals involved develop a crisis plan that identifies potential triggers that could lead to a crisis and strategies to manage such triggers be shared with the GP and the person with depression and other relevant people involved in the person's care.	Teams working with people with complex and severe depression should develop comprehensive multidisciplinary care plans in collaboration with the person with depression (and their family or carer, if agreed with the person)	The care plan should: identify clearly the roles and responsibilities of all health and social care professionals involved develop a crisis plan that identifies potential triggers that could lead to a crisis and strategies to manage such triggers be shared with the GP and the person with depression and other relevant people involved in the person's care.	
care plans	0	0.4412	2	Teams working with people with complex and severe depression should develop comprehensive multidisciplinary care plans in collaboration with the person with depression (and their family or carer, if agreed with the person)	Teams working with people with complex and severe depression should develop comprehensive multidisciplinary care plans in collaboration with the person with depression (and their family or carer, if agreed with the person)	
care professionals	0	0.4412	2	The care plan should: identify clearly the roles and responsibilities of all health and social care professionals involved develop a crisis plan that identifies potential triggers that could lead to a crisis and strategies to manage such triggers be shared with the GP and the person with depression and other relevant people involved in the person's care.	The care plan should: identify clearly the roles and responsibilities of all health and social care professionals involved develop a crisis plan that identifies potential triggers that could lead to a crisis and strategies to manage such triggers be shared with the GP and the person with depression and other relevant people involved in the person's care.	
comprehensive multidisciplinary	0	0.4412	2	Teams working with people with complex and severe depression should develop comprehensive multidisciplinary care plans in collaboration with the person with depression (and their family or carer, if agreed with the person)	Teams working with people with complex and severe depression should develop comprehensive multidisciplinary care plans in collaboration with the person with depression (and their family or carer, if agreed with the person)	
crisis plan	0	0.4412	2	The care plan should: identify clearly the roles and responsibilities of all health and social care professionals involved develop a crisis plan that identifies potential triggers that could lead to a crisis and strategies to manage such triggers be shared with the GP and the person with depression and other relevant people involved in the person's care.	The care plan should: identify clearly the roles and responsibilities of all health and social care professionals involved develop a crisis plan that identifies potential triggers that could lead to a crisis and strategies to manage such triggers be shared with the GP and the person with depression and other relevant people involved in the person's care.	
multidisciplinary care	0	0.4412	2	Teams working with people with complex and severe depression should develop comprehensive multidisciplinary care plans in collaboration with the person with depression (and their family or carer, if agreed with the person)	Teams working with people with complex and severe depression should develop comprehensive multidisciplinary care plans in collaboration with the person with depression (and their family or carer, if agreed with the person)	
potential triggers	0	0.4412	2	The care plan should: identify clearly the roles and responsibilities of all health and social care professionals involved develop a crisis plan that identifies potential triggers that could lead to a crisis and strategies to manage such triggers be shared with the GP and the person with depression and other relevant people involved in the person's care.	The care plan should: identify clearly the roles and responsibilities of all health and social care professionals involved develop a crisis plan that identifies potential triggers that could lead to a crisis and strategies to manage such triggers be shared with the GP and the person with depression and other relevant people involved in the person's care.	
relevant people	0	0.4412	2	The care plan should: identify clearly the roles and responsibilities of all health and social care professionals involved develop a crisis plan that identifies potential triggers that could lead to a crisis and strategies to manage such triggers be shared with the GP and the person with depression and other relevant people involved in the person's care.	The care plan should: identify clearly the roles and responsibilities of all health and social care professionals involved develop a crisis plan that identifies potential triggers that could lead to a crisis and strategies to manage such triggers be shared with the GP and the person with depression and other relevant people involved in the person's care.	
social care	0	0.4412	2	The care plan should: identify clearly the roles and responsibilities of all health and social care professionals involved develop a crisis plan that identifies potential triggers that could lead to a crisis and strategies to manage such triggers be shared with the GP and the person with depression and other relevant people involved in the person's care.	The care plan should: identify clearly the roles and responsibilities of all health and social care professionals involved develop a crisis plan that identifies potential triggers that could lead to a crisis and strategies to manage such triggers be shared with the GP and the person with depression and other relevant people involved in the person's care.	
relapse prevention	0	0.4254	16	The effectiveness of maintenance ECT for relapse prevention in people with severe and recurring	Continuation and relapse prevention	Psychological interventions for relapse prevention	Continuation and relapse prevention	Using medication for relapse prevention	Psychological interventions for relapse prevention	Delivering psychological interventions for relapse prevention	For all people with depression who are having individual CBT for relapse prevention, the duration of treatment should typically be in the range of 16 to 20 sessions over 3 to 4 months	The effectiveness of maintenance ECT for relapse prevention in people with severe and recurring	Continuation and relapse prevention	Psychological interventions for relapse prevention	Continuation and relapse prevention	Using medication for relapse prevention	Psychological interventions for relapse prevention	Delivering psychological interventions for relapse prevention	For all people with depression who are having individual CBT for relapse prevention, the duration of treatment should typically be in the range of 16 to 20 sessions over 3 to 4 months	
riskbenefit ratio	0	0.4249	6	Do not use antidepressants routinely to treat persistent subthreshold depressive symptoms or mild depression because the riskbenefit ratio is poor, but consider them for people with: a past history of moderate or severe depression or initial presentation of subthreshold depressive symptoms that have been present for a long period (typically at least 2 years) or subthreshold depressive symptoms or mild depression that persist(s) after other interventions.	Do not use antidepressants routinely to treat persistent subthreshold depressive symptoms or mild depression because the riskbenefit ratio is poor, but consider them for people with: a past history of moderate or severe depression or initial presentation of subthreshold depressive symptoms that have been present for a long period (typically at least 2 years) or	GMC guidance if off-label medication is prescribed, and monitor carefully for adverse effects be familiar with primary evidence and consider obtaining a second opinion when using unusual combinations, the evidence for the efficacy of a chosen strategy is limited or the riskbenefit ratio is unclear document the rationale for the chosen combination.	Do not use antidepressants routinely to treat persistent subthreshold depressive symptoms or mild depression because the riskbenefit ratio is poor, but consider them for people with: a past history of moderate or severe depression or initial presentation of subthreshold depressive symptoms that have been present for a long period (typically at least 2 years) or subthreshold depressive symptoms or mild depression that persist(s) after other interventions.	Do not use antidepressants routinely to treat persistent subthreshold depressive symptoms or mild depression because the riskbenefit ratio is poor, but consider them for people with: a past history of moderate or severe depression or initial presentation of subthreshold depressive symptoms that have been present for a long period (typically at least 2 years) or	GMC guidance if off-label medication is prescribed, and monitor carefully for adverse effects be familiar with primary evidence and consider obtaining a second opinion when using unusual combinations, the evidence for the efficacy of a chosen strategy is limited or the riskbenefit ratio is unclear document the rationale for the chosen combination.	
cardiovascular disease	0	0.4203	6	Do not offer antiplatelet therapy (aspirin or clopidogrel) for adults with type 2 diabetes without cardiovascular disease.	For guidance on the primary and secondary prevention of cardiovascular disease in adults with type 2 diabetes, see the NICE guidelines on cardiovascular disease and myocardial infarction.	Do not offer antiplatelet therapy (aspirin or clopidogrel) for adults with type 2 diabetes without cardiovascular disease.	For guidance on the primary and secondary prevention of cardiovascular disease in adults with type 2 diabetes, see the NICE guidelines on cardiovascular disease and myocardial infarction.	When prescribing lithium: monitor renal and thyroid function before treatment and every 6 months during treatment (more often if there is evidence of renal impairment) consider ECG monitoring in people with depression who are at high risk of cardiovascular disease	When prescribing lithium: monitor renal and thyroid function before treatment and every 6 months during treatment (more often if there is evidence of renal impairment) consider ECG monitoring in people with depression who are at high risk of cardiovascular disease	
dependence augmentation	0	0.4203	2	The following strategies should not be used routinely: augmentation of an antidepressant with a benzodiazepine for more than 2 weeks as there is a risk of dependence augmentation of an antidepressant with buspirone , carbamazepine , lamotrigine or valproate as there is insufficient evidence for their use augmentation of an antidepressant with pindolol or thyroid hormones as there is inconsistent evidence of effectiveness .	The following strategies should not be used routinely: augmentation of an antidepressant with a benzodiazepine for more than 2 weeks as there is a risk of dependence augmentation of an antidepressant with buspirone , carbamazepine , lamotrigine or valproate as there is insufficient evidence for their use augmentation of an antidepressant with pindolol or thyroid hormones as there is inconsistent evidence of effectiveness .	
disease depression	0	0.4203	0	
high risk	0	0.4203	4	Last updated May 2017 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities.	Last updated May 2017 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities.	When prescribing lithium: monitor renal and thyroid function before treatment and every 6 months during treatment (more often if there is evidence of renal impairment) consider ECG monitoring in people with depression who are at high risk of cardiovascular disease	When prescribing lithium: monitor renal and thyroid function before treatment and every 6 months during treatment (more often if there is evidence of renal impairment) consider ECG monitoring in people with depression who are at high risk of cardiovascular disease	
inconsistent evidence	0	0.4203	2	The following strategies should not be used routinely: augmentation of an antidepressant with a benzodiazepine for more than 2 weeks as there is a risk of dependence augmentation of an antidepressant with buspirone , carbamazepine , lamotrigine or valproate as there is insufficient evidence for their use augmentation of an antidepressant with pindolol or thyroid hormones as there is inconsistent evidence of effectiveness .	The following strategies should not be used routinely: augmentation of an antidepressant with a benzodiazepine for more than 2 weeks as there is a risk of dependence augmentation of an antidepressant with buspirone , carbamazepine , lamotrigine or valproate as there is insufficient evidence for their use augmentation of an antidepressant with pindolol or thyroid hormones as there is inconsistent evidence of effectiveness .	
insufficient evidence	0	0.4203	2	The following strategies should not be used routinely: augmentation of an antidepressant with a benzodiazepine for more than 2 weeks as there is a risk of dependence augmentation of an antidepressant with buspirone , carbamazepine , lamotrigine or valproate as there is insufficient evidence for their use augmentation of an antidepressant with pindolol or thyroid hormones as there is inconsistent evidence of effectiveness .	The following strategies should not be used routinely: augmentation of an antidepressant with a benzodiazepine for more than 2 weeks as there is a risk of dependence augmentation of an antidepressant with buspirone , carbamazepine , lamotrigine or valproate as there is insufficient evidence for their use augmentation of an antidepressant with pindolol or thyroid hormones as there is inconsistent evidence of effectiveness .	
renal impairment	0	0.4203	2	When prescribing lithium: monitor renal and thyroid function before treatment and every 6 months during treatment (more often if there is evidence of renal impairment) consider ECG monitoring in people with depression who are at high risk of cardiovascular disease	When prescribing lithium: monitor renal and thyroid function before treatment and every 6 months during treatment (more often if there is evidence of renal impairment) consider ECG monitoring in people with depression who are at high risk of cardiovascular disease	
thyroid function	0	0.4203	2	When prescribing lithium: monitor renal and thyroid function before treatment and every 6 months during treatment (more often if there is evidence of renal impairment) consider ECG monitoring in people with depression who are at high risk of cardiovascular disease	When prescribing lithium: monitor renal and thyroid function before treatment and every 6 months during treatment (more often if there is evidence of renal impairment) consider ECG monitoring in people with depression who are at high risk of cardiovascular disease	
thyroid hormones	0	0.4203	2	The following strategies should not be used routinely: augmentation of an antidepressant with a benzodiazepine for more than 2 weeks as there is a risk of dependence augmentation of an antidepressant with buspirone , carbamazepine , lamotrigine or valproate as there is insufficient evidence for their use augmentation of an antidepressant with pindolol or thyroid hormones as there is inconsistent evidence of effectiveness .	The following strategies should not be used routinely: augmentation of an antidepressant with a benzodiazepine for more than 2 weeks as there is a risk of dependence augmentation of an antidepressant with buspirone , carbamazepine , lamotrigine or valproate as there is insufficient evidence for their use augmentation of an antidepressant with pindolol or thyroid hormones as there is inconsistent evidence of effectiveness .	
follow-up sessions	0	0.4199	8	Also consider providing: two sessions per week for the first 2 to 3 weeks of treatment for people with moderate or severe depression follow-up sessions typically consisting of three to four sessions over the following 3 to 6 months for all people with depression.	Also consider providing: two sessions per week for the first 3 to 4 weeks of treatment for people with moderate or severe depression follow-up sessions typically consisting of three to four sessions over the following 3 to 6 months for all people with depression.	If the duration of treatment needs to be extended to achieve remission it should: consist of two sessions per week for the first 2 to 3 weeks of treatment include additional follow-up sessions, typically consisting of four to six sessions over	Mindfulness-based cognitive therapy should normally be delivered in groups of 8 to 15 participants and consist of weekly 2-hour meetings over 8 weeks and four follow-up sessions in the 12 months after the end of treatment.	Also consider providing: two sessions per week for the first 2 to 3 weeks of treatment for people with moderate or severe depression follow-up sessions typically consisting of three to four sessions over the following 3 to 6 months for all people with depression.	Also consider providing: two sessions per week for the first 3 to 4 weeks of treatment for people with moderate or severe depression follow-up sessions typically consisting of three to four sessions over the following 3 to 6 months for all people with depression.	If the duration of treatment needs to be extended to achieve remission it should: consist of two sessions per week for the first 2 to 3 weeks of treatment include additional follow-up sessions, typically consisting of four to six sessions over	Mindfulness-based cognitive therapy should normally be delivered in groups of 8 to 15 participants and consist of weekly 2-hour meetings over 8 weeks and four follow-up sessions in the 12 months after the end of treatment.	
antidepressant effect	0	0.4108	2	When prescribing antidepressants, explore any concerns the person with depression has about taking medication, explain fully the reasons for prescribing, and provide information about taking antidepressants, including: the gradual development of the full antidepressant effect the importance of taking medication as prescribed and the need to continue treatment after remission potential side effects the potential for interactions with other medications the risk and nature of discontinuation symptoms with all antidepressants, particularly with drugs with a shorter half-life (such as paroxetine and venlafaxine), and how these symptoms can be minimised the fact that addiction does not occur with antidepressants.	When prescribing antidepressants, explore any concerns the person with depression has about taking medication, explain fully the reasons for prescribing, and provide information about taking antidepressants, including: the gradual development of the full antidepressant effect the importance of taking medication as prescribed and the need to continue treatment after remission potential side effects the potential for interactions with other medications the risk and nature of discontinuation symptoms with all antidepressants, particularly with drugs with a shorter half-life (such as paroxetine and venlafaxine), and how these symptoms can be minimised the fact that addiction does not occur with antidepressants.	
full antidepressant	0	0.4108	2	When prescribing antidepressants, explore any concerns the person with depression has about taking medication, explain fully the reasons for prescribing, and provide information about taking antidepressants, including: the gradual development of the full antidepressant effect the importance of taking medication as prescribed and the need to continue treatment after remission potential side effects the potential for interactions with other medications the risk and nature of discontinuation symptoms with all antidepressants, particularly with drugs with a shorter half-life (such as paroxetine and venlafaxine), and how these symptoms can be minimised the fact that addiction does not occur with antidepressants.	When prescribing antidepressants, explore any concerns the person with depression has about taking medication, explain fully the reasons for prescribing, and provide information about taking antidepressants, including: the gradual development of the full antidepressant effect the importance of taking medication as prescribed and the need to continue treatment after remission potential side effects the potential for interactions with other medications the risk and nature of discontinuation symptoms with all antidepressants, particularly with drugs with a shorter half-life (such as paroxetine and venlafaxine), and how these symptoms can be minimised the fact that addiction does not occur with antidepressants.	
gradual development	0	0.4108	2	When prescribing antidepressants, explore any concerns the person with depression has about taking medication, explain fully the reasons for prescribing, and provide information about taking antidepressants, including: the gradual development of the full antidepressant effect the importance of taking medication as prescribed and the need to continue treatment after remission potential side effects the potential for interactions with other medications the risk and nature of discontinuation symptoms with all antidepressants, particularly with drugs with a shorter half-life (such as paroxetine and venlafaxine), and how these symptoms can be minimised the fact that addiction does not occur with antidepressants.	When prescribing antidepressants, explore any concerns the person with depression has about taking medication, explain fully the reasons for prescribing, and provide information about taking antidepressants, including: the gradual development of the full antidepressant effect the importance of taking medication as prescribed and the need to continue treatment after remission potential side effects the potential for interactions with other medications the risk and nature of discontinuation symptoms with all antidepressants, particularly with drugs with a shorter half-life (such as paroxetine and venlafaxine), and how these symptoms can be minimised the fact that addiction does not occur with antidepressants.	
potential side	0	0.4108	2	When prescribing antidepressants, explore any concerns the person with depression has about taking medication, explain fully the reasons for prescribing, and provide information about taking antidepressants, including: the gradual development of the full antidepressant effect the importance of taking medication as prescribed and the need to continue treatment after remission potential side effects the potential for interactions with other medications the risk and nature of discontinuation symptoms with all antidepressants, particularly with drugs with a shorter half-life (such as paroxetine and venlafaxine), and how these symptoms can be minimised the fact that addiction does not occur with antidepressants.	When prescribing antidepressants, explore any concerns the person with depression has about taking medication, explain fully the reasons for prescribing, and provide information about taking antidepressants, including: the gradual development of the full antidepressant effect the importance of taking medication as prescribed and the need to continue treatment after remission potential side effects the potential for interactions with other medications the risk and nature of discontinuation symptoms with all antidepressants, particularly with drugs with a shorter half-life (such as paroxetine and venlafaxine), and how these symptoms can be minimised the fact that addiction does not occur with antidepressants.	
remission potential	0	0.4108	2	When prescribing antidepressants, explore any concerns the person with depression has about taking medication, explain fully the reasons for prescribing, and provide information about taking antidepressants, including: the gradual development of the full antidepressant effect the importance of taking medication as prescribed and the need to continue treatment after remission potential side effects the potential for interactions with other medications the risk and nature of discontinuation symptoms with all antidepressants, particularly with drugs with a shorter half-life (such as paroxetine and venlafaxine), and how these symptoms can be minimised the fact that addiction does not occur with antidepressants.	When prescribing antidepressants, explore any concerns the person with depression has about taking medication, explain fully the reasons for prescribing, and provide information about taking antidepressants, including: the gradual development of the full antidepressant effect the importance of taking medication as prescribed and the need to continue treatment after remission potential side effects the potential for interactions with other medications the risk and nature of discontinuation symptoms with all antidepressants, particularly with drugs with a shorter half-life (such as paroxetine and venlafaxine), and how these symptoms can be minimised the fact that addiction does not occur with antidepressants.	
functional impairment	0	0.4004	14	In practical terms, clinicians are not expected to switch to DSM-IV but should be aware that the threshold for mild depression is higher than ICD-10 (five symptoms instead of four) and that degree of functional impairment should be routinely assessed before making a diagnosis	Be alert to possible depression (particularly in people with a past history of depression or a chronic physical health problem with associated functional impairment) and consider asking people who may have depression two questions, specifically:	Note that a comprehensive assessment of depression should not rely simply on a symptom count, but should take into account the degree of functional impairment and or disability (see section ).	In addition to assessing symptoms and associated functional impairment, consider how the following factors may have affected the development, course and severity of a person's depression: any history of depression and comorbid mental health or physical disorders any past history of mood elevation (to determine if the depression may be part of bipolar disorder )	Assessment, support, psychoeducation, active monitoring and referral for further assessment and interventions a Complex depression includes depression that shows an inadequate response to multiple treatments, is complicated by psychotic symptoms, and or is associated with significant psychiatric comorbidity or psychosocial factors. b Only for depression where the person also has a chronic physical health problem and associated functional impairment (see depression in adults with a chronic physical health problem: recognition and management NICE clinical guideline 91).	Be alert to possible depression (particularly in people with a past history of depression or a chronic physical health problem with associated functional impairment) and consider asking people who may have depression two questions, specifically:	For people with severe depression and those with moderate depression and complex problems, consider: referring to specialist mental health services for a programme of coordinated multiprofessional care providing collaborative care if the depression is in the context of a chronic physical health problem with associated functional impairment .	In practical terms, clinicians are not expected to switch to DSM-IV but should be aware that the threshold for mild depression is higher than ICD-10 (five symptoms instead of four) and that degree of functional impairment should be routinely assessed before making a diagnosis	Be alert to possible depression (particularly in people with a past history of depression or a chronic physical health problem with associated functional impairment) and consider asking people who may have depression two questions, specifically:	Note that a comprehensive assessment of depression should not rely simply on a symptom count, but should take into account the degree of functional impairment and or disability (see section ).	In addition to assessing symptoms and associated functional impairment, consider how the following factors may have affected the development, course and severity of a person's depression: any history of depression and comorbid mental health or physical disorders any past history of mood elevation (to determine if the depression may be part of bipolar disorder )	Assessment, support, psychoeducation, active monitoring and referral for further assessment and interventions a Complex depression includes depression that shows an inadequate response to multiple treatments, is complicated by psychotic symptoms, and or is associated with significant psychiatric comorbidity or psychosocial factors. b Only for depression where the person also has a chronic physical health problem and associated functional impairment (see depression in adults with a chronic physical health problem: recognition and management NICE clinical guideline 91).	Be alert to possible depression (particularly in people with a past history of depression or a chronic physical health problem with associated functional impairment) and consider asking people who may have depression two questions, specifically:	For people with severe depression and those with moderate depression and complex problems, consider: referring to specialist mental health services for a programme of coordinated multiprofessional care providing collaborative care if the depression is in the context of a chronic physical health problem with associated functional impairment .	
cognitive therapy	0	0.399	6	Last updated April 2018 continue antidepressant treatment) or who have residual symptoms, should be offered one of the following psychological interventions: individual CBT for people who have relapsed despite antidepressant medication and for people with a significant history of depression and residual symptoms despite treatment mindfulness-based cognitive therapy for people who are currently well but have experienced three or more previous episodes of depression.	People with depression who are considered to be at significant risk of relapse (including those who have relapsed despite antidepressant treatment or who are unable or choose not to continue antidepressant treatment) or who have residual symptoms, should be offered one of the following psychological interventions: individual CBT for people who have relapsed despite antidepressant medication and for people with a significant history of depression and residual symptoms despite treatment mindfulness-based cognitive therapy for people who are currently well but have experienced three or more previous episodes of depression.	Mindfulness-based cognitive therapy should normally be delivered in groups of 8 to 15 participants and consist of weekly 2-hour meetings over 8 weeks and four follow-up sessions in the 12 months after the end of treatment.	Last updated April 2018 continue antidepressant treatment) or who have residual symptoms, should be offered one of the following psychological interventions: individual CBT for people who have relapsed despite antidepressant medication and for people with a significant history of depression and residual symptoms despite treatment mindfulness-based cognitive therapy for people who are currently well but have experienced three or more previous episodes of depression.	People with depression who are considered to be at significant risk of relapse (including those who have relapsed despite antidepressant treatment or who are unable or choose not to continue antidepressant treatment) or who have residual symptoms, should be offered one of the following psychological interventions: individual CBT for people who have relapsed despite antidepressant medication and for people with a significant history of depression and residual symptoms despite treatment mindfulness-based cognitive therapy for people who are currently well but have experienced three or more previous episodes of depression.	Mindfulness-based cognitive therapy should normally be delivered in groups of 8 to 15 participants and consist of weekly 2-hour meetings over 8 weeks and four follow-up sessions in the 12 months after the end of treatment.	
mindfulness-based cognitive	0	0.399	6	Last updated April 2018 continue antidepressant treatment) or who have residual symptoms, should be offered one of the following psychological interventions: individual CBT for people who have relapsed despite antidepressant medication and for people with a significant history of depression and residual symptoms despite treatment mindfulness-based cognitive therapy for people who are currently well but have experienced three or more previous episodes of depression.	People with depression who are considered to be at significant risk of relapse (including those who have relapsed despite antidepressant treatment or who are unable or choose not to continue antidepressant treatment) or who have residual symptoms, should be offered one of the following psychological interventions: individual CBT for people who have relapsed despite antidepressant medication and for people with a significant history of depression and residual symptoms despite treatment mindfulness-based cognitive therapy for people who are currently well but have experienced three or more previous episodes of depression.	Mindfulness-based cognitive therapy should normally be delivered in groups of 8 to 15 participants and consist of weekly 2-hour meetings over 8 weeks and four follow-up sessions in the 12 months after the end of treatment.	Last updated April 2018 continue antidepressant treatment) or who have residual symptoms, should be offered one of the following psychological interventions: individual CBT for people who have relapsed despite antidepressant medication and for people with a significant history of depression and residual symptoms despite treatment mindfulness-based cognitive therapy for people who are currently well but have experienced three or more previous episodes of depression.	People with depression who are considered to be at significant risk of relapse (including those who have relapsed despite antidepressant treatment or who are unable or choose not to continue antidepressant treatment) or who have residual symptoms, should be offered one of the following psychological interventions: individual CBT for people who have relapsed despite antidepressant medication and for people with a significant history of depression and residual symptoms despite treatment mindfulness-based cognitive therapy for people who are currently well but have experienced three or more previous episodes of depression.	Mindfulness-based cognitive therapy should normally be delivered in groups of 8 to 15 participants and consist of weekly 2-hour meetings over 8 weeks and four follow-up sessions in the 12 months after the end of treatment.	
prevention people	0	0.3938	0	
severe depression	0	0.3931	22	Do not use antidepressants routinely to treat persistent subthreshold depressive symptoms or mild depression because the riskbenefit ratio is poor, but consider them for people with: a past history of moderate or severe depression or initial presentation of subthreshold depressive symptoms that have been present for a long period (typically at least 2 years) or subthreshold depressive symptoms or mild depression that persist(s) after other interventions.	For people with moderate or severe depression, provide a combination of antidepressant medication and a high-intensity psychological intervention (CBT or IPT).	For people with recurrent severe depression or depression with psychotic symptoms and for those who have been treated under the Mental Health Act, consider developing advance decisions and advance statements collaboratively with the person	Do not use antidepressants routinely to treat persistent subthreshold depressive symptoms or mild depression because the riskbenefit ratio is poor, but consider them for people with: a past history of moderate or severe depression or initial presentation of subthreshold depressive symptoms that have been present for a long period (typically at least 2 years) or	For people with moderate or severe depression, provide a combination of antidepressant medication and a high-intensity psychological intervention (CBT or IPT).	Also consider providing: two sessions per week for the first 2 to 3 weeks of treatment for people with moderate or severe depression follow-up sessions typically consisting of three to four sessions over the following 3 to 6 months for all people with depression.	For people with severe depression, consider providing two sessions per week for the first 2 to 3 weeks of treatment.	Also consider providing: two sessions per week for the first 3 to 4 weeks of treatment for people with moderate or severe depression follow-up sessions typically consisting of three to four sessions over the following 3 to 6 months for all people with depression.	For people with long-standing moderate or severe depression who would benefit from additional social or vocational support, consider: befriending as an adjunct to pharmacological or psychological treatments; befriending should be by trained volunteers providing, typically, at least weekly contact for between 2 and 6 months a rehabilitation programme if a person's depression has resulted in loss of work or disengagement from other social activities over a longer term.	For people with severe depression and those with moderate depression and complex problems, consider: referring to specialist mental health services for a programme of coordinated multiprofessional care providing collaborative care if the depression is in the context of a chronic physical health problem with associated functional impairment .	Teams working with people with complex and severe depression should develop comprehensive multidisciplinary care plans in collaboration with the person with depression (and their family or carer, if agreed with the person)	Do not use antidepressants routinely to treat persistent subthreshold depressive symptoms or mild depression because the riskbenefit ratio is poor, but consider them for people with: a past history of moderate or severe depression or initial presentation of subthreshold depressive symptoms that have been present for a long period (typically at least 2 years) or subthreshold depressive symptoms or mild depression that persist(s) after other interventions.	For people with moderate or severe depression, provide a combination of antidepressant medication and a high-intensity psychological intervention (CBT or IPT).	For people with recurrent severe depression or depression with psychotic symptoms and for those who have been treated under the Mental Health Act, consider developing advance decisions and advance statements collaboratively with the person	Do not use antidepressants routinely to treat persistent subthreshold depressive symptoms or mild depression because the riskbenefit ratio is poor, but consider them for people with: a past history of moderate or severe depression or initial presentation of subthreshold depressive symptoms that have been present for a long period (typically at least 2 years) or	For people with moderate or severe depression, provide a combination of antidepressant medication and a high-intensity psychological intervention (CBT or IPT).	Also consider providing: two sessions per week for the first 2 to 3 weeks of treatment for people with moderate or severe depression follow-up sessions typically consisting of three to four sessions over the following 3 to 6 months for all people with depression.	For people with severe depression, consider providing two sessions per week for the first 2 to 3 weeks of treatment.	Also consider providing: two sessions per week for the first 3 to 4 weeks of treatment for people with moderate or severe depression follow-up sessions typically consisting of three to four sessions over the following 3 to 6 months for all people with depression.	For people with long-standing moderate or severe depression who would benefit from additional social or vocational support, consider: befriending as an adjunct to pharmacological or psychological treatments; befriending should be by trained volunteers providing, typically, at least weekly contact for between 2 and 6 months a rehabilitation programme if a person's depression has resulted in loss of work or disengagement from other social activities over a longer term.	For people with severe depression and those with moderate depression and complex problems, consider: referring to specialist mental health services for a programme of coordinated multiprofessional care providing collaborative care if the depression is in the context of a chronic physical health problem with associated functional impairment .	Teams working with people with complex and severe depression should develop comprehensive multidisciplinary care plans in collaboration with the person with depression (and their family or carer, if agreed with the person)	
depression follow-up	0	0.3835	4	Also consider providing: two sessions per week for the first 2 to 3 weeks of treatment for people with moderate or severe depression follow-up sessions typically consisting of three to four sessions over the following 3 to 6 months for all people with depression.	Also consider providing: two sessions per week for the first 3 to 4 weeks of treatment for people with moderate or severe depression follow-up sessions typically consisting of three to four sessions over the following 3 to 6 months for all people with depression.	Also consider providing: two sessions per week for the first 2 to 3 weeks of treatment for people with moderate or severe depression follow-up sessions typically consisting of three to four sessions over the following 3 to 6 months for all people with depression.	Also consider providing: two sessions per week for the first 3 to 4 weeks of treatment for people with moderate or severe depression follow-up sessions typically consisting of three to four sessions over the following 3 to 6 months for all people with depression.	
advance decisions	0	0.3834	2	For people with recurrent severe depression or depression with psychotic symptoms and for those who have been treated under the Mental Health Act, consider developing advance decisions and advance statements collaboratively with the person	For people with recurrent severe depression or depression with psychotic symptoms and for those who have been treated under the Mental Health Act, consider developing advance decisions and advance statements collaboratively with the person	
advance statements	0	0.3834	2	For people with recurrent severe depression or depression with psychotic symptoms and for those who have been treated under the Mental Health Act, consider developing advance decisions and advance statements collaboratively with the person	For people with recurrent severe depression or depression with psychotic symptoms and for those who have been treated under the Mental Health Act, consider developing advance decisions and advance statements collaboratively with the person	
carer support	0	0.3834	2	When families or carers are involved in supporting a person with severe or chronic depression, consider: providing written and verbal information on depression and its management, including how families or carers can support the person offering a carer's assessment of their caring, physical and mental health needs if necessary providing information about local family or carer support groups and voluntary organisations, and helping families or carers to access these negotiating between the person and their family or carer about confidentiality and the sharing of information.	When families or carers are involved in supporting a person with severe or chronic depression, consider: providing written and verbal information on depression and its management, including how families or carers can support the person offering a carer's assessment of their caring, physical and mental health needs if necessary providing information about local family or carer support groups and voluntary organisations, and helping families or carers to access these negotiating between the person and their family or carer about confidentiality and the sharing of information.	
chronic depression	0	0.3834	2	When families or carers are involved in supporting a person with severe or chronic depression, consider: providing written and verbal information on depression and its management, including how families or carers can support the person offering a carer's assessment of their caring, physical and mental health needs if necessary providing information about local family or carer support groups and voluntary organisations, and helping families or carers to access these negotiating between the person and their family or carer about confidentiality and the sharing of information.	When families or carers are involved in supporting a person with severe or chronic depression, consider: providing written and verbal information on depression and its management, including how families or carers can support the person offering a carer's assessment of their caring, physical and mental health needs if necessary providing information about local family or carer support groups and voluntary organisations, and helping families or carers to access these negotiating between the person and their family or carer about confidentiality and the sharing of information.	
health act	1	0.3834	2	For people with recurrent severe depression or depression with psychotic symptoms and for those who have been treated under the Mental Health Act, consider developing advance decisions and advance statements collaboratively with the person	For people with recurrent severe depression or depression with psychotic symptoms and for those who have been treated under the Mental Health Act, consider developing advance decisions and advance statements collaboratively with the person	
initial management	0	0.3834	2	Step 1: recognition, assessment and initial management	Step 1: recognition, assessment and initial management	
local family	0	0.3834	2	When families or carers are involved in supporting a person with severe or chronic depression, consider: providing written and verbal information on depression and its management, including how families or carers can support the person offering a carer's assessment of their caring, physical and mental health needs if necessary providing information about local family or carer support groups and voluntary organisations, and helping families or carers to access these negotiating between the person and their family or carer about confidentiality and the sharing of information.	When families or carers are involved in supporting a person with severe or chronic depression, consider: providing written and verbal information on depression and its management, including how families or carers can support the person offering a carer's assessment of their caring, physical and mental health needs if necessary providing information about local family or carer support groups and voluntary organisations, and helping families or carers to access these negotiating between the person and their family or carer about confidentiality and the sharing of information.	
mental state	1	0.3834	2	If a person answers 'yes' to either of the depression identification questions (see recommendation ), a practitioner who is competent to perform a mental health assessment should review the person's mental state and associated functional, interpersonal and social difficulties.	If a person answers 'yes' to either of the depression identification questions (see recommendation ), a practitioner who is competent to perform a mental health assessment should review the person's mental state and associated functional, interpersonal and social difficulties.	
professional depression	0	0.3834	0	
recurrent severe	0	0.3834	2	For people with recurrent severe depression or depression with psychotic symptoms and for those who have been treated under the Mental Health Act, consider developing advance decisions and advance statements collaboratively with the person	For people with recurrent severe depression or depression with psychotic symptoms and for those who have been treated under the Mental Health Act, consider developing advance decisions and advance statements collaboratively with the person	
social difficulties	0	0.3834	2	If a person answers 'yes' to either of the depression identification questions (see recommendation ), a practitioner who is competent to perform a mental health assessment should review the person's mental state and associated functional, interpersonal and social difficulties.	If a person answers 'yes' to either of the depression identification questions (see recommendation ), a practitioner who is competent to perform a mental health assessment should review the person's mental state and associated functional, interpersonal and social difficulties.	
verbal information	0	0.3834	2	When families or carers are involved in supporting a person with severe or chronic depression, consider: providing written and verbal information on depression and its management, including how families or carers can support the person offering a carer's assessment of their caring, physical and mental health needs if necessary providing information about local family or carer support groups and voluntary organisations, and helping families or carers to access these negotiating between the person and their family or carer about confidentiality and the sharing of information.	When families or carers are involved in supporting a person with severe or chronic depression, consider: providing written and verbal information on depression and its management, including how families or carers can support the person offering a carer's assessment of their caring, physical and mental health needs if necessary providing information about local family or carer support groups and voluntary organisations, and helping families or carers to access these negotiating between the person and their family or carer about confidentiality and the sharing of information.	
voluntary organisations	0	0.3834	2	When families or carers are involved in supporting a person with severe or chronic depression, consider: providing written and verbal information on depression and its management, including how families or carers can support the person offering a carer's assessment of their caring, physical and mental health needs if necessary providing information about local family or carer support groups and voluntary organisations, and helping families or carers to access these negotiating between the person and their family or carer about confidentiality and the sharing of information.	When families or carers are involved in supporting a person with severe or chronic depression, consider: providing written and verbal information on depression and its management, including how families or carers can support the person offering a carer's assessment of their caring, physical and mental health needs if necessary providing information about local family or carer support groups and voluntary organisations, and helping families or carers to access these negotiating between the person and their family or carer about confidentiality and the sharing of information.	
collaborative careb	0	0.365	2	Medication, high-intensity psychological interventions, combined treatments, collaborative careb and referral for further assessment and interventions	Medication, high-intensity psychological interventions, combined treatments, collaborative careb and referral for further assessment and interventions	
combined treatments	0	0.365	2	Medication, high-intensity psychological interventions, combined treatments, collaborative careb and referral for further assessment and interventions	Medication, high-intensity psychological interventions, combined treatments, collaborative careb and referral for further assessment and interventions	
complex depression	0	0.365	2	Assessment, support, psychoeducation, active monitoring and referral for further assessment and interventions a Complex depression includes depression that shows an inadequate response to multiple treatments, is complicated by psychotic symptoms, and or is associated with significant psychiatric comorbidity or psychosocial factors. b Only for depression where the person also has a chronic physical health problem and associated functional impairment (see depression in adults with a chronic physical health problem: recognition and management NICE clinical guideline 91).	Assessment, support, psychoeducation, active monitoring and referral for further assessment and interventions a Complex depression includes depression that shows an inadequate response to multiple treatments, is complicated by psychotic symptoms, and or is associated with significant psychiatric comorbidity or psychosocial factors. b Only for depression where the person also has a chronic physical health problem and associated functional impairment (see depression in adults with a chronic physical health problem: recognition and management NICE clinical guideline 91).	
complexa depression	0	0.365	2	STEP 4: Severe and complexa depression; risk to life; severe self-neglect	STEP 4: Severe and complexa depression; risk to life; severe self-neglect	
inadequate response	0	0.365	2	Assessment, support, psychoeducation, active monitoring and referral for further assessment and interventions a Complex depression includes depression that shows an inadequate response to multiple treatments, is complicated by psychotic symptoms, and or is associated with significant psychiatric comorbidity or psychosocial factors. b Only for depression where the person also has a chronic physical health problem and associated functional impairment (see depression in adults with a chronic physical health problem: recognition and management NICE clinical guideline 91).	Assessment, support, psychoeducation, active monitoring and referral for further assessment and interventions a Complex depression includes depression that shows an inadequate response to multiple treatments, is complicated by psychotic symptoms, and or is associated with significant psychiatric comorbidity or psychosocial factors. b Only for depression where the person also has a chronic physical health problem and associated functional impairment (see depression in adults with a chronic physical health problem: recognition and management NICE clinical guideline 91).	
interventions assessment	0	0.365	0	
interventions low-intensity	0	0.365	0	
management nice	0	0.365	2	Assessment, support, psychoeducation, active monitoring and referral for further assessment and interventions a Complex depression includes depression that shows an inadequate response to multiple treatments, is complicated by psychotic symptoms, and or is associated with significant psychiatric comorbidity or psychosocial factors. b Only for depression where the person also has a chronic physical health problem and associated functional impairment (see depression in adults with a chronic physical health problem: recognition and management NICE clinical guideline 91).	Assessment, support, psychoeducation, active monitoring and referral for further assessment and interventions a Complex depression includes depression that shows an inadequate response to multiple treatments, is complicated by psychotic symptoms, and or is associated with significant psychiatric comorbidity or psychosocial factors. b Only for depression where the person also has a chronic physical health problem and associated functional impairment (see depression in adults with a chronic physical health problem: recognition and management NICE clinical guideline 91).	
multiple treatments	0	0.365	2	Assessment, support, psychoeducation, active monitoring and referral for further assessment and interventions a Complex depression includes depression that shows an inadequate response to multiple treatments, is complicated by psychotic symptoms, and or is associated with significant psychiatric comorbidity or psychosocial factors. b Only for depression where the person also has a chronic physical health problem and associated functional impairment (see depression in adults with a chronic physical health problem: recognition and management NICE clinical guideline 91).	Assessment, support, psychoeducation, active monitoring and referral for further assessment and interventions a Complex depression includes depression that shows an inadequate response to multiple treatments, is complicated by psychotic symptoms, and or is associated with significant psychiatric comorbidity or psychosocial factors. b Only for depression where the person also has a chronic physical health problem and associated functional impairment (see depression in adults with a chronic physical health problem: recognition and management NICE clinical guideline 91).	
psychiatric comorbidity	0	0.365	2	Assessment, support, psychoeducation, active monitoring and referral for further assessment and interventions a Complex depression includes depression that shows an inadequate response to multiple treatments, is complicated by psychotic symptoms, and or is associated with significant psychiatric comorbidity or psychosocial factors. b Only for depression where the person also has a chronic physical health problem and associated functional impairment (see depression in adults with a chronic physical health problem: recognition and management NICE clinical guideline 91).	Assessment, support, psychoeducation, active monitoring and referral for further assessment and interventions a Complex depression includes depression that shows an inadequate response to multiple treatments, is complicated by psychotic symptoms, and or is associated with significant psychiatric comorbidity or psychosocial factors. b Only for depression where the person also has a chronic physical health problem and associated functional impairment (see depression in adults with a chronic physical health problem: recognition and management NICE clinical guideline 91).	
psychosocial factors	0	0.365	2	Assessment, support, psychoeducation, active monitoring and referral for further assessment and interventions a Complex depression includes depression that shows an inadequate response to multiple treatments, is complicated by psychotic symptoms, and or is associated with significant psychiatric comorbidity or psychosocial factors. b Only for depression where the person also has a chronic physical health problem and associated functional impairment (see depression in adults with a chronic physical health problem: recognition and management NICE clinical guideline 91).	Assessment, support, psychoeducation, active monitoring and referral for further assessment and interventions a Complex depression includes depression that shows an inadequate response to multiple treatments, is complicated by psychotic symptoms, and or is associated with significant psychiatric comorbidity or psychosocial factors. b Only for depression where the person also has a chronic physical health problem and associated functional impairment (see depression in adults with a chronic physical health problem: recognition and management NICE clinical guideline 91).	
self-neglect depression	0	0.365	0	
severe self-neglect	0	0.365	2	STEP 4: Severe and complexa depression; risk to life; severe self-neglect	STEP 4: Severe and complexa depression; risk to life; severe self-neglect	
significant psychiatric	0	0.365	2	Assessment, support, psychoeducation, active monitoring and referral for further assessment and interventions a Complex depression includes depression that shows an inadequate response to multiple treatments, is complicated by psychotic symptoms, and or is associated with significant psychiatric comorbidity or psychosocial factors. b Only for depression where the person also has a chronic physical health problem and associated functional impairment (see depression in adults with a chronic physical health problem: recognition and management NICE clinical guideline 91).	Assessment, support, psychoeducation, active monitoring and referral for further assessment and interventions a Complex depression includes depression that shows an inadequate response to multiple treatments, is complicated by psychotic symptoms, and or is associated with significant psychiatric comorbidity or psychosocial factors. b Only for depression where the person also has a chronic physical health problem and associated functional impairment (see depression in adults with a chronic physical health problem: recognition and management NICE clinical guideline 91).	
past history	0	0.3626	12	Therefore it is also important to consider both personal past history and family history of depression when undertaking a diagnostic assessment (see appendix for further details).	Be alert to possible depression (particularly in people with a past history of depression or a chronic physical health problem with associated functional impairment) and consider asking people who may have depression two questions, specifically:	Do not use antidepressants routinely to treat persistent subthreshold depressive symptoms or mild depression because the riskbenefit ratio is poor, but consider them for people with: a past history of moderate or severe depression or initial presentation of subthreshold depressive symptoms that have been present for a long period (typically at least 2 years) or subthreshold depressive symptoms or mild depression that persist(s) after other interventions.	In addition to assessing symptoms and associated functional impairment, consider how the following factors may have affected the development, course and severity of a person's depression: any history of depression and comorbid mental health or physical disorders any past history of mood elevation (to determine if the depression may be part of bipolar disorder )	Be alert to possible depression (particularly in people with a past history of depression or a chronic physical health problem with associated functional impairment) and consider asking people who may have depression two questions, specifically:	Do not use antidepressants routinely to treat persistent subthreshold depressive symptoms or mild depression because the riskbenefit ratio is poor, but consider them for people with: a past history of moderate or severe depression or initial presentation of subthreshold depressive symptoms that have been present for a long period (typically at least 2 years) or	Therefore it is also important to consider both personal past history and family history of depression when undertaking a diagnostic assessment (see appendix for further details).	Be alert to possible depression (particularly in people with a past history of depression or a chronic physical health problem with associated functional impairment) and consider asking people who may have depression two questions, specifically:	Do not use antidepressants routinely to treat persistent subthreshold depressive symptoms or mild depression because the riskbenefit ratio is poor, but consider them for people with: a past history of moderate or severe depression or initial presentation of subthreshold depressive symptoms that have been present for a long period (typically at least 2 years) or subthreshold depressive symptoms or mild depression that persist(s) after other interventions.	In addition to assessing symptoms and associated functional impairment, consider how the following factors may have affected the development, course and severity of a person's depression: any history of depression and comorbid mental health or physical disorders any past history of mood elevation (to determine if the depression may be part of bipolar disorder )	Be alert to possible depression (particularly in people with a past history of depression or a chronic physical health problem with associated functional impairment) and consider asking people who may have depression two questions, specifically:	Do not use antidepressants routinely to treat persistent subthreshold depressive symptoms or mild depression because the riskbenefit ratio is poor, but consider them for people with: a past history of moderate or severe depression or initial presentation of subthreshold depressive symptoms that have been present for a long period (typically at least 2 years) or	
individual cbt	0	0.3603	8	Last updated April 2018 continue antidepressant treatment) or who have residual symptoms, should be offered one of the following psychological interventions: individual CBT for people who have relapsed despite antidepressant medication and for people with a significant history of depression and residual symptoms despite treatment mindfulness-based cognitive therapy for people who are currently well but have experienced three or more previous episodes of depression.	For all people with depression having individual CBT, the duration of treatment should typically be in the range of 16 to 20 sessions over 3 to 4 months	People with depression who are considered to be at significant risk of relapse (including those who have relapsed despite antidepressant treatment or who are unable or choose not to continue antidepressant treatment) or who have residual symptoms, should be offered one of the following psychological interventions: individual CBT for people who have relapsed despite antidepressant medication and for people with a significant history of depression and residual symptoms despite treatment mindfulness-based cognitive therapy for people who are currently well but have experienced three or more previous episodes of depression.	For all people with depression who are having individual CBT for relapse prevention, the duration of treatment should typically be in the range of 16 to 20 sessions over 3 to 4 months	Last updated April 2018 continue antidepressant treatment) or who have residual symptoms, should be offered one of the following psychological interventions: individual CBT for people who have relapsed despite antidepressant medication and for people with a significant history of depression and residual symptoms despite treatment mindfulness-based cognitive therapy for people who are currently well but have experienced three or more previous episodes of depression.	For all people with depression having individual CBT, the duration of treatment should typically be in the range of 16 to 20 sessions over 3 to 4 months	People with depression who are considered to be at significant risk of relapse (including those who have relapsed despite antidepressant treatment or who are unable or choose not to continue antidepressant treatment) or who have residual symptoms, should be offered one of the following psychological interventions: individual CBT for people who have relapsed despite antidepressant medication and for people with a significant history of depression and residual symptoms despite treatment mindfulness-based cognitive therapy for people who are currently well but have experienced three or more previous episodes of depression.	For all people with depression who are having individual CBT for relapse prevention, the duration of treatment should typically be in the range of 16 to 20 sessions over 3 to 4 months	
2-hour meetings	0	0.3529	2	Mindfulness-based cognitive therapy should normally be delivered in groups of 8 to 15 participants and consist of weekly 2-hour meetings over 8 weeks and four follow-up sessions in the 12 months after the end of treatment.	Mindfulness-based cognitive therapy should normally be delivered in groups of 8 to 15 participants and consist of weekly 2-hour meetings over 8 weeks and four follow-up sessions in the 12 months after the end of treatment.	
additional follow-up	0	0.3529	2	If the duration of treatment needs to be extended to achieve remission it should: consist of two sessions per week for the first 2 to 3 weeks of treatment include additional follow-up sessions, typically consisting of four to six sessions over	If the duration of treatment needs to be extended to achieve remission it should: consist of two sessions per week for the first 2 to 3 weeks of treatment include additional follow-up sessions, typically consisting of four to six sessions over	
delivering psychological	0	0.3529	2	Delivering psychological interventions for relapse prevention	Delivering psychological interventions for relapse prevention	
weekly 2-hour	0	0.3529	2	Mindfulness-based cognitive therapy should normally be delivered in groups of 8 to 15 participants and consist of weekly 2-hour meetings over 8 weeks and four follow-up sessions in the 12 months after the end of treatment.	Mindfulness-based cognitive therapy should normally be delivered in groups of 8 to 15 participants and consist of weekly 2-hour meetings over 8 weeks and four follow-up sessions in the 12 months after the end of treatment.	
adequate social	0	0.3333	2	If there is a risk of self-harm or suicide: assess whether the person has adequate social support and is aware of sources of help arrange help appropriate to the level of risk (see section ) advise the person to seek further help if the situation deteriorates.	If there is a risk of self-harm or suicide: assess whether the person has adequate social support and is aware of sources of help arrange help appropriate to the level of risk (see section ) advise the person to seek further help if the situation deteriorates.	
agent lithium	0	0.3333	0	
effects tolerable	0	0.3333	2	People who have had multiple episodes of depression, and who have had a good response to treatment with an antidepressant and an augmenting agent, should remain on this combination after remission if they find the side effects tolerable and acceptable	People who have had multiple episodes of depression, and who have had a good response to treatment with an antidepressant and an augmenting agent, should remain on this combination after remission if they find the side effects tolerable and acceptable	
good response	0	0.3333	2	People who have had multiple episodes of depression, and who have had a good response to treatment with an antidepressant and an augmenting agent, should remain on this combination after remission if they find the side effects tolerable and acceptable	People who have had multiple episodes of depression, and who have had a good response to treatment with an antidepressant and an augmenting agent, should remain on this combination after remission if they find the side effects tolerable and acceptable	
long-term maintenance	0	0.3333	2	People with depression on long-term maintenance treatment should be	People with depression on long-term maintenance treatment should be	
maintenance treatment	0	0.3333	2	People with depression on long-term maintenance treatment should be	People with depression on long-term maintenance treatment should be	
multiple episodes	0	0.3333	2	People who have had multiple episodes of depression, and who have had a good response to treatment with an antidepressant and an augmenting agent, should remain on this combination after remission if they find the side effects tolerable and acceptable	People who have had multiple episodes of depression, and who have had a good response to treatment with an antidepressant and an augmenting agent, should remain on this combination after remission if they find the side effects tolerable and acceptable	
social support	1	0.3333	2	If there is a risk of self-harm or suicide: assess whether the person has adequate social support and is aware of sources of help arrange help appropriate to the level of risk (see section ) advise the person to seek further help if the situation deteriorates.	If there is a risk of self-harm or suicide: assess whether the person has adequate social support and is aware of sources of help arrange help appropriate to the level of risk (see section ) advise the person to seek further help if the situation deteriorates.	
sole agent	0	0.3333	2	Lithium should not be used as a sole agent to prevent recurrence.	Lithium should not be used as a sole agent to prevent recurrence.	
nice guideline	0	0.326	20	For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services.	For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity.	Provide lifestyle advice (see section in this guideline and the lifestyle interventions section in hypertension in adults NICE guideline CG127) if blood	For guidance on the primary and secondary prevention of cardiovascular disease in adults with type 2 diabetes, see the NICE guidelines on cardiovascular disease and myocardial infarction.	For guidance on HbA1c targets for women with type 2 diabetes who are pregnant or planning to become pregnant, see the NICE guideline on diabetes in pregnancy.	For more information, see the NICE guideline on diabetes in pregnancy.	For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services.	For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity.	Provide lifestyle advice (see section in this guideline and the lifestyle interventions section in hypertension in adults NICE guideline CG127) if blood	For guidance on the primary and secondary prevention of cardiovascular disease in adults with type 2 diabetes, see the NICE guidelines on cardiovascular disease and myocardial infarction.	For guidance on HbA1c targets for women with type 2 diabetes who are pregnant or planning to become pregnant, see the NICE guideline on diabetes in pregnancy.	For more information, see the NICE guideline on diabetes in pregnancy.	NICE has also produced a guideline on depression in adults with a chronic physical health problem (NICE guideline CG91).	This guideline covers people whose depression occurs as the primary diagnosis; the relevant NICE guidelines should be consulted for depression occurring in the context of other disorders (see our topic page on depression).	Making decisions using NICE guidelines explains how we use words to show the strength (or certainty) of our recommendations, and has information about prescribing medicines (including off-label use), professional guidelines, standards and laws (including on consent and mental capacity), and safeguarding.	When the person has an anxiety disorder and comorbid depression or depressive symptoms, consult the NICE guideline for the relevant anxiety disorder (see find guidance) and consider treating the anxiety disorder first (since effective treatment of the anxiety disorder will often improve the depression or the depressive symptoms).	NICE has also produced a guideline on depression in adults with a chronic physical health problem (NICE guideline CG91).	This guideline covers people whose depression occurs as the primary diagnosis; the relevant NICE guidelines should be consulted for depression occurring in the context of other disorders (see our topic page on depression).	Making decisions using NICE guidelines explains how we use words to show the strength (or certainty) of our recommendations, and has information about prescribing medicines (including off-label use), professional guidelines, standards and laws (including on consent and mental capacity), and safeguarding.	When the person has an anxiety disorder and comorbid depression or depressive symptoms, consult the NICE guideline for the relevant anxiety disorder (see find guidance) and consider treating the anxiety disorder first (since effective treatment of the anxiety disorder will often improve the depression or the depressive symptoms).	
conditions notice-of-rights	0	0.2592	102	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	Depression in adults: recognition and management (CG90) conditions notice-of-rights)	
comorbid depression	0	0.25	2	When the person has an anxiety disorder and comorbid depression or depressive symptoms, consult the NICE guideline for the relevant anxiety disorder (see find guidance) and consider treating the anxiety disorder first (since effective treatment of the anxiety disorder will often improve the depression or the depressive symptoms).	When the person has an anxiety disorder and comorbid depression or depressive symptoms, consult the NICE guideline for the relevant anxiety disorder (see find guidance) and consider treating the anxiety disorder first (since effective treatment of the anxiety disorder will often improve the depression or the depressive symptoms).	
depression advice	0	0.25	2	Offer people with depression advice on sleep hygiene if needed, including: establishing regular sleep and wake times avoiding excess eating, smoking or drinking alcohol before sleep creating a proper environment for sleep taking regular physical exercise.	Offer people with depression advice on sleep hygiene if needed, including: establishing regular sleep and wake times avoiding excess eating, smoking or drinking alcohol before sleep creating a proper environment for sleep taking regular physical exercise.	
drinking alcohol	0	0.25	2	Offer people with depression advice on sleep hygiene if needed, including: establishing regular sleep and wake times avoiding excess eating, smoking or drinking alcohol before sleep creating a proper environment for sleep taking regular physical exercise.	Offer people with depression advice on sleep hygiene if needed, including: establishing regular sleep and wake times avoiding excess eating, smoking or drinking alcohol before sleep creating a proper environment for sleep taking regular physical exercise.	
effective treatment	0	0.25	2	When the person has an anxiety disorder and comorbid depression or depressive symptoms, consult the NICE guideline for the relevant anxiety disorder (see find guidance) and consider treating the anxiety disorder first (since effective treatment of the anxiety disorder will often improve the depression or the depressive symptoms).	When the person has an anxiety disorder and comorbid depression or depressive symptoms, consult the NICE guideline for the relevant anxiety disorder (see find guidance) and consider treating the anxiety disorder first (since effective treatment of the anxiety disorder will often improve the depression or the depressive symptoms).	
excess eating	0	0.25	2	Offer people with depression advice on sleep hygiene if needed, including: establishing regular sleep and wake times avoiding excess eating, smoking or drinking alcohol before sleep creating a proper environment for sleep taking regular physical exercise.	Offer people with depression advice on sleep hygiene if needed, including: establishing regular sleep and wake times avoiding excess eating, smoking or drinking alcohol before sleep creating a proper environment for sleep taking regular physical exercise.	
general measures	0	0.25	2	General measures	General measures	
offer people	0	0.25	2	Offer people with depression advice on sleep hygiene if needed, including: establishing regular sleep and wake times avoiding excess eating, smoking or drinking alcohol before sleep creating a proper environment for sleep taking regular physical exercise.	Offer people with depression advice on sleep hygiene if needed, including: establishing regular sleep and wake times avoiding excess eating, smoking or drinking alcohol before sleep creating a proper environment for sleep taking regular physical exercise.	
physical exercise	0	0.25	2	Offer people with depression advice on sleep hygiene if needed, including: establishing regular sleep and wake times avoiding excess eating, smoking or drinking alcohol before sleep creating a proper environment for sleep taking regular physical exercise.	Offer people with depression advice on sleep hygiene if needed, including: establishing regular sleep and wake times avoiding excess eating, smoking or drinking alcohol before sleep creating a proper environment for sleep taking regular physical exercise.	
proper environment	0	0.25	2	Offer people with depression advice on sleep hygiene if needed, including: establishing regular sleep and wake times avoiding excess eating, smoking or drinking alcohol before sleep creating a proper environment for sleep taking regular physical exercise.	Offer people with depression advice on sleep hygiene if needed, including: establishing regular sleep and wake times avoiding excess eating, smoking or drinking alcohol before sleep creating a proper environment for sleep taking regular physical exercise.	
regular physical	0	0.25	2	Offer people with depression advice on sleep hygiene if needed, including: establishing regular sleep and wake times avoiding excess eating, smoking or drinking alcohol before sleep creating a proper environment for sleep taking regular physical exercise.	Offer people with depression advice on sleep hygiene if needed, including: establishing regular sleep and wake times avoiding excess eating, smoking or drinking alcohol before sleep creating a proper environment for sleep taking regular physical exercise.	
regular sleep	0	0.25	2	Offer people with depression advice on sleep hygiene if needed, including: establishing regular sleep and wake times avoiding excess eating, smoking or drinking alcohol before sleep creating a proper environment for sleep taking regular physical exercise.	Offer people with depression advice on sleep hygiene if needed, including: establishing regular sleep and wake times avoiding excess eating, smoking or drinking alcohol before sleep creating a proper environment for sleep taking regular physical exercise.	
relevant anxiety	0	0.25	2	When the person has an anxiety disorder and comorbid depression or depressive symptoms, consult the NICE guideline for the relevant anxiety disorder (see find guidance) and consider treating the anxiety disorder first (since effective treatment of the anxiety disorder will often improve the depression or the depressive symptoms).	When the person has an anxiety disorder and comorbid depression or depressive symptoms, consult the NICE guideline for the relevant anxiety disorder (see find guidance) and consider treating the anxiety disorder first (since effective treatment of the anxiety disorder will often improve the depression or the depressive symptoms).	
sleep hygiene	0	0.25	2	Offer people with depression advice on sleep hygiene if needed, including: establishing regular sleep and wake times avoiding excess eating, smoking or drinking alcohol before sleep creating a proper environment for sleep taking regular physical exercise.	Offer people with depression advice on sleep hygiene if needed, including: establishing regular sleep and wake times avoiding excess eating, smoking or drinking alcohol before sleep creating a proper environment for sleep taking regular physical exercise.	
wake times	0	0.25	2	Offer people with depression advice on sleep hygiene if needed, including: establishing regular sleep and wake times avoiding excess eating, smoking or drinking alcohol before sleep creating a proper environment for sleep taking regular physical exercise.	Offer people with depression advice on sleep hygiene if needed, including: establishing regular sleep and wake times avoiding excess eating, smoking or drinking alcohol before sleep creating a proper environment for sleep taking regular physical exercise.	
